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ABSTRACT

NOVEL TRAF6-PROTEIN INTERACTIONS AND THE MOLECULAR
MECHANISMS BY WHICH THEY REGULATE TRAF6 DEPENDENT SIGNALING

By
An-Jey Andrew Su
August 2016

Dissertation supervised by Philip E. Auron, Ph.D.
TRAF6 is an E3 ubiquitin ligase that is unique among TRAF family proteins in
both its structure and protein-protein interaction specificity. It is further distinguished by
its ability to transduce a multiplicity of receptors in varied biological systems. Although
TRAF6 activity is induced by these receptors, the mechanisms by which TRAF6 is
activated under these stimulating conditions remain largely unclear. To address this,
standard molecular biological techniques were used to gain insight into the interplay of
three proteins with TRAF6: 1) Syntenin-1 (Syn); 2) SRY (sex determining region Y)-box
4 (Sox4); and 3) IL-1 receptor associated kinase 1 (IRAK1).

These three proteins

physically interact with TRAF6 and affect its signaling activity by modulating subcellular
localization, conformation or activation of the NF-κB/Rel family of transcription factors
under stimulating conditions in cell lines of various tissue types. While many previous

iv

studies focused on cytoplasmic TRAF6 and its activation, there are a several reports on
the nuclear localization of TRAF6 as well as TRAF3 and TRAF4 in response to either
extracellular stimulation or disease. Ectopic Syn or Sox4 was found to not only attenuate
TRAF6 signaling, translocates it into the nucleus of hematopoietic and monocytic cells.
Syn attenuates TRAF6 activity in an ubiquitin and Sox4 dependent manner. This, and the
observation that Syn is impaired in its ability to attenuate a non-ubiquitinated TRAF6
mutein (TRAF6ΔK), led to a hypothesis that Syn associates with TRAF6 in the
cytoplasm following activation by IRAK1. Notably, knockdown of Sox4 was found to
potentiate TRAF6 activation and abrogates Syn inhibition of TRAF6. Contrary to prior
reports, use of domain deletions in both TRAF6 and Syn demonstrate that the full-length
molecules are not necessary for their interaction. Instead, mutagenesis or deletion of a
newly identified TRAF Interaction motif (TIM) in Syn affects TRAF6 signaling and
localization. Interestingly, Syn also localizes to the nucleus when overexpressed with
either wild type (WT) or a constitutively active TRAF6 (RZcc). This study demonstrates
that Sox4 also attenuates TRAF6 signaling and identifies a unique Sox4 TIM that is
necessary for binding TRAF6.

TRAF6 and Sox4 colocalize under stimulatory

conditions, thus providing a novel mechanism for TRAF6 entry into the nucleus. In sum,
TIR and TNF receptor signaling through TRAF6 dependent NF-κB activity is modulated
by novel interactions with the Sox4 transcription factor in cooperation with Syn The pair
act on TRAF6 nucleocytoplasmic partitioning, conformation and modification state,
modulating TRAF6c-dependent ell morphogenesis and intracellular signaling.
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Chapter 1
INTRODUCTION

1.1 Cell signaling, Signal Integration and Signal Transduction
The ability for biological systems to respond in an appropriate manner to various
stimuli is critical for the maintenance of normal organismal physiology. Multicellular
organisms must deal with both external and internal signal inputs that may be
mechanical, electrical and/or chemical. Such systems typically display receptors on the
cell surface to receive these multimodal inputs and then initiate specific responses.
Additionally, cells must do this with a limited number of gene products at their disposal
for use in their signaling networks. Complexity and emergent properties in biology have
evolved to deal with variable inputs that stimulate multiple pathways using multiple
outputs that are integrated network responses to the inputs. This behavior is conducted
with a backdrop of interactions between multiple cell types and multiple contexts and
environments for each cell type or combination of cell types (Butcher, Berg et al. 2004).
While characterization of specific signaling pathways and their associated end responses
have received intensive research, less studied is the integration of multiple receptor signal
inputs that are differentially recognized by the network to trigger a specific cellular
response (Gutierrez, O'Keeffe et al. 2008). The result is reflected in the literature as
incongruent reports often reflecting either contradictory or divergent signaling functions
for single molecules.
Extracellular signals need to be interpreted, integrated and amplified.

This

process elicits cellular responses such as proliferation, differentiation, secretion,
1

contraction, metabolism and membrane excitation.

Receptors act as catalysts and

amplifiers for this process. In a signaling cascade, intracellular adapter proteins are used
to effect downstream signal convergence and the final determination of cellular response.
Two general regulatory mechanisms become apparent when considering the control of
cellular signal transduction: 1) protein-protein interactions and 2) spatio-temporal control
of signaling machinery. Specificity of multifunctional signaling machinery is achieved
through protein–protein interactions involving specific structural domains or binding
motifs and adapter/scaffold proteins. Additionally, the subcellular spatial and temporal
expression of each molecular component is clearly important in the context of signal
transduction (Meier and Somers 2011). Spatiotemporal control provides a regulatory
mechanism for controlling the players involved in protein-protein interactions.

An

example of this bi-modal control of intracellular signaling can be seen with inducible
transcription factors that mediate rapid, but transient changes in gene expression in
response to cellular demand. In this study, signal convergence for multimodal receptor
activation of members of the Rel/NF-κB transcription factor family, through the signaling
adapter TRAF6 (Tumor necrosis factor receptor associated factor 6) is examined.
TRAF6 is a very busy molecule, mediating signaling for many receptor systems critical
for normal cellular and organismal physiology. As such, the regulation and activation of
TRAF6 must be exquisitely regulated. Specifically, I am interested in how TRAF6
signaling is modulated by both protein-protein interactions and subcellular localization.
1.2 Biophysiological systems share recurrent organization and components
An allegory to the pitfalls modern molecular biologist must avoid is found in
Saxe’s six blind men of Indostan and their elephant, who were “each in isolation
2

potentially correct, but all were ultimately wrong!” Armed with a reductionist strategy,
investigators studying their favorite protein(s) in the alphabet soup of intracellular signal
transduction networks can lose perspective of the integrative nature of biological systems.
The central nervous system (CNS) along with the immune and endocrine systems
together form a regulatory network in higher animals and man termed the Neuroimmune
Super System (NISS) (Berczi, Quintanar-Stephano et al. 2009). The healthy brain and
spinal cord are under continual immune surveillance to guard against potential mediators
of infection and damage. Uncontrolled response in the brain can be particularly
deleterious, as in the case of meningitis. Loss of immunity is just as bad, often resulting
in cerebral infections. While it is established that cells from the immune system interact
with the CNS within the meningeal compartment of the central nervous system (CNS)
(Ousman and Kubes 2012, Ransohoff and Engelhardt 2012), it was believed that the CNS
lacked a classic lymphatic drainage system. Most recently, it has been discovered that Tcells gain entry into the CNS via functional lymphatic vessels that line the dural sinuses
of mice (Louveau, Smirnov et al. 2015). The vessels express all of the molecular
hallmarks of lymphatic endothelial cells, are able to carry both fluid and immune cells
from the cerebrospinal fluid, and are connected to the deep cervical lymph nodes. While
this finding is very exciting, many previously held assumptions of NISS processes would
now need reconsideration. One such topic might be the comparative similarities between
the synaptic structures found in the immune system and those between neurons (Dustin
and Colman 2002). Such similarities harken to the of conserved organizational principles
across biological systems.

3

1.3 Conserved Organizational Principles and Components Among Various Biological
Synapses
A synapse is a stable adhesive junction between two cells across which
information is relayed by direct secretion. Synapses are used by both the nervous system
and immune system to directly convey and transduce highly controlled secretory signals
between cell populations. Each of these synapse types is built around a microdomain
structure composed of central active domains of exocytosis and endocytosis that are
encircled by outer adhesion domains (Figure 1.1).

Surface molecules that are

incorporated into and around the active domains may modulate the functional state of the
synapse (Dustin and Colman 2002). In 2002, Dustin and Coleman proposed four criteria
for defining synaptic junctions: (1) cells remain individual; (2) the apposed membranes
are held together by adhesion molecules; (3) the junction is stable either through adhesion
clamp or cytoskeleton polarity; and (4) directed secretion in response to signals from
microdomains. Analysis of the origins of the IS pattern formation over the past 15 years
has seen an emergent modularity to synapse design that has provided solutions to
lymphocyte biology and phagocytic processes (Dustin and Colman 2002, Dustin 2009,
Goodridge, Reyes et al. 2011). As the components most critical for lymphocyte signaling
became known, efforts were made to uncover the subcellular localization of those
components, both under resting and stimulated conditions (Paul 2003). Seminal studies
by Monks et al. provided images that showed a variety of molecules accumulating at the
Interface between T cells and antigen-presenting cells (APCs).

These molecules’

membrane surface, were spatially segregated over time into distinct structures termed

4

Figure 1.1 Comparative schematics of immunological and neural synapses A) CNS
synapse B) Effector immunological synapses with T-Cell as presynaptic and target
cell as postsynaptic C) Inductive immunological synapse with DC as presynaptic
and T-Helper cell as postsynaptic D) Diagram of IS formation. Green, TCR-MHCp
interactions and MHCp in exocytic vesicles; red, LFA-1:ICAM-1 interaction; blue,
soluble contents of exocytic vesicles and diffusing contents after release; yellow,
CD43 at boundaries; orange, microtubules; cross-hatch, material in synaptic cleft
(From Dustin, M. L. and D. R. Colman [2002]. "Neural and immunological synaptic
relations." Science 298[5594]: 785-789. Reprinted with permission from AAAS.)
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supramolecular activation complexes (SMACs) (Monks, Freiberg et al. 1998, Wetzel,
McKeithan et al. 2002). The immunological synapse (IS) is formed on the plane of
adhesion between T cell and APCs where the molecules involved in antigen recognition
and adhesive molecules rearrange and cluster into a characteristic ring like pattern of
adhesion molecules surrounding a central supramolecular activation cluster (cSMAC)
(Dustin and Shaw 1999, Davis 2002).
The area of cell membrane where the IS forms is populated by lipid
microdomains, where various signaling molecules collect to transmit the antigen
recognition signal into the cell. This activates the T cell defense programs and the lipid
microdomains are utilized in spatiotemporal control of the signaling components. Lipid
microdomains have also been demonstrated as an important mechanism for the
RANK/TRAF6/NF-κB signaling axis found in osteoimmunological systems (Ha, Kwak
et al. 2003).

Metazoan physiological systems are rife with this type of shared

mechanistic organization. Given the integrated nature of organismal systems that arise
from undifferentiated totipotent cells, it is not surprising that biological systems share
mechanistic modalities that include the overlap of critical keystone molecules that are
able to bridge the many cell surface receptor signaling systems. TRAF6 is one such
keystone molecule. TRAF6 is uniquely poised to bridge a diverse array of physiological
processes, including adaptive and innate immunity, bone metabolism and the
development of several tissues including lymph nodes, mammary glands, skin and the
central nervous system (Wu and Arron 2003).

6

1.4 TRAF6 is unique among TRAF family proteins
TRAF6 is an intracellular signal transducer that functions as an E3 ubiquitin
ligase. TRAF6 belongs to a family of proteins that were initially identified by the
capability to interact with and regulate signaling through different members of the TNFR
superfamily (Takeuchi, Rothe et al. 1996, Locksley, Killeen et al. 2001). The TNFR
superfamily consists of at least 26 members, including: Fas antigen; CD27; CD30; CD40;
TNFR1; and TNFR2, which mediate immune regulation and inflammatory responses. In
mammals, six different TRAF proteins (TRAF1-TRAF6) have been described with
TRAF1 clearly distinct from the others with respect to the architecture of the N-Terminal
domain (Figure 1.2). Among the members of the TRAF protein family, only TRAF6 has
been demonstrated to transduce both TNFR family signaling and that for the unrelated
interleukin-1/18 receptor/Toll-like receptor (IL-1R/TLR) superfamily that possess a
conserved cytoplasmic TIR (Toll I-1 Receptor (TIR) domain (Table 1). Upon TLR1/2/4,
but not TLR3/9, signaling, TRAF6 translocates to mitochondria where it binds to ECSIT
to induce mitochondrial reactive oxygen species (mROS) and enhance bacterial killing
(West, Brodsky et al. 2011). TRAF6 also mediates signaling for some growth factor
receptors including: transforming growth factor beta (TGFβ), nerve growth factor (NGF),
and endothelial growth factor (EGF). TRAF6 signaling activates many transcription
factors including: NF-κB, Jun-Fos dimers (Activator protein-1 or AP-1), Interferon
regulatory factors (IRFs) and CCAAT/enhancer binding protein beta (C/EBPβ). Such
activity stimulates the production of cytokines or the differentiation of cells into several
distinct phenotypes (Wu and Arron 2003).

TRAF6 has been demonstrated, using

knockout mice and RNAi technology, to be critical for CD40 signaling and receptor
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activator of nuclear factor κB (RANK) signaling (Lomaga, Yeh et al. 1999, Davies, Mak
et al. 2005). RANK is known to mediate both canonical (TAK1/IKKα, β, γ) and noncanonical (NIK/IKKα) NF-κB pathways (Mizukami, Takaesu et al. 2002, Novack, Yin et
al. 2003, Xiao, Balasubramanian et al. 2012) (Figure 1.3).

Figure 1.2 Structural Organization of The Known TRAF Family Proteins. Shown is
the number of amino acids (right) of murine TRAF proteins* and human TRAF
proteins. Boxes represent the relative positions of described protein domains and
modules as indicated. TRAF6 features shown reflect positions as reported for
human TRAF6. The “module” containing both the TRAF-N (Coiled-coil) and
TRAF-C (MATH) domains has historically been referred collectively as the
“TRAF” domain, even though it contains two distinct, structurally independent,
domains. Similarly, the “RING-Zinc Finger” module contains multiple Zinc Finger
domains.
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Table 1 TRAF Family Member Functions And Primary Subcellular Localization.
Functions and localization was derived from online databases (Gene Cards, UniProt,
The Human Protein Atlas), this research study and the literature cited herein.

9

In the mammalian immune system, when CD40 ligand on T cells engage CD40
on B cells, numerous signals within B cells initiate, including the activation of Mitogenactivated protein kinase (MAPK) and both classical and non-canonical NF-κB (Karin
2008, Hostager and Bishop 2013). The herpes viral oncoprotein, Tio, depends on TRAF6
and Inhibitor of κB kinase (IKKγ or NEMO), and enhances the expression of the
noncanonical NF-κB proteins, p100 and RelB (de Jong, Albrecht et al. 2010). Further,
OX40 activated the ubiquitin ligase TRAF6, which triggered induction of the kinase
NIK in CD4+ T cells and the noncanonical transcription factor NF-κB pathway (Xiao,
Balasubramanian et al. 2012). Thus, TRAF6 differentially affects both the canonical
and non-canonical NF-κB activation pathways by recruiting both TAK1 and NIK,
respectively.

However,

the

incompletely understood or

mechanistic details of this phenomenon remain

may

be

confounded by

the cell lineage, type

or

developmental state. As such, greater detail is an important direction for future research.
The

current

understanding

partially derives

from

research

in

the field

of

neurotrophic signaling, suggesting that the underpinnings are dependent upon both
direct and indirect protein-protein interactions; namely, TRAF6 interacts with specific
domains of variably expressed scaffolding proteins and isoforms of those proteins
(Geetha and Wooten 2002, Wooten, Geetha et al. 2005) and/or polyubiquitination by
TRAF6 of those extramolecular proteins. In Schwann cells, TRAF6 and an adapter
protein RIP2 bind directly to the p75NTR receptor in a ligand dependent manner to
activate NF-κB. In the neuronal cell line PC12, IRAK1 and atypical PKC (aPKC)
complex with TRAF6 and recruit p62/SQSTM1 to promote nerve growth factor
(NGF) activation of NF-κB. The various domains of the protein p62, also known as
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Figure 1.3 RANKL Binding To RANK Activates Canonical And Non-Canonical
Signaling To The Transcription Factor NF-κB. Signaling from RANKL and other
receptors converge on a two different IκB kinase complexes that phosphorylate the
NF-κB inhibitory proteins I-κB.
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sequestosome 1 (SQSTM1) can bind to RIP, aPKCs, TRAF6 and polyubiquitin chains in
order to regulate proteosomal degradation of ubiquitinated proteins (Seibenhener, Babu et
al. 2004, Babu, Geetha et al. 2005, Moscat, Diaz-Meco et al. 2007). Moreover, SQTM1
modulates RANK signaling to NF-κB and mutations in SQSTM1 are associated with
both sporadic and hereditary Paget's disease of Bone (PDB) in different populations.
PDB is a hereditary disorder characterized by excessive localized bone resorption by
osteoclasts (Layfield and Hocking 2004). Recent work in immunobiology has implicated
the herpes viral oncoprotein Tio, which promotes growth and transformation of human T
cells in a recombinant herpes virus Saimiri background and to potently induce canonical
NF-κB signaling through membrane recruitment of TRAF6. In addition to triggering
canonical NF-κB signaling in NEMO/IKKγ-dependent activation of the p52 and RelB
isoforms of NF-κB, Tio also induces NEMO/IKKγ-independent generation of active NFκB p52 from its inactive p100 precursor (de Jong, Albrecht et al. 2010, de Jong, Albrecht
et al. 2013). Taken together the Tio and p62 studies underscore TRAF6’s role as a
keystone adaptor molecule utilizing protein-protein interactions with other adaptor
molecules to regulate both the canonical and noncanonical NF-κB activation pathways.
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Figure 1.4 Exon–intron Structure of Human TRAF Genes. The exon–intron
structures of the human genes encoding TRAF2 to TRAF6 according to the NCBI
entries NT_025667 (TRAF2), NT_010019 (TRAF3), NT_030828 (TRAF4),
NT_021877 (TRAF5) and NT_024229 (TRAF6) were matched with the cDNA
sequences encoding TRAF2 to TRAF6 [accession numbers U12597 (TRAF2),
U19260 (TRAF3), X80200 (TRAF4), AB000509 (TRAF5) and U78798 (TRAF6)
Only exons encoding parts of the cDNA translated into protein were considered in
this illustration. Thus, exons numbered in this scheme with as 1 do not necessarily
correspond to exon 1 of the respective gene in the database. Exons encoding parts of
the TRAF domain were summarized and labeled TD. The number of nucleotides
encoded by each exon is indicated in the box representing the respective exon. Gray
boxes indicate exons containing multiples of three nucleotides. Modified from
(Glauner, Siegmund et al. 2002).
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1.5 TRAF6 molecular domain structure and function
TRAF6 is a 61-kDa protein consisting of several distinct modules with specific
functions. The architecture of the TRAF family proteins is largely homologous, with the
seven mammalian TRAFs hallmarked by distinct amino and carboxyl structures (Figure
1.2) that consists of two distinct modules: an amino Ring-Zinc (RZ) module and a
carboxyl TRAF module. TRAF7 The human TRAF6 gene is located at chromosome
11p12. The exon–intron structures of human TRAF genes are diagrammed in (Figure
1.4). Remarkably, analyses of the human TRAF2, 3, 4, 5 and 6 genes revealed that they
all share a stretch of three to six consecutive exons with a multiple of three nucleotides
encoding the zinc finger domains of these molecules (Figure 1.4). Thus, any combination
of these exons results potentially in an in-frame splice-form of the respective TRAF
isotype (Glauner, Siegmund et al. 2002). The implication of such similarities in splice
forms could account for differential subcellular localization and/or functionality amongst
the TRAF family isoforms and isotypes. (For a through review and characterization of
evolutionary consequences upon TRAF family genomic structure and functional
implications please see (Grech, Quinn et al. 2000)).
Proceeding from the amino termini in TRAF2 through 7, the RZ module contains
a RING zinc finger (Really Interesting New Gene) domain, which is common to E3
ligases, followed by four to seven non-RING zinc fingers. The RZ module is followed
by the TRAF module, which is separated into TRAF-N and TRAF-C domains. The
TRAF-N is a coiled-coil (cc) domain is comprised of a single alpha helix, which is
required for TRAF coiled-coil oligomerization, as implied by correlation with the X-ray
crystal structures of TRAF2 and TRAF3. TRAF modules potentially oligomerize as both
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homotypic and heterotypic dimers and trimers. The structure of the TRAF module of
TRAF2 reveals a trimer where the coiled-coil (TRAF-N) domain forms a single stalk-like
structure and the Ig-like anti-parallel -stranded MATH (Meprin and TRAF homology
domain)/TRAF-C domain forms three interacting globulin structures beyond the stalk
that terminate the oligomer (Ye, Park et al. 1999, Glauner, Siegmund et al. 2002). The
trimeric form of the TRAF2 C-terminal TRAF module is shown in Figure 1.5A. With the
exception of TRAF7, the remaining six members of the TRAF family possess a carboxylterminal MATH domain that folds into a beta-sandwich structure that contains a groove
that specifically interacts with receptors or intracellular proteins bearing a TRAF
interaction motif (TIM). For a thorough review of TRAF7 please see (Zotti, Vito et al.
2012).

Importantly, TRAF1 through 5 all have similar TIM specificities, whereas

TRAF6 binds distinct TIM sequences.

This is reflected in the distinct amino acid

composition of the MATH domain groove that binds the TIM (Figure 1.5C). Peptides
with the sequence P-X-E-X-X-(acidic or aromatic residue) bind TRAF6 while, a
PXQX(T/S) motif specifies binding to the other TRAFs, such as TRAF2 and TRAF3.
Synthetic transduction TIM peptides (Figure 1.5D) have been shown to inhibit TRAF
activity (Poblenz, Jacoby et al. 2007). Interestingly, the reported crystal structures of the
TRAF6 MATH domain (residues 346-504) only contained a monomeric TRAF6 MATH
domain (Figure 1.5B) and not a coiled-coil multimerization domain (Ye, Arron et al.
2002). The TRAF6 MATH domain is structurally similar to both the TRAF2 and TRAF3
MATH domains, which both crystallized as trimers (McWhirter, Pullen et al. 1999, Park,
Burkitt et al. 1999), possibly because the crystallized fragments of TRAF2 and TRAF3
included both coiled-coil and MATH domains. Furthermore, it is known that the TRAF6
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MATH contains a polyproline loop that is unique to the TRAF6 MATH and facilitates
Src binding (Wong, Besser et al. 1999) and PI3K activity (Wang, Wara-Aswapati et al.
2006) (Figure 1.6). This would support the functionality of the coiled-coil domain in
oligomerization of TRAF molecules. Moreover, the divergent peptide-binding groove in
the MATH domain of TRAF6, as compared to other TRAFs (Figure 1.5C), confers
unique biological functions to TRAF6; it does not interact with peptide motifs that are
recognized by TRAF1, -2, -3 or -5 (TIMs).

Comparing the peptide bound crystal

structures of TRAF6 and TRAF2 reveals that bound TRAF6-binding peptides display a
40o rotation in chain vector from that of the TRAF2-binding peptides. As a result, sidechains of TRAF6-binding peptides interact with surface pockets on TRAF6 that are
vastly different from those on TRAF2 (Ye, Arron et al. 2002), as well as other TRAFs.
TRAF Domain proteins are intracellular proteins that can act as adapters, binding
either the cytoplasmic tails of receptors, upstream regulators, or downstream effectors
(Table 2). Both CD40 and RANK can recruit TRAF1, 2, 3, 5 and 6 to their cytoplasmic
tails. TRAF6 binds to more distinct TIM sites (T6IM) than the other TRAFs. There are
two distinct types of TIM: PXEXX(Ar/Ac) motif with the last residue either aromatic or
acidic for TRAF6 (Figure 1.5D), and a conserved PXQX(T/S) motif with the last residue
either a threonine or serine for TRAFs 1, 2, 3 and 5 (Wu and Arron 2003, Yoshida,
Takaesu et al. 2008). Similar to TRAF6, TRAF4 also bears a non-conserved substitution
in the MATH binding site, helping to explain differences in receptor specificity (Ye, Park
et al. 1999, Grech, Quinn et al. 2000, Rousseau, Rio et al. 2011). By aligning various
crystallized TRAF-receptor complexes it is possible to derive the TIM sequence. The
core of four conserved residues of the TIM are labeled P-2 to P3, centered about the zero
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position (P0) that is invariably a Glu (Wu and Arron 2003). Although, proteins bearing a
TIM peptide are highly variable in their primary sequences, the conserved motif serves to
converge this diverse set upon the MATH domain of TRAF proteins. Regardless, TRAF6
specificity is the most distinct, resulting in greater selectivity for specific TIM interaction.
In summary, there are three ways that TRAF proteins can be recruited to and actuated by
ligand-engaged receptors: (1) Members of the TNF receptor superfamily that do not
contain intracellular death domains, such as NFR2 and CD40, recruit TRAFs directly by
TIM sequences in their intracellular tails; (2) Those that contain an intracellular death
domain, such as TNFR1, utilize the adapter protein TRADD via a death domain-death
domain (DD) interaction that results in TRADD assembling a complex of TRAF2 and
RIP for survival signaling that competes with a DD interaction with FADD that activates
caspase 8 for the induction of apoptosis; (3) Members of the TIR superfamily, containing
a protein interaction module known as the TIR domain, recruit Myeloid differentiation
primary response gene 88 (MyD88), a TIR domain and DD containing protein, and
various IRAKs. IRAK1 then recruits TRAF6 by their T6IM (Gravallese, Galson et al.
2001).
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Figure 1.5 TRAF Structural Models and Sequence Analysis for MATH DomainProtein Interactions.
A) Structural model of TRAF2 coiled-coil (CC)
domain/MATH domain trimerization, shown by the symmetrical interaction of
trimerized MATH/TRAF-C domains (cyan, blue and green) and yellow for the three
coiled-coil domains (from (Ye, Park et al. 1999). B) Accessible solvent surface
contour representation of a single TRAF6 and TRAF2 MATH domain in an
orientation similar to that shown in A. The superimposed worm representations of
receptor peptide backbones are shown in magenta, emphasizing distinct orientations
and specific MATH domain contacts (arrows). C) Conservation of exposed contact
residues within the MATH domain of TRAF family proteins representing key
features of the TIM grooves that interact with TIM peptides (from (Ye, Park et al.
1999). D) The three conserved key amino acids of proteins bearing TRAF6 TIM
peptides identified from the structural analysis of peptide interactions with distinct
sites on the MATH domain surface.
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Figure 1.6 The Unique TRAF6 Interaction Motif (T6IM) Allows Receptor
Interaction Specificity for Signaling to C-Src and Subsequent PI3K Activation.
Differences in the MATH domain and TRAF6 Interaction Motif (T6IM) between
that of TRAF6 and other TRAFs, such as TRAF2 and TRAF5, provide unique
receptor interaction specificities for signaling to c-Src and subsequent PI3K
activation. Key: Red arrows indicate tyrosine phosphorylation targets; Dotted
double-ended arrows indicate protein-protein interactions; and solid single-ended
arrow indicates a likely IRAK relocalization form IL-1 receptor at the plasma
membrane to cytoplasmic TRAF6. The multiple, promiscuous, TIM targets for
TRAF2 and TRAF5 on the cytoplasmic region of RANK, and the unique
membrane-proximal binding of TRAF6 to a TIM of distinct specificity, reflects the
differences emphasized in the text for TRAF6 vs. other TRAFs.
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TRAF Domain Proteins

Binding Partners

TRAF 1,2,3,5

CD40

TRAF 1,2

TRADD

TRAF6

IRAK1, Sox4

TRAF2

TNFR1

TRAF6

IL-1, CD40, RANK, TLR4

Table 2 Examples of Receptors and Intracellular binding Partners that bind to
TRAF Domain Proteins. TRAF Domain proteins are intracellular proteins that can
act as adapters, binding either the cytoplasmic tails of receptors, upstream
regulators, or downstream effectors.
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1.6 IRAK1 Initiates TRAF6 Ubiquitination Of Downstream Targets
TLR4 is the principal signal-transducing receptor for lipopolysaccharide (LPS), a
component of the outer membrane of Gram-negative bacteria, (Poltorak, He et al. 1998,
Chow, Young et al. 1999).

Activated TLR/IL1R (TIR) recruit the adapter protein

Myeloid differentiation primary response gene 88 (MyD88) to their cytoplasmic TIR
domains, initiating assembly of the Myddosome, a multi-protein complex composed of
MyD88, and the serine/threonine kinases: IL-1R-associated kinases (IRAK), IRAK4,
IRAK1 and IRAK2. This complex initiates the MyD88-dependent signaling pathway
that has been implicated in LPS-induced tyrosine phosphorylation (Zeisel, Druet et al.
2005). IRAK2 activates IRAK1 through IRAK4-dependent phosphorylation. IRAK1
phosphorylation by IRAK4 results in a conformational change, dissociating IRAK1 from
the TLR4 complex. IRAK1 then either binds to then activates TRAF6 in the cytoplasm,
(Akira and Takeda 2004) or TRAF6 dynamically interacts with receptor-bound IRAK1,
resulting in rapid release and transfer to TRAF6 (Jiang, Johnson et al. 2003, Muroi and
Tanamoto 2008). Structurally, IRAK1 consists of an amino terminal domain (NTD) that
contains a death domain (DD) that interacts with the DD of MyD88, and a proline-serinethreonine rich region (ProST Domain) followed by a central kinase domain that has been
shown to be dispensable for NF-κB activation (Li, Commane et al. 2001) (Figure 1.7).
This might be due to the redundant functions of IRAK2 (Rhyasen and Starczynowski
2015). The carboxyl terminal domain (CTD) of IRAK1 contains three potential TRAF6binding sites (Glu544, Glu587, Glu706).

Mutating these Glu to Ala was found to

significantly reduce NF-κB activation (Ye, Arron et al. 2002).
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Figure 1.7 Structural Domain Architecture and Associated Functions of IRAK1.
Amino Acid numbering is indicated for human IRAK1 and is annotated according
to ELM Analysis (http://elm.eu.org/). The ProST Domain is a proline-serinethreonine rich region that is heavily phosphorylated upon IRAK1 activation
(Kollewe, Mackensen et al. 2004).
The NTD (death domain and ProST Region) plus the first half of the CTD were
demonstrated to be sufficient for IL-1-induced activation of NF-κB (Li, Commane et al.
2001). The ephemeral nature of the IRAK1-TRAF6 interaction might account for the
dearth of reports in the literature of TRAF6 being recruited by TIR to the membrane, as is
the case with TRAF6 and RANK (Wong, Besser et al. 1999) or TRAF2/3 by CD40
(Hostager, Catlett et al. 2000).

In particular, there is an absence of micrographic

evidence for this interaction, although biochemical evidence has been reported to support
a TRAF6-TIR interaction (Cao, Xiong et al. 1996, Qian, Commane et al. 2001, Jiang,
Mak et al. 2004, Kollewe, Mackensen et al. 2004).
Covalent attachment of ubiquitin to proteins is a reversible, post-translational
modification (similar to phosphorylation or acetylation) that distinguishes select proteins
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for regulation and signal propagation. Ubiquitylated proteins interact with other proteins
bearing ubiquitin-binding modules (Rahighi and Dikic 2012). To act an E3 ubiquitin
ligase, TRAF6 forms a complex with the E2 ubiquitin conjugating enzyme Ubc13 and
Ubc-like protein Uev1A. This enables TRAF6 auto-ubiquitination, trans-ubiquitination,
activation and downstream ubiquitination of targets such as TAK1 through a nondegradative Lys63-linked polyubiquitination (Wang, Deng et al. 2001, Seibenhener, Babu
et al. 2004, Rong, Cheng et al. 2007, Balkhi, Fitzgerald et al. 2008). TRAF6 can also
mediate Lys48-linked polyubiquitination, which induces proteosomal degradation of
proteins such as RIP1 and IRAK1 (Newton, Matsumoto et al. 2008). Since IRAK1
activates TRAF6, this is a feed-forward mechanism for attenuation of TRAF6 signaling.
Here, TRAF6 binds to Lys48-linked polyubiquitinated proteins like IRAK1 and they
translocate together into the proteasome where IRAK1 undergoes proteosomal
degradation while TRAF6 is recycled through de-ubiquitination, rather than by
degradation. The enzyme, Cylindromatosis (CYLD) is responsible for deubiquitinating
Lys63-linked-TRAF6, -TRAF2 and - NEMO/IKKγ (Jensen and Whitehead 2003,
Kovalenko, Chable-Bessia et al. 2003, Trompouki, Hatzivassiliou et al. 2003, Yoshida,
Jono et al. 2005, Wooten, Geetha et al. 2008). In addition to de-ubiquitinating enzymes
(DUBs), proteins such as A20 act as ubiquitin-editing enzymes; substituting Lys63 linked
poly-ubiquitin with Lys48 linked poly-ubiquitin on its target proteins (Sun 2008,
Coornaert, Carpentier et al. 2009).
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1.7 Shared signaling systems utilized in Osteoimmunology
In bone remodeling, osteoclasts resorb old and damaged bone, which is then
replaced by new bone deposited by osteoblasts.

Imbalances in either resorption or

deposition of bone leads to a pathological decrease or increase in bone mass, the former
often being caused by inflammatory diseases of the immune system. For example, the
autoimmune disease rheumatoid arthritis is an abnormal or prolonged activation of the
immune system that causes bone loss by excessive osteoclast activity (Guo, Yamashita et
al. 2008). The first reports that cells of the immune system could influence the functions
of bone cells were made over 40 years ago. Then, in the 1980’s, antigen stimulated
immune cells were shown to produce soluble factors that stimulate osteoclast bone
resorption, and interleukin 1 (IL-1) was identified as one of these factors (Stashenko,
Dewhirst et al. 1987, Blair, Zheng et al. 2007). Accumulating evidence suggests that
bone destruction associated with rheumatoid arthritis is caused by the enhanced activity
of osteoclasts, resulting from the activation of the Th17 subset of helper T cells (Miossec
2003). Such work promoted the now decade old research field of osteoimmunology,
which investigates the interplay between the skeletal and immune systems at the
molecular level (Arron and Choi 2000, Lorenzo, Horowitz et al. 2008). Numerous
studies have shown that the two systems share a number of regulatory molecules
including cytokines, receptors, signaling molecules and transcription factors. This is
particularly true when comparing B cell with osteoclast biology (Takayanagi 2007).
Together, Tumor necrosis factor alpha (TNFα) synergizes with Receptor Activator of
Nuclear Factor Kappa B Ligand (RANKL) for enhanced osteoclast activation and activity
(Jimi, Aoki et al. 2004). TNFα is considered one of the key inflammatory mediators
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during bacterial infections. Blood leukocytes, such as monocytes/macrophages, secrete
TNFα as a host defense against bacterial infections (Chen, Pan et al. 2009, FunakoshiTago, Kamada et al. 2009). Trimeric RANKL (a member of the TNF family) in stromal
cells is the essential osteoclastogenic ligand. Each RANKL trimer recognizes either a
single trimeric RANK (a member of the TNF receptor family) or the trimeric
osteoprotegerin (OPG) decoy receptor, which inhibits osteoclastogenesis (Boyle, Simonet
et al. 2003, Warren, Nelson et al. 2014). Trimerization of RANK is a good example of a
strategy for increasing and concentrating the signaling of an extracellular ligand in order
to activate the downstream, intracellular signaling cascades. It is common for a single
ligand to engage multiple rather than an individual receptor (Korpelainen, Karkkainen et
al. 1999). Multimeric receptor complexes may be homotypic or heterogeneous in subunit
composition.

Oligomerization of active receptors allows the formation of receptor

complexes composed of distinct, but similar subunits, which can have different signaling
potentials (Pawson and Nash 2000). Signaling by RANK in response to its ligand,
RANKL, stimulates osteoclast formation and bone resorption. Cells may also utilize
receptor modularity of the extracellular (ligand-binding) and intracellular (signaling)
regions. This allows a wide variety of signals to use limited regulatory componentry
(Katritch, Cherezov et al. 2012).

Additionally, cells

may also express different

receptors for the same ligand. This ligand may have different effects depending on the
effector domain of the receptor. For example, TLR4 and MD-2 form a heterodimer that
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recognizes LPS (lipopolysaccharide) from Gram-negative bacteria (Kim, Park et al.
2007). Intracellularly, the receptors: TLR4, IL-1R and TNF-R signal to NF-κB through a
common IKK-dependent pathway that allows us to view them as variations on a common
theme (Figure 1.8).

Figure 1.8 TIR and TNFR Signaling Pathways Converge During the Activation of
IKKs.
Phosphorylation activates IKK, resulting in IkBα phosphorylation,
ubiquitination and degradation. Signal transduction through TNFR recruits RIPK,
when poly-ubiquitinated, binds TAB adaptor proteins, inducing TAK1 activation.
Activated IKKβ phosphorylates IkBα, which is modified with Lys48-linked chains.
This form of IkBα is subsequently transported to the proteasome, where it is
degraded, enabling NF-kB nuclear translocation.
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1.8 TLR4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme
In mammals, the TIR family members are important mediators of inflammation,
innate and adaptive immune responses. The specificity of distinct TLRs is achieved
through alternate and combinatorial adaptor usage (Yin, Lin et al. 2009). MyD88 can
recruit IRAK molecules to the plasma membrane. Notably though, TRAF6 has not been
visually demonstrated to be stably recruited by TIR to the membrane. Thus, after TIR
activation, IRAK is bound to the receptor and either interacts with TRAF6 after release or
TRAF6 interacts in a “kiss and run” fashion with receptor bound IRAK. Toll-like
receptors (TLRs), as well as the receptors for tumor necrosis factor (TNF-R) and
interleukin-1 (IL-1R), are important for initiating osteoimmunity function by the noncanonical NF-B pathway via developmental signals activating NIK and IKK kinases.
This activation causes proteolytic degradation of the inhibitory IκBδ domain of NFBp100, generating active NF-B-p50, resulting in nuclear translocation of RelA:p50,
RelB:p50 and RelB:p52 dimers, facilitating target gene expression. The canonical
pathway is activated through pathogen and inflammatory signals activating NIK and
IKK kinases. This activation results in the degradation of IκBα/IκBβ/IκBε, allowing for
the nuclear translocation of RelA:p50, RelA:RelA and cRel:p50 dimers, which then
activate a different set of genes from the noncanonical pathway. (Modified from (Shih,
Tsui et al. 2011)). Nevertheless, the principles of signaling are similar, involving the
recruitment of specific adaptor proteins and the activation of kinase cascades in which
protein-protein interactions are controlled by poly-ubiquitination (Verstrepen, Bekaert et
al. 2008). MyD88 and IRAK1 play crucial roles as adaptor molecules in signal
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transduction of the TLR/IL-1R superfamily, and it is known that expression of these
proteins leads to the activation of NF-κB in a TRAF6 dependent manner.
1.9 TRAF6 transduces both Canonical and Non-canonical Signaling to NF-κB
The transcription factor NF-κB is a member of the widely expressed family of
Rel-related transcription factors that are required for the induction of many genes. In
particular, these genes have been associated with the osteoimmunological and
neurobiological systems (Kuner, Schubenel et al. 1998, Arron and Choi 2000, Lorenzo,
Horowitz et al. 2008). Furthermore, NF-κB has been demonstrated to critically regulate
cancer, adaptive and innate immune response, apoptosis, inflammation, and cellular
differentiation (Li and Stark 2002). In mammals, the family has five members: p50, p52,
RelA (p65), c-Rel and RelB. NF-κB consists of a 50-kDa protein (p50) and a 65-kDa
protein (p65), as well as larger p100 and p105 heterodimers with smaller Rel family
isoforms of NF-κB. Family members can homo and hetero dimerize through a shared
300 amino acid N-terminal DNA binding/dimerization domain, called the Rel homology
domain, of which there are two different classes that possess a distinct intra-domain and
DNA binding specificity (Chen, Ghosh et al. 1998, Wang, Huang et al. 2012). Such
modularity provides a platform for differential binding to gene expression enhancers,
promoters and the control over gene expression. The extensive range of stimuli that
activates Rel family members underscores their importance in the integration of stimuli
for transcriptional responses.

The complete details by which such diverse stimuli

converge to activate this family of transcription factors have not yet been totally resolved
and remains a highly researched topic of scientific investigation (Mercurio and Manning
1999, Oeckinghaus, Hayden et al. 2011, Sun 2011).
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NF-κB is activated through two signaling cascades: the classical (canonical) and
non-canonical pathways. Regarding immunological systems, the canonical pathway has
historically been associated with inflammatory responses, while the non-canonical
pathway is described to mediate immune cell differentiation and maturation and
secondary lymphoid organogenesis. Such differential effects arise from differences in the
activation signals, regulatory mechanisms and involvement of specific NF-κB subunits.
The non-canonical pathway predominantly targets activation of the p100/RelB complex
via p100 processing to p52 to release the covalent IκBδ inhibitor, while the canonical
pathway activates RelA/p50 and other NF-κB dimer complexes inhibited by non-covalent
association with IκB and IκB inhibitors (n.b., p50 may be derived from constitutive
p105 processing to release the covalent IκB inhibitor). Despite the distinctions between
the two pathways, recent studies have revealed numerous crosstalk mechanisms between
pathways. This crosstalk involves control of NF-κB monomer expression, interdependent
proteolytic processing events of precursors, and the recent identification of IκBδ activity
that is induced by one pathway and subsequently degraded by another (Oeckinghaus,
Hayden et al. 2011, Shih, Tsui et al. 2011). Regardless of this revised model, a brief
review of the signaling mechanisms both distinct and common to each pathway remains
relevant for research (including this study) that involves activation by receptors of both
pathways, where TRAF6 overexpression can act as a surrogate or dominant positive for
NF-κB activity (Wang, Wara-Aswapati et al. 2006, Wang, Galson et al. 2010). The
ability of p62 (Sequestosome 1/SQSTM1) to complex with TRAF6 and other signaling
adapter proteins may explain how TRAF6 activates both canonical and non-canonical
NF-κB signaling pathways (de Jong, Albrecht et al. 2010, Zotti, Scudiero et al. 2014).
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Recently, OX40 (CD134) has been implicated in TRAF6 mediated non-canonical NF-κB
activity. OX40 is a member of the TNFR superfamily that is expressed on primary CD4+
T cells when they are activated by CD28+ TCR ligation. In activated primary CD4+ T
cells, OX40 co-stimulates the cells to sustain NF-κB activity in an antigen-independent
manner (Hildebrand, Yi et al. 2011).

Here, TRAF6 and cIAP2 were found to

cooperatively activate the non-canonical NF-κB pathway. OX40 directly recruited
TRAF6 and TRAF2/TRAF3/cIAP2/NIK complexes in which TRAF6 acted as the E3
ligase to mediate Lys63-linked polyubiquitination of cIAP2 (Fan, Xiao et al. 2015).
Taken together, TRAF6 can be considered another example of cells using adaptor
molecules to integrate the multi-variant receptor activation signals by converging on
limited, keystone effector molecules.
1.10 Mechanisms of NF-κB Regulation by phosphorylation of I-κB
Activation and nuclear translocation of NF-κB requires signal dependent
phosphorylation, ubiquitination and proteosomal degradation of I-κB (Beg, Finco et al.
1993, Heck, Bender et al. 1997). The classical pathway for NF-κB activation requires
IKK and IKKβ, as well as NEMO/IKK, whereas non-canonical signaling involves an
IKK complex composed of two IKKα subunits and are NEMO independent (Figure 1.3).
The canonical pathway is induced by pro-inflammatory signals such as cytokines,
pathogen-associated molecular patterns (PAMPs), and some danger-associated molecular
patterns (DAMPs). Receptor activation ultimately triggers IKK activity, where IκBα is
phosphorylated in an IKKβ and NEMO/IKKγ dependent manner. This results in the
nuclear translocation of mostly p65-containing heterodimers.

The non-canonical

pathway is induced by certain TNF family cytokines, such as CD40L, BAFF and
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lymphotoxin-β (LT-β) (Oeckinghaus, Hayden et al. 2011). Here, a stimulus such as
CD40L activates CD40 and NF-κB inducing kinase (NIK).

Activation of NIK is

classically regulated by TRAF3, TRAF2 and additional ubiquitin ligases. Receptor for
lymphotoxin-β (LT-βR) and leads to homodimerization and IKKα phosphorylation of
p100 associated with RelB, thereby resulting in the partial processing of p100 and the
generation of transcriptionally active p52-RelB heterodimers. There is speculation and
some evidence for an unidentified TRAF6 dependent pathway X (see above), stimulated
by CD40 that activates the IKK holoenzyme composed of all three subunits. In most
cases, the activity of this complex depends on IKKβ (Karin 2008).

One strategy for

treating CD40-driven inflammatory disorders is to block the downstream effectors of
CD40. Blocking TRAF6 in MHC II (+) cells diminishes inflammation, but is complicated
by CD40-TRAF6 blockade induced immunosuppression.
1.11 Dual targeting of proteins is a means for controlling cell signaling and transcription
Corralling genetic material and transcriptional machinery to the nucleus
segregates it from the translational and metabolic machinery in the cytoplasm. This
provides a regulatory opportunity for cell signaling and gene regulation using nucleocytoplasmic shuttling. Among the numerous examples of nucleo-cytoplasmic shuttling
proteins are the transcription factor 4 (Sox4) and its binding partner, the adapter protein,
Syntenin (Syn) (Zimmermann, Tomatis et al. 2001, Beekman, Vervoort et al. 2012).
Syntenin affects cancer cell motility and invasion through distinct biochemical and
signaling pathways, including focal adhesion kinase and p38 mitogen-activated protein
kinase (MAPK), resulting in activation of the NF-κB pathway (Boukerche, Aissaoui et al.
2010). Activation of NF-κB is a classical example of eukaryotic cell signaling regulation
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by subcellular sequestration via protein-protein interactions. Cells assemble proteins in
the cytosol, but use selective bi-directional transport between the cytoplasm and the
nucleus to regulate gene expression, signal transduction and cell cycle. Latent NF-κB
resides in the cytoplasm in an inhibited complex, bound by one of the IκB family
members, as previously discussed. IκB masks the nuclear localization signal (NLS) of
both the NF-κB р65 and p50 subunits from interacting with the karyopherin-α/importinβ1 complex, whereas IκB masks only one NLS, resulting in dynamic nucleocytoplasmic
shuttling (Malek, Chen et al. 2001). NLSs are short peptide motifs that mediate the
nuclear import of proteins by binding to karyopherins/importins. There are at least two
nuclear import pathways: 1) the classical nuclear localization sequences (cNLSs) which
involve the receptors importin-α/karyopherin-α and importin-β/karyopherin-β1; and 2)
the karyopherin-β2 pathway, involving the proline-tyrosine (PY)-NLSs and the receptor
transportin-1/karyopherin-β2 (Marfori, Mynott et al. 2011). β-karyopherins are a family
of soluble transport receptors that transport macromolecules through the nuclear pore
complex (NPC) by an energy-dependent process. Unmasking of the NLS on NF-κB p65
and subsequent nuclear import as the cargo of the ternary karyopherin-α/importinβ1/cargo complex requires proteosomal degradation of I-κB.

Untethered to the

cytoplasm, NF-κB enters the nucleus, where it binds to B binding sites affecting the
transcriptional profile of target genes (Baeuerle and Baltimore 1988, Baeuerle and
Baltimore 1989, Ghosh and Baltimore 1990).
The phenomenon of dual targeting or dual distribution of proteins is abundant in
eukaryotic cells. Echoforms is the term that for, identical or nearly identical proteins that
are dually/differentially localized/targeted within a cell. This contrasts with isoforms,

32

which are related, but distinct, proteins that may be similarly localized. The targeting of
echoforms can be determined prior to synthesis of the protein by generating multiple,
different mRNAs derived from a single gene, or dual targeting of a single translation
product (Figure 1.9). Regardless, the differential subcellular positioning of echoforms
strategically increases the complexity of eukaryotic signaling effectors from a finite pool
of gene products.

Kisslov et al reported that dual targeted proteins are more

evolutionarily conserved than proteins that are exclusively targeted. They argue that
maintenance of dual targeting is evolutionarily driven by a dual or discrete functionality
of a single protein in different cellular compartments, without regard to the dual targeting
mechanism (Kisslov, Naamati et al. 2014).
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Figure 1.9 Mechanisms for Dual Targeting of a Single Translation
Product. (A) Two signals compete for different organelles on the same
polypeptide. (B) Ambiguous targeting signal is recognized by two organelles. (C)
Changes in the targeting signal accessibility caused by protein (i) folding (ii) binding
to cellular factors (iii) modification or (iv) cleavage by a protease that exposes a
targeting signal. (D) Reverse translocation, polypeptides move back to the cytosol
during translocation into an organelle. (E) Trapping of proteins in an organelle by
folding. (F) Export of proteins out of an organelle. (G) Release of proteins from
organelles due to membrane permeabilization or breakage. (H) Vesicular release of
proteins from organelles. (I) Release of proteins from organelles through tethering
of membranes. Used with permission from the author (Kalderon and Pines 2014).
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1.12 Sox4 Molecular Domain Structure and Function
All Sox-family proteins share a conserved SRY‐ box or HMG‐ box (high
mobility group‐ box) AT-rich DNA binding domain. Sox transcription factors were
initially identified with the discovery of the sex determining factor, sex determining
region on Y Chromosome (SRY) (Gubbay, Collignon et al. 1990). SRY and Sox proteins
are highly conserved in the HMG domain and belong to the same subgroup within the
superfamily of HMG-box proteins. In this superfamily, Sox proteins are characterized by
having a single HMG domain that binds DNA in a sequence specific manner. Sox
proteins bind to the minor groove of DNA via the consensus sequence 5’‐ A/T A/T CAA
A/T G‐ 3’ (Laudet, Stehelin et al. 1993, Harley, Lovell-Badge et al. 1994). When Sox
proteins bind to the DNA minor groove, the DNA bends at an angle of 70-85° providing
an additional structural component to the gene regulatory mechanism (Werner, Bianchi et
al. 1995, Jauch, Ng et al. 2012). The Sox family can be subdivided into groups A
through H based upon a consensus within the HMG box sequence. Sox4 is a member of
the C subgroup of Sox proteins, which also includes Sox11 and Sox12 (Bowles, Schepers
et al. 2000). Group C members are distinguished from other Sox family subgroups by a
conserved C-terminal transactivation domain (Figure 1.10). The HMG box of Sox4 binds
to and bends DNA with high affinity to the minor groove of DNA with the sequence
AACAAT with the optimal 10bp sequence containing 5’ AG and 3’ G nucleotides
directly adjacent to the core sequence (Vervoort, van Boxtel et al. 2013). The SoxC
proteins Sox4/11/12 are expressed widely in embryonic tissues, with the highest
expression levels found in neural
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Figure 1.10 Comparison of Murine and Human Domain Structure of the SoxC
Group Family of Proteins. Sox4, Sox11 and Sox12 (formerly known as Sox 22)
constitute the group C of Sry-related HMG box proteins. Members feature two
functional domains: an Sry-related HMG box (Sox) DNA-binding domain and TAD
comprised of the last 33 amino acids of the C terminus. The TAD is 66% identical
across all vertebrate SoxC proteins, 97% identical amongst Sox4 and Sox11
orthologues and 79% identical amongst Sox12 orthologues. SoxC protein domain
architecture critically control cell fate and differentiation in major developmental
processes, and that their up regulation may be a critical determinant of cancer
progression. Human molecular domain positions are derived from those reported
by (Penzo-Mendez, Dy et al. 2007) and denoted in UniProt, * Denotes Murine
amino acid positions as described by (Dy, Penzo-Mendez et al. 2008).
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and mesenchymal progenitor cells. Sox4 was first identified as a transcription factor
required for B- and T-lymphocyte differentiation. The expression pattern of Sox4 during
mouse embryogenesis has been analyzed by both whole mount and section in situ
hybridization studies, which show that Sox4 is expressed in the mesenchyme of the
branchial arches, trachea, esophagus and nervous system (Maschhoff, Anziano et al.
2003). Later in embryonic development, Sox4 is expressed in the embryonic growth
plate where its expression is regulated via parathyroid hormone and parathyroid
hormone-related protein receptor. Sox4 and Sox11 knockout mice develop multiple organ
defects (Schilham et al., 1996; Sock et al., 2004), whereas Sox12 knockout mice are
grossly normal (Hoser et al., 2008). However, various combinations of homo- and
heterozygous SoxC mutations indicate that continued and cumulative activities of these
three genes are required for widespread organ development; increasingly severe organ
hypoplasia phenotypes were found with decreasing wild-type SoxC alleles (Bhattaram et
al., 2010). Partially SoxC-deficient embryos (Sox11-/-, Sox4+/- Sox11+/-, etc.) also display
malformation of various organs. For example, Sox4-/-Sox11-/- embryos are minute at E9.5
and show highly severe organ defects and extensive cell death. Nevertheless, these
embryos appropriately express genes involved in cell lineages and embryo patterning,
such as Pax1/7, Otx2 (orthodenticle homolog 2), Shh and Bmp4 (bone morphogenetic
protein 4) (Bhattaram et al., 2010). This suggests that SoxC proteins play important roles
during early embryogenesis in sustaining neural and mesenchymal progenitor cells, rather
than in cell lineage specification. In support of this, a reported target of SoxC
is Tead2 (TEA domain family member 2), which is a transcriptional mediator of the
Hippo signaling pathway that is crucial for organ size regulation (Bhattaram et al., 2010).
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Additionally, Sox4-deficient mice exhibit arrest of B-cell development at the pro-B-cell
stage. Thus, Sox4 appears to be critical for normal development and maturation of
endocardial cushions and for normal B-cell maturation. However, its function(s) in these
processes is not yet clear (Maschhoff, Anziano et al. 2003). Interestingly, Sox4 and
Sox11 have been shown to have redundant functions in multiple systems, including an
importance in the establishment of pan-neuronal protein expression and retinal ganglion
cell development (Bergsland, Werme et al. 2006, Jiang, Ding et al. 2013).
1.13 Sox4 localization depends on Syntenin
Transcription factors like NF-κB and Sox proteins need to be translocated to the
nucleus after translation in order to bind DNA and directly regulate gene expression.
Control of the import and export of transcription factors is important for cell development
and defense scenarios.

Improper nucleo-cytoplasmic shuttling of Sox transcription

factors is associated with cancer and developmental disorders. Mutations or problems
that disrupt the proper timing, location or expression levels of Sox factors can lead to
defects in organogenesis or other developmental disorders such as human sex reversal
syndrome (HSR). The etiology of HSR is defective nuclear import of SRY and Sox9
(Preiss, Argentaro et al. 2001, Smith and Koopman 2004). Sox4 has a bipartite nuclear
localization signal (BP-NLS or -NLS) at positions 60-77 and 129-136, as identified by
the Nuclear Protein Database (NPD, http://npd.hgu.mrc.ac.uk/user/index.php). Half of
Sox4’s BP-NLS is located within the N-terminus of the HMG box and just distal to it
within the C-terminus, and allows Sox4 to be dually localized to both the nucleus and the
cytoplasm (Figures 1.11). Sox4 has been reported to accumulate with Syntenin in the
nucleus (Farr, Easty et al. 1993, Beekman, Vervoort et al. 2012). Syntenin interacts with
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both the NTD and CTD of Sox4, but binds to 33 C-terminal residues of Sox4 to prevent
poly-ubiquitin independent proteosomal degradation of Sox4 and co-relocalization with
Syntenin to the nucleus.

Figure 1.11 Sox4 Protein Domain Organization and Amino Acid Sequence. A)
Molecular Architecture of Human Sox4 Domains B) primary amino acid sequence
annotated to show a Bi-Partite Nuclear Localization Signal (Underlined) (Kaur,
Delluc-Clavieres et al. 2010), and a potential TRAF6 Interaction Motif (Red). GRR
and SRR represent glycine- and serine- rich regions respectively that are subject to
posttranslational modification and either supports (GRR) or abrogates (SRR)
apoptosis (Hur, Hur et al. 2004).
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1.14 Syntenin is a dual PDZ domain containing scaffolding protein
The SDCBP gene encodes the 298aa, 33kDa protein, Syntenin-1 (Syn). Syn was
initially identified as a binding partner of syndecan-1 (Grootjans, Zimmermann et al.
1997). Concurrently, Syn was also identified as a melanoma differentiation-associated
gene 9 (mda9) in a melanoma cell line treated with IFN-γ (Lin, Jiang et al. 1998). Syn is
an adapter protein that couples transmembrane proteoglycans with cytoskeletal
components and is involved in intracellular vesicle transport.

Structurally, Syn is

composed of an N-terminal domain comprised of the first 113 amino acids followed by
two adjacent PDZ domains (PDZ1 and PDZ2) and a short 24 amino acid CTD (Figure
10).

The NTD can recruit the transcription factor Sox4 and eukaryotic translation

initiation factor 4A (EIF4A) into signaling complexes and is important for
homodimerization and heterodimerization with Syntenin 2 (Geijsen, Uings et al. 2001).
Within the NTD of Syn are tyrosine residues that can be targeted by Src kinase for
phosphorylation and act as docking sites for zeta-chain-associated protein 70 (ZAP70)
and Src kinases (Beekman and Coffer 2008, Read and Gorman 2009). Importantly, the
NTD has been demonstrated to be involved in binding both free ubiquitin and
ubiquitinated proteins. Specifically, the L4YPXL motif (amino acids 3 to 7 in Figure 10)
was demonstrated to be a novel ubiquitin-binding motif for Syn binding ubiquitin as an
obligate dimer. The three LYPXL motifs in the NTD at positions 5, 47 and 51, are
necessary for the interaction with ALIX/Aip1 during syndecan-lead cargo recruitment to
exosomal compartments (Rajesh, Bago et al. 2011). ALIX/Aip1 is a Lys 63-specific
polyubiquitin binding adaptor protein that may regulate retroviral budding, endosome and
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receptor trafficking and cytoskeleton-associated tyrosine kinases (Trioulier, Torch et al.
2004, Dowlatshahi, Sandrin et al. 2012).
The CTD of Syn has been shown to be necessary, but insufficient, for interaction
with CD63, and along with the NTD stabilizes the full length protein (Cierpicki,
Bushweller et al. 2005).

Both the NTD and CTD have been shown to regulate

interactions between the PDZ domains of Syn and its binding partners, as mentioned
above. Additionally, phosphorylation of the NTD disrupts Syn interaction with the
receptor protein tyrosine phosphatase (rPTP) CD148, demonstrating that posttranslational modifications of the NTD affect interactions between the dual PDZ domains
and binding targets (Harrod and Justement 2002). Recently it has been shown that the Nand CTD of Syn modulates targeting to the plasma membrane. Phosphorylation of Tyr56
in the NTD decreases Syn localization of to the plasma membrane, while the basic
residues K280/R281 at the CTD increased localization to the membrane (Wawrzyniak,
Vermeiren et al. 2012). It remains unclear however, the exact mechanism by which the
N- and CTD of Syn contribute to Syn function.
Postsynaptic density protein, Disc large, Zona occludens (PDZ) domains are
protein-protein interaction modules that predominate in submembranous scaffolding
proteins. The PDZ domains of Syn serve as scaffolds for binding multiple peptide motifs
with low to medium affinity (Beekman and Coffer 2008). However, these PDZ domains
bind to multiple peptide motifs (class I, class II and other sequences) with low to medium
affinity, rather than by a unique sequence. Such degenerate specificity is not unique to
the Syn PDZ domains, but accounts for Syn localization, tissue expression and
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Figure 1.12 Molecular Domains and Interaction Motifs of Syntenin. Human
Syntenin is a 33Kda protein encoded by 298 amino acids. Above the diagram of the
linear sequence is a ribbon model of the tandem PDZ domains showing the
unstructured linker (194-204) that may contain an imperfect T6IM. Below the
cartoon is the amino acid sequence for human Syn, annotated with specific domains
and binding motifs for TRAF6 and Ubiquitin (Underlined).
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scaffolding protein function. Syntenin is widely expressed in all adult tissues (Grootjans,
Zimmermann et al. 1997, Zimmermann, Tomatis et al. 2001).
Most protein ligands show preference for the PDZ2 domain of Syn, but peptides
derived from IL-5Rα, merlin and neurexin interact with the PDZ1 domain with high
affinity (Beekman and Coffer 2008). Additionally, the Syntenin PDZ domains have been
found to interact with membrane lipids using surface plasmon resonance experiments
with liposomes modeled after the inner leaflet of the cell membrane. Syn directly and
strongly

interacts

with

membrane

phosphoinositol

lipids

and

especially

phophatidydylinsositol (4,5) bisphosphonate (PI(4,5)P2) (Zimmermann, Tomatis et al.
2001, Zimmermann, Meerschaert et al. 2002, Zimmermann, Zhang et al. 2005). Later
studies showed that Syntenin-2 also interacts with PI(4,5)P2 and organizes nuclear
PI(4,5)P2 pools, which are crucial for cell survival and proliferation (Mortier, Wuytens
et al. 2005). However, PDZ domain affinity for PI(4,5)P2 is insufficient for directing
PDZ-containing proteins to subcellular PI(4,5)P2 pools or to compartments rich in other
phosphoinositides). This is akin to what is known for most PH domains, which also
weakly bind PI(4,5)P2 and cannot solely target their host proteins to phosphoinositide‐
rich domains (Lemmon 2003). Since PI(4,5)P2 is not present in certain cellular
compartments, this could represent a way to direct Syn to interact with a subset of protein
targets enriched within specific subcellular compartments. While the dual PDZ domains
of Syn are independent, and can independently integrate with C-terminal peptides,
binding studies suggest that an intact full tandem PDZ works cooperatively (Grootjans,
Zimmermann et al. 1997). Crystal studies reveal extensive contact sites between the
domains which are tethered by a short, unstructured five residue linker (Cierpicki,
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Bushweller et al. 2005).

Such intramolecular interactions fix the PDZ domain

orientation. This orientation coupled with moderate affinities for the C-terminus of
various peptides may be the structural underpinnings for the assembly of multimeric
protein complexes (Figure 1.13).
Syn activation of the PI3K-Akt pathway in human melanoma cells has been
linked to increased angiogenesis. Fibronectin activation of Focal Adhesion Kinase (FAK)
and c-Src kinases is modulated by Syn and initiates the PI3K-Akt pathway. Activated Akt
causes Hypoxia-inducible factor 1α (HIF-1α) translocation to the nucleus, which induces
insulin growth factor-binding protein-2 (IGFBP-2) expression. After secretion, IGFBP-2
interacts with αVβ3 integrin on endothelial cells, supporting pro-angiogenic factor
Vascular Endothelial Growth Factor A (VEGF-A) expression (Das, Bhutia et al. 2012).
Finally, Syn was shown to directly interact with TRAF6, resulting in IL-1R and TLR-4induced NF-κB activation (Chen, Du et al. 2008).
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Figure 1.13 Structural Basis for select Syntenin protein-protein Interactions.
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Chapter 2
HYPOTHESIS AND SPECIFIC AIMS

Proper cellular response to both internal and external signals requires exact
spatio-temporal positioning of intracellular components to facilitate their interaction and
organize a coordinated response from a limited number of cellular effector molecules.
Adaptor molecules are used to assemble protein complexes to converge diverse signaling
pathways under variant conditions. TRAF6 is a keystone adapter protein that transduces
signaling from a wide array of upstream receptors. TRAF6 is able to uniquely interact
with proteins via its structural architecture and biological activities Specifically, its ability
to auto-ubiquitinate, which sustains downstream E3 ligase activity and signaling as well
as its unique MATH domain, which bears a TIM groove. The TIM groove allows
TRAF6 to uniquely interact with TRAF6 interaction motif (T6IM) peptides and T6IM
bearing proteins.

Further, it has been shown that TRAF6 can also make intra and

intermolecular interactions head to head (RZ-RZ) and head to tail (RZ-MATH) to
autoinhibit downstream signaling (Yin, Lin et al. 2009, Wang, Galson et al. 2010).
Overexpression of just the coiled-coil plus MATH domain sequence (ccMATH) has a
dominant-negative effect on IL-1β/LPS signaling, as well as an antagonistic effect for
TRAF6 recruitment by upstream activators (Darnay and Aggarwal 1999). Similarly,
ectopic expression of TRAF6WT or RZcc can act as a dominant positive and GFP fused
TRAF6 constructs localize to the cytoplasm (Baud, Liu et al. 1999, Wang, WaraAswapati et al. 2006, Wang, Galson et al. 2010).

Since ectopic dominant-positive

expression is independent of upstream activators, I hypothesized the existence of
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additional potential inhibitory intra- and inter-molecular interactions between the MATH
domain and TIM bearing proteins and sought to continue investigating TRAF6 regulation
and dynamics. In a timely study by Chen et al., overexpression of Syn was found to
inhibit TIR signaling to NF-κB, but not TNFα induced NF-κB activation in a dose
dependent manner.

Furthermore, Syn associates with TRAF6 under physiological

conditions, and dissociates from TRAF6 upon TIR stimulation (Chen, Du et al. 2008).
Therefore, there may exist competition for TRAF6 between IRAK1 and Syn, as
overexpression of IRAK1 disrupted the interaction of Syn with TRAF6 or Syn might
otherwise sustain the auto inhibitory effect of closed RZ-MATH associated TRAF6.
Initially I hypothesized that Syn associated with TRAF6 via a putative T6IM, but
surprisingly, Syn was also able to inhibit the RZcc dominant positive activity for NF-κB.
This observation coupled with the discovery that Syn overexpression caused the
intranuclear relocalization of TRAF6 into the nucleus made me consider the possibility
that Syn was acting as an adapter protein for another T6IM bearing protein that directly
associated with TRAF6.

Another timely paper was published characterizing the

stabilizing effect of Syn binding to the CTD of Sox4 (Beekman, Vervoort et al. 2012) and
I quickly discovered a novel T6IM within Sox4, perhaps providing a mechanism for
Syn’s effect upon TRAF6 activation and subcellular localization.
2.1 Overall Goal
The overall goal of this study is to identify novel TRAF6 Interaction Motif
(T6IM)-bearing proteins that interact with TRAF6 and characterize their regulatory
functions mechanisms upon downstream signaling. Such insights will help to explain the
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phenomenon in which over-expressed ectopic TRAF6 in 293 cells acts as a dominant
positive for NF-κB activity.
2.2 Hypothesis
1. TRAF6 Interaction Motif (T6IM) controls TRAF6 signaling-bearing proteins such
as IRAK1, disrupting TRAF6 RZ-MATH domain auto-regulation and competes
with another inhibitory TIM-based TRAF6 binding protein.

2. Syn uses the T6IM bearing transcription factor, Sox4 as an adapter molecule to
coordinately both inhibit TRAF6-dependent NF-κB activity and to also
translocate cytoplasmic TRAF6 into the nucleus.
2.3 Specific Aims
Aim 1. Characterize IRAK1 modulation of TRAF6 auto-regulation and localization
Aim 2. Identify the molecular determinants of Syntenin-1/TRAF6 interaction
Aim 3. Understand the nature of Syntenin-mediated nuclear localization of TRAF6
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Chapter 3
MATERIALS AND METHODS

3.1 Cell Culture
All cell lines were maintained at 37°C under 5% CO2 in sterile 100x20mm tissue
culture dishes treated by Vacuum Gas Plasma (BD Biosciences). Human 293 (CRL1573) and 293T (CRL-11268) cells were obtained from American Type Cell Collection
(Manassas, VA) and were cultured in EMEM medium supplemented with 10% heat
inactivated fetal bovine serum (Tissue Culture Biologicals Lot #103283), 2 mg/mL LGlutamine and 1% penicillin/streptomycin solution (Sigma).

293R cells are stably

transfected 293 cells (American Type Culture Collection CTRL-1573) that ectopically
express the IL-1R receptor (Wang et al., 2006). 293R cells were maintained and cultured
in the same culture media as the 293 and 293T cells. 293R cells were cultured from
cryopreserved aliquots of cells previously derived as described (Asea, Rehli et al. 2002,
Yoshida, Kumar et al. 2004).
THP-1 cells were cultured in RPMI media (10-040-CV, Cellgro) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 1% Penicillin/Streptomycin
Solution (30-002-CI, Cellgro) and 500 µl of 2ME (21985-023, Invitrogen). Murine RAW
264.7 (#TIB-71, American Type Culture Collection, Manassas, VA) were cultured in
DMEM (10-013-CV, Cellgro) supplemented with 10% heat-inactivated fetal bovine
serum

(HyClone

SH30070

Lot#AYC60564,

AWC10533)

Penicillin/Streptomycin Solution (Sigma) at 37°C under 5% CO2.
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and

1%

Rat PC12 pheochromocytoma cells were provided by Dr. Yong-Jian Liu
(University of Pittsburgh) and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% horse serum and 5% fetal calf serum (Invitrogen,
USA). For experiments, PC12 cells were seeded onto matrigel (Corning) treated
multiwell Lab-Tek Chambered Coverglass (Nunc) for at least 24 hours prior to treatment.
NGF (100 ng/mL) was then added. Neurite outgrowth was measured using a modified
protocol as previously described, at 24-hour timepoints up to 120h as indicated in the
legend to each figure (Park, Lee et al. 2002, Hong, Noh et al. 2003)
Murine 4B12 cells and calvaria-derived stromal (CDS) cells were a gift from Dr.
Lynda F. Bonewald (University of Missouri at Kansas City, MO). 4B12 and CDS cells
were cultured separately in α-MEM (SIGMA#M4526), containing L-glutamine
(2.92mg/mL) (GIBCO#12561) supplemented with 10% Fetal Bovine Serum (Hyclone),
penicillin/streptomycin at 100 U/mL; or α-MEM supplemented with 10% Fetal Bovine
Serum, penicillin/streptomycin, L-glutamine (GIBCO#10378-016). The 4B12 cells are
maintained in α-MEM supplemented with 10% FBS and 30% calvarial-derived stromal
cell conditioned media (CSCM). To prepare CSCM, calvaria-derived stromal cells were
cluttered until confluent in α-MEM supplemented with10% FBS. Media was changed,
and cultured for an additional 4 days. Conditioned media was then collected and
centrifuged to remove cell debris (10000 Å~ g, 30 min), and filter through a 0.45 /um
pore-size filter. CSCM was then added at ~10mL media/55cm2 or 30mL/150cm2 dish.
Murine ST2T cells were established by infecting the mouse stromal line ST2 with
the retroviral vector expressing RANKL and provided by Dr. Deborah L. Galson
(University of Pittsburgh) (Lean, Matsuo et al. 2000). For co-culture, bone marrow cells
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or RAW264.7 were seeded at 6x105 cells/cm2 with 6x104 /cm2 ST2-T cells and cultured
in the presence of 108 M 1,25-dihydroxyvitamin D3 and 107 M dexamethasone.
For osteoblast-free culture, 4B12 and RAW264.7 cells were cultured in the
presence of 10 ng/mL recombinant human M-CSF (Genzyme) and 50 ng/mL
recombinant mice RANKL (R&D Systems) to generate osteoclast-like cells. Cells were
plated overnight at a density of 2 × 104 cells/well in a 6-well plate in DMEM (Life
Technologies, Inc. Rockville, MD) and heat inactivated 10% FBS (HyClone). The next
day the medium was changed to DMEM supplemented with 10% FBS and 50 ng/mL
RANKL (R&D Systems). After 24h, the medium was replaced by DMEM, pH 7.2
[13.53 g DMEM (Sigma), 0.78 g sodium bicarbonate (Sigma), 10% FBS, and 50 ng/mL
RANKL (R&D Systems). For each sample, cells were fixed and stained for tartrateresistant acid phosphatase (TRAP) or lysed for RNA extraction.
3.2 Transfections
Reporters or expression plasmids were transfected into cells with FuGENE HD
transfection reagents (Roche Applied Science, Indianapolis, IN) or X-tremeGENE HP
transfection reagent (Roche Applied Science, Indianapolis, IN). At least one day before
transfection, cells were seeded into tissue culture plates (Bioscience) or Lab-Tek
Chambered Coverglass (Nunc) at a density = Relative Area * 2x104 according to the table
below with normal culture media and allowed to settle overnight.
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PLATE SIZE
96 well
24 well
12 well
6 well

GROWTH AREA (cm2)
0.32
1.88
3.83
9.4

Relative Area
1x
5x
10x
30x

Table 3 Cell Density Seeding Formula for Various Tissue Culture Plates. Relative
Growth Area (cm2) for tissue culture plates used in determining seeding density of
cells prior to transfection
Prior to transfection, cells were allowed to reach 60-70% confluency. A 3:1
reagent (μl) : DNA (μg) ratio was used in all transfections. This mixture was prepared as
a 1:1 (volume : volume) of transfection reagent (TR):DNA. Plasmids were added into a
microfuge tube with proper volume of serum-free Opti-MEM medium (Gibco). Room
temperature FuGENE HD or X-trememGENE HP was diluted in another microfuge tube
with an equal volume of serum-free Opti-MEM medium as that used for plasmids, The
TR solution was then added directly to the plasmid solution, mixed gently and incubated
at room temperature for 15-20 min. The plasmid-TR mixtures were then added (drop
wise) into indicated wells containing the pre-seeded cells and incubated at 37oC under
5% CO2 for at least 24 hours prior to subsequent treatment or analysis.
3.3 Luciferase bulk-cell assay for NF-κB activity
The NF-κB luciferase reporter, NF-κB/pGL2, contains a c-fos core promoter and
four tandem repeats of NF-κB p65/p50 heterodimer binding sequences (Yoshida, Kumar
et al. 2004). The XT-Luc IL1B vector was generated previously as described in (Unlu,
Kumar et al. 2007). Briefly, BDC454 clone (Clark et al., 1986;Shirakawa et al., 1993)
was partial digested with XbaI and TaqI to remove the appropriate length of human
genomic IL1B DNA from −3757 downstream to +12. This 3.76 kbp sequence was
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inserted into the SmaI site of the pGL3Basic vector. The IL-1β XN Luciferase reporter
was generated according to the Figure 3.1 in collaboration with Dr. Luke O’Neill (Trinity
College, Dublin, Ireland). In most cases 20ng of luciferase reporter was co-transfected
with indicated expression plasmids into cells for at least 24 hours prior to assay, with the
transfection procedure described in the previous section.

Luciferase Assay System

(Promega, #E-1501) was used to quantify NF-κB activity. 1x cell lysis buffer (Promega,
Madison, WI) was freshly prepared and allowed to equilibrate to room temperature. The
transfected cells were then lysed with 50μL of 1X cell lysis buffer in each well and
shaken for 20 min. 20 μl of supernatant from each well was used for luciferase activity
analysis using a VERITAS luminometer (Turnaer BioSystems, Sunnyvale, CA)
according to the manufacturer’s instructions.
3.4 Reporters and Expression Plasmids
The human wild-type TRAF6 and mutant coding sequences were engineered in
both untagged pcDNA3.1 (ﬂ) and dual-tagged pFLAG CMV 5a-YFP expression vectors
in the EcoRI and EcoRV sites by PCR subcloning strategies. The sequences coding for
TRAF6 (1-273) is designated as RZ; TRAF6 (1-358) as RZcc; TRAF6 (346) were
subcloned into pFLAG CMV 5a plasmid (Sigma-Aldrich) as previously described
(Wang, Galson et al. 2010). A mutant version of full-length TRAF6 containing lysine
(K) to arginine (R) mutations at all lysine residues (referred to as TRAF6Δ K32-518R or
TRAF6ΔK) and murine TRAF6 (mTRAF6) were provided as a gift by Dr. Yongwon
Choi (University of Pennsylvania School of Medicine) (Walsh, Kim et al. 2008).
The tagged human wild-type Syn and mutant Syn expression plasmids were a gift
from Dr. Paul J. Coffer (Utrecht, Netherlands). Murine Syntenin-1 in pCMV-Sport6
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expression vector was purchased from Open BioSystems (Thermo Scientific Catalog
#MMM1013-77128). Human Sox4 and SDCBP (Syn) in pLX304 expression vectors
were purchased from DNASU plasmid repository (Arizona State University, Tempe,
AZ). Tec kinase, BTK and variant expression vectors were provided by Dr. Lawrence P.
Kane (University of Pittsburgh). Both full-length murine Tec and BTK and their PH
domains (first 152 aa Tec & first 174 aa for BTK) were inserted into vector pEGFP-N1
(Clontech) between Xho1 and BamH1 in the multi-cloning site (MCS) of the vector.
These engineered Tec kinase family reporters are CMV-driven and have Kan/Neo
resistance. The HcRed tagged human Sequestosome-1/P62 expression plasmid (P62HcRed) was previously created in our lab (Wang, Galson et al. 2010) using human p62pcDNA3.1 (courtesy of Dr. Deborah Galson, University of Pittsburgh) and a pFLAG
CMV5a-HcRed1 expression plasmid. Briefly, using PCR, the NLS was deleted from the
HcRed1/Nuc vector (Clontech) and HcRed1 was then inserted into the Eco RV and Bam
HI sites of pFLAG-CMV5a. P62 was then cloned from p62-pcDNA3.1 by PCR and
newly generated EcoRI and BglII sites were used to insert the sequence into the pFLAGCMV5a-HcRed1 plasmid. The human MyD88 and HA-tagged human TLR4 plasmid
was provided by Felix Randow and prepared as previously described (Randow and Seed
2001, Asea, Rehli et al. 2002). pEYFP-C1 vector was obtained from Clontech (Mountain
view, CA Catalog #6005-1).

54

Figure 3.1 Schematic Map and Design of PGL2- IL-1β-XN Luciferase Reporter.
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Expression
PLASMIDS
LV Syntenin
LV Sox4
mTRAF6

mSyn
F-Syn
ΔN Syn
ΔPDZ1+2 Syn
ΔPDZ1
ΔPDZ2
mKATE Syn
Myc Syn
XN
XT
IRAK1
MyD88
TRAF6ΔK
TRAF6C70AYFP
TRAF6-YFP
EYFP
TRAF6-EYFP
TRAF6
TRAF6
IRAKHcRed
Akt-GFP
BTK-GFP
Tec-GFP
PH-ATK-GFP
PH-BTK-GFP
PH-Tec-GFP
TLR4

VECTOR
pLX304
pLenti6.2/
V5-DEST
pFLAG
pCMVSPORT6
pFLAG
pMT2
pMT2
pcDNA3
pMT2
pcDNA3
pcDNA3
pGL2
pGL2
pcDNA
pcDNA
pFLAG
pFLAG
pFLAG
pEYFPC1
pcDNA
pcDNA3.1
pFLAG
pcDNA

pcDNA

species

source

label/tag

human

DNASU

-

human
murine

DNASU
Choi

FLAG
o

murine
human
human
human
human
human
human
human
human
human
human
human
murine

Section 1.01
penBiosyste
ms
Coffer
Coffer
Coffer
Coffer
Coffer
Coffer
Coffer
O'Neill
Auron
Auron
Auron
Choi

Human
Auron
human
human
human
human
human
human
human
human
human
human
human

Auron
Auron
Clontech
Auron
Auron
Auron
Auron
Kane
Galson
Galson
Kane
Galson
Galson
Randow

FLAG
HA
HA
HA
HA
mKATE
Myc
Luciferase
Luciferase
FLAG
FLAG/Y
FP
EYFP
EFYP
EYFP
FLAG
HcRed
GFP
GFP
GFP
GFP
GFP
GFP
HA

Table 4 Expression and Reporter Plasmids Used in this Study.
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clone ID
HsCD00
436572
HsCD00
329922

Section 1.02
017442

6005-1

4

Figure 3.2 Schematic Maps of the TRAF6 constructs Used in this Study. All
constructs were FLAG tagged or dually tagged with FLAG and YFP in subcellular
localization studies. Construct design and preparation was as previously described
(Wang, Galson et al. 2010). The C70A mutein was prepared by site-directed
mutagenesis and subcloned into the TRAF6-YFP construct. TRAF6ΔK and the
corresponding murine wtTRAF6 plasmid were provided by Dr. Y.W. Choi
(University of Pennsylvania) (Walsh, Kim et al. 2008).
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Figure 3.3 Schematic Maps of the Syn Constructs Used in this Study. All human
sequence constructs were HA tagged and verified by sequencing.
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3.5 Statistical Analysis
In all bulk cell luciferase assays, RLU values are reported as the mean of three
experimental replicates along with the associated standard deviation (s.d.) for this
calculated mean to quantify the scatter or variability between experimental replicates.
Each experiment was then repeated at least three times to verify the overall trend and
pattern of the experimental results. Graphs then are a single experiment containing three
experimental replicates, representative of results from at least three biological replicates.
The reported error for each mean provides an estimate of the s.d. of the overall
population from a small sample size rather than the precision of the experimental mean to
the actual population mean. SEM can be misleading because by definition it produces a
smaller value than the s.d. SEM was not reported because SEM quantifies how precisely
you know the true mean of the population, which is more appropriate in cases with large
sample sizes. Recently, concern over the wide misuse of P values has been addressed
(Baker 2016). In this study, the nature of the TRAF6 dominant positive signal is robust
enough (orders of magnitude) that, it not only serves as an internal positive control but
also obviates the need to calculate statistical significance in observed differences.
3.6 Immunoprecipitation and Western Blotting
Western blotting. After indicated treatments, 293 or 293T cells were detached by
pipetting and transferred to microcentrifuge tubes. Cells were spun down with a benchtop microcentrifuge at 5000 rpm for 3 min. aspirated culture medium and washed
remaining cell pellets once with 1xPBS. Pellets were re-suspended in 50μL of ice-cold
lysis buffer per 106 cells. Cell lysate was then incubated on ice for 30 minutes with
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vortexing every 10 minutes, and then centrifuged at 14,000 rpm (10,000-15,500x g) at
4°C for 10 minutes. Supernatant was harvested and mixed with an equal volume of
2xSDS-PAGE sample buffer supplemented with fresh 2-mercapto ethanol (Bio-Rad) and
incubated at 98°C for 15-30 min. Heat denatured samples were then loaded into a precast
4-12% gradient SDS-polyacylamide gel (Lonza) and run with 1x Laemmli buffer (25mM
Tris, 192mM Glycine, 0.1% SDS; pH 8.3) at 100V for about 2 hours. Resolved proteins
were transferred from the SDS-polyacrylamide gel onto a PVDF membrane in 1X Tobin
buffer (3.03g TRIS, 14.4g glycine, 150mL methanol per liter of solution, pH 8.3).
Membranes were incubated in 5% non-fat milk with 1xTPBS (10 mM phosphate,
140mM NaCl, 3 mM KCl, 0.05% Tween 20; pH 7.4) with slight shaking for 1 hour, and
then incubated with indicated primary antibody for another 1-2 hours at RT with shaking
or O.N. at 4°C. Membranes were then washed in 1xTTBS with slight shaking for 3-5
minutes to remove primary antibody. The membrane was then incubated in a 1:10,000
dilution of secondary antibody in 5% non-fat milk with 1xTTBS with slight shaking for 1
hour. The secondary antibody was removed and the membrane washed in 1xTTBS with
slight shaking for 3-5 minutes.

Finally, the membrane was incubated with

chemiluminescent substrate (Thermo Scientific, Waltham, MA) at RT for 5 minutes to
prepare for signal visualization by X-ray film exposure.
Immunoprecipitation. Cell lysate supernatant was diluted using the same type of
lysis buffer as described above into 200μL per 106 cells. A specific antibody was added
and the sample and then rocked at 4°C for 2-5 hours. Then, 30μL of 50% protein A/G
conjugated agarose slurry (Protein A/G PLUS-Agarose IP Reagent sc-2003) pre-absorbed
by non-specific IgG (Normal rabbit IgG sc-2027, Santa Cruz Biotechnology) was added
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to each sample tube and rocked at 4°C overnight. The next day, agarose beads were
centrifuged at 10,000rpm for 1 min. Supernatant was then aspirated and beads rinsed
with 500μL lysis buffer three times. 100μL 1xSDS-PAGE sample buffer was added to
each sample tube containing the agarose beads. Re-suspended agarose beads by vortexing
and then incubated at 98°C for 10 minutes. SDS-PAGE and immuno-blotting procedures
followed as described above for sample analysis.
3.7 Reagents and Antibodies
Depending on the experiment, RAW264.7 or 4B12 cells were stimulated with
either 1μg/mL of E. coli 055:B5 Lipopolysaccharide (LPS) (Sigma) or 50ng/mL
recombinant murine RANKL (R&D Systems) for indicated time periods. RAW264.7 or
293R cells were stimulated with 100ng/mL IL-1β (Millipore) for 6-8 hours prior to assay.
In neurite growth assays, 293 and PC12 cells were stimulated with 50ng/mL
recombinant human NGF (Millipore) for indicated time periods. The primary antibodies
for immunoprecipitation experiments include: Rabbit anti HA-probe (Y-11) (Santa Cruz
Biotechnology, sc-805), Rabbit anti TRAF6 (H-274) (Santa Cruz Biotechnology, sc7221), Goat anti Sox4 PAb (c-20) (Santa Cruz Biotechnology, sc-17326), Mouse anti
HA-Tag (6E2) ( Cell Signaling Technology, 2367S), Mouse anti GFP mAb (4B10) Cell
Signaling Technology, 2955S), and mouse IgG1 anti FLAG M2 Monoclonal Ab F1804
(Roche). For western blotting, the secondary HRP conjugated antibodies were purchased
from Santa Cruz Biotechnology, including: Donkey anti-Goat HRP (sc-2020), Goat antiRabbit IgG-HRP (sc-2004), Donkey anti Goat HRP (sc-2020), Goat anti-mouse IgG-HRP
(sc-2031). In imaging studies, the Syntenin primary antibody was used to visualize
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subcellular localization was purchased from Abnova (SDCBP MaxPab rabbit polyclonal
antibody (D01)). Cells interrogated for endogenous TRAF6 were probed with TRAF6
(H-274) sc-7221 Rabbit (Santa Cruz Biotechnology), Anti rabbit Alexa 488-conjugated
secondary antibody were from Molecular Probes (Eugene, OR).
3.8 Immunoflourescent staining
To visualize the subcellular localization of endogenous proteins, cells were
seeded onto Lab-Tec glass chambered cover slides (Nunc) the day prior to treatment.
Chambered slides were pretreated with either gelatin or matrigel (BD Biosciences). After
relevant stimulatory conditions (6h-5 days), the culture media was removed by aspiration
and cells were fixed using a 3.7 % formaldehyde solution made by diluting a 37%
formaldehyde stock with 1x PBS that has been freshly diluted from 10x PBS and warmed
to 37°C pre-warmed to 37°C for 10 minutes. 37% Formaldehyde solution (SigmaAldrich catalog no. F-1268 or F-1635). In most cases, slides of fixed cells were treated
with ProLong™ Gold antifade mounting solution (ThermoFisher Scientific) to suppress
photobleaching and encourage signal preservation in case of long-term storage and
analysis. ProLong™ Gold with DAPI (ThermoFisher Scientific Cat# P36935) was used
to visualize the nuclei in experiments where necessary.
3.9 ELM Analysis
Many protein-protein interactions occur between large globular domains but an
estimated 15-40% are mediated by functional microdomains of 3-10 amino acids in size
called Short Linear Motifs (SLiMs) (Neduva and Russell 2006). These often occur in
intrinsically disordered regions and are involved in a number of functions such as
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binding, cleavage, subcellular targeting and posttranslational modifications. The ELM
web server (http://elm.eu.org/) uses an algorithm that facilitates the exploration and
identification of SLiM-mediated interactions within PPI networks. The website enables
enquiries at the single protein level as well as within large-scale proteomic studies.
Therefore, ELM analysis is useful in guiding experimental studies and facilitating the
analysis of pathways within PPI networks. The web server is freely available
at http://i.elm.eu.org (Dinkel, Van Roey et al. 2014).
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Peptides
YFP
TRAF6
TRAF6ΔR
TRAF6C70
RZcc
Syn
SynΔN
SynΔP1
SynΔP2
SynΔP1+2
Sox4

Untagged
Proteins
(KDa)
27
61
47
61
42
33
20
12
18
11
47

FLAGtagged
Proteins
(KDa)
29
63
49
63
44
35
x
x
x
x
x

HA-tagged
Proteins
(KDa)
x
x
x
x
x
36
21
13
19
12
x

Dualtagged
Proteins
(KDa)
29
90
76
90
71
63
48
40
46
39
x

Residues

1-507
125-522
1-522
1-358
1-298
110-298
187-298
1-193
1-105
1-474

Table 5 Calculated molecular sizes of un-tagged and dual-tagged TRAF6 and
Syntenin proteins used in Co-IP and western blot analysis. The formula used for
the calculation: M.W. = Numbers of residues X 0.117 kDa.
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3.10 Neuronal Differentiation and quantitative morphology
A modified procedure adapted from Das et al. was used to assess differentiation
and neurite outgrowth (Das, Freudenrich et al. 2004, Pool, Thiemann et al. 2008). 293 or
PC12 cells were plated onto 12-well tissue culture plates coated with 40 μg/mL of rat tail
collagen Type I (Sigma, St. Louis, MO) according to the manufacturer-recommended
procedure. Cells were plated at a relatively low density (2x103 cells/cm2) in DMEM/F12
medium containing 10%FBS, 2 mM HEPES, and 44 mM Na-bicarbonate. The next day
after plating, the medium was replaced with serum free DMEM/F12 medium
supplemented with 50 ng/mL NGF (human recombinant NGF, Sigma) and 0.25% bovine
serum albumin (BSA; tissue culture grade from Sigma) with or without the
pharmacologic inhibitors U0126, bisindolylmaleimide I (Bis I), or edelfosine (ET-18; all
from Calbiochem, La Jolla, CA). Exposure to vehicle alone (culture medium) was used as
the control. The cells were fed on Days 2, 4, and 6 by the addition of a concentrated stock
of NGF for a final concentration of 50 ng/m.

Neurite growth was determined by

manually tracing the length of the longest neurite per cell (using NIH Image software) for
all cells in a field that had an identifiable neurite and for which the entire neurite arbor
could be visualized. Data from the two fields in each well were pooled, and each well
was designated as a ‘‘n’’ of one. Experiments were repeated at least three times using
cultures prepared on separate days.
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3.11 RNA Expression analyses
1x106 cells were plated into 6-well plates (353846, FALCON).

Following

treatments, cells pellets were resuspended in 500µl of TRIzol reagent (15596-026,
Invitrogen). After addition of 170µl of Chloroform (C606-1, Fisher) samples were
vortexed, incubated at room temperature for 15min, and centrifuged at 13000 RPM in
4°C for 15min. The aqueous layer was removed, combined with an equal volume of
Isopropanol (BP2632-4, Fisher), 1µl of Glycogen (9510, Ambion) and centrifuged at
13000RPM in 4°C for 10 min. Sample pellets were then washed with 500µl of 75%
Ethanol (111ACS200, Pharmaco-AAPER) and centrifuged for 10min in room
temperature at 14000 RPM. Air-dried pellets were resuspended in 30µl of RNAse free
water and subjected to DNAse treatments using Turbo DNA-free reagents (AM1907,
Ambion) according to the manufacturer instructions in order to eliminate genomic DNA
contamination. RNA was converted to cDNA using GoScript Reverse Transcription
System (A5001, Promega). Relative expression levels were calculated using Ct
method using B2M and 18srRNA as an endogenous controls. In certain experiments
RNA was directly subjected to an RT-PCR utilizing the Access RT-PCR system (A1250,
Promega).

cDNA was analyzed using quantitative PCR (qPCR) carried out in a

StepOnePlus Applied Biosystems Real Time Instrument (40 cycles). Relative expression
levels were calculated using Ct method.
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Gene
hTRAF6
hSox4
hSDCBP
mTRAF6
mSox4
mSDCBP

Forward
GTTGCTGAAATCGAAGCACA
ACCGGGACCTGGATTTTAAC
GATAAAGCGCACAAGGTGCT
TCCACACAATGCAAGGAGAA
CTCGTCCTCTTCCTCCTCCT
CAACGGACAGAACGTCATTG

Reverse
CGGGTTTGCCAGTGTAGAAT
AAACCAGGTTGGAGATGCTG
CATTTCTGGCTGCAGAGCTA
CCATGACCTCTTCGTGGTTT
GCCGGGTTCGAAGTTAAAAT
GGTGTGATCCATCAGGCTTT

Table 6 mRNA analysis and qPCR primer sequences.
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Chapter 4
RESULTS

4.1 IRAK1 modulation of TRAF6 auto-regulation and localization
4.1.1 Rationale
In 2010 our research group reported on the trans and cis intramolecular
interactions between the TRAF6 RZ and MATH domains (Wang, Galson et al. 2010) and
confirmed the homotypic RZ-RZ domain interaction demonstrated by others (Wooff,
Pastushok et al. 2004). The results of our study produced a model arguing that TRAF6
activity depends on interconversion between a “closed” inactive and an “open” active
structure. Open TRAF6 can be “auto”-ubiquitinated, thus sustaining action upon other
downstream proteins (Figure 4.1). While it is known that MyD88, TRAF6 and IRAK1
are all involved in TIR signaling to activate NF-κB, the full details of this process remain
unresolved (Figure 4.2). Although the overexpression of MyD88, IRAK1 or TRAF6 can
each individually as a dominant positive for NF-κB activity in 293 cells, it is has been
demonstrated that IRAK1 and not MyD88 induces oligomerization of TRAF6, which is
sufficient for signaling to JNK and IKK (Baud, Liu et al. 1999). Further, the X-ray
crystal structures of TRAF2 and TRAF3, containing the coiled-coil and MATH
(ccMATH) domains, reveal that both proteins can form trimers associated via the coiledcoil domain (Park, Burkitt et al. 1999, Ni, Welsh et al. 2000). Strikingly, the published
structure of TRAF6 contained only a MATH domain monomer, without a coiled-coil
domain (Ye, Cirilli et al. 2002). It is unclear whether the omission in the crystallized
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protein of the coiled-coil multimerization region during crystallization was intentional or
necessary in order to produce a diffracting crystal. Glutaraldehyde crosslinking studies of
purified TRAF proteins revealed both dimer and trimer forms for TRAF1, 2, and 3.
However, TRAF6 appeared to generate a complex and less-clear pattern of
multimerization (Pullen, Labadia et al. 1999).

The group that reported the TRAF6

monomeric structure generated a trimeric model of TRAF6 by graphical superimposition
of the TRAF6 MATH domain backbone onto the 3-fold symmetry observed in the
TRAF2 structure (Ye, Cirilli et al. 2002, Ferrao, Li et al. 2012).

Figure 4.1 A Model for TRAF6 Activation and Inhibition by Intra and Extra
Molecular Interactions. TRAF6 activity depends on interconversion between a
“closed” inactive and an “open” active structure.
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Figure 4.2 Map of TRAF6 Mediated LPS and IL-1 Signaling. TRAF6 plays central
roles in response of LPS and IL-1 Signaling to nucleus. TIR sigaling involves
recruitment of the adapter proteins myd88 and IRAK1 with recruit TRAF6 and
promotes activation of transcription factors such as NF-κB, via IKK or by
activating PI3 kinase, which can then activate the transcription factors AP-1 or
C/EBPβ. These transcription factors acivate genes that lead to the production of
pro-inflammatory cytokines.
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One factor contributing to the challenges of crystallizing TRAF6 could be that the RZMATH interaction is highly dynamic and the associated free energy is not favorable for
crystal formation. In an effort to gain insight into the TRAF6 intramolecular interactions
and also to understand why ectopic expression of TRAF6 acts as a dominant positive for
NF-κB, I hypothesized that IRAK1 activates TRAF6 by disrupting the intra/intermolecular RZ-MATH domain interaction, opening the “closed” TRAF6 structure. To
investigate this, plasmids for full length TRAF6, the RZ domain of TRAF6 and IRAK1
were co-expressed in 293 cells. Since wtTRAF6 and the RZ are known to associate , it
seemed likely that co-expression of IRAK1 would disrupt this interaction and permit
visualization of the results by performing both co-Immunopreciptation experiments well
as microscopic examination of the subcellular distribution for ectopically expressed
chimeric fluorescently-labeled molecules (e.g., TRAF6-YFP, RZ-YFP, MATH-YFP,
ccMATH-YFP and IRAK1-HcRed).
4.1.2 Subcellular Distribution of IRAK1 co-expressed with “open” and “closed” TRAF6
In agreement with previous reports, ectopic TRAF6-YFP was found to distribute
to cytosolic speckles and several larger 1-2μm punctate in 293 cells while YFP was
distributed diffusely throughout the cell (Figure 4.3A-B). Interestingly, in RAW264.7
cells, endogenous TRAF6 also displayed a pattern similar to that of ectopic TRAF6 in
293 with some additional aggregation in what appears to be the nucleus (Figure 4.3C).
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Figure 4.3 IRAK1 Reduces the Number of Large TRAF6 Sequestosomes. A-B)
confocal images show ectopic TRAF6 localized to sequestosome like cytoplasmic
speckles or punctae. 40ng of either pFLAG-YFP or pFLAG-TRAF6-YFP was
transfected into 293 cells seeded into a 24 well culture dish the prior day. C)
Epiflourescent image of RAW264.7 cells stained for endogenous TRAF6. In preosteoclasts, TRAF6 appears to reside in cytoplasmic speckles, punctae or a nucleuslike structure (yellow wedges). In all conditions 3 independent biological replicates
were conducted and several fields were taken at 200x. A representative subfield is
displayed and scale bar: 20μm.
Our group previously demonstrated that the size of ectopic TRAF6 punctae correlates
with TRAF6 induced NF-κB activity in a non-linear inverted U response (Wang, Galson
et al. 2010).

One hypothesis on the nature of these large punctae is that they are

autophagic sequestosomes, targeting TRAF6 for recycling by the ubiquitin binding
protein p62/SQSTM1 and various DUBs. To investigate this, p62-HcRed and TRAF6YFP were ectopically expressed in 293 cells and then examined by confocal microscopy
as to their subcellular distribution.

In agreement with our previous findings (Wang,

Galson et al. 2010), TRAF6-YFP colocalizes with p62-HcRed when co-expressed in 293
cells (Figure 4.4). ELM analysis reveals a canonical TRAF6 interaction motif in p62 at
AA positions 322-328, indicating the potential for p62 to interact with TRAF6 in a
MATH-dependent manner (Figure 4.5).
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Figure 4.4 SQSTM1/p62 and TRAF6 Colocalize in Cytoplasmic Sequestosomes.
40ng of each expression plasmid was co-transfected into 293 cells. After 24h,
confocal images of ectopic p62-HcRed1 (red) and TRAF6-YFP (green) were taken.
At right, display of both red and green channels produces a merged image where
yellow color represents co-localization of the two fluorescent-tagged proteins.
Displayed image individual channels from a subfield from a collection of fields
acquired from multiple fields taken from three independent experiments. Scale bar:
20μm.
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Figure 4.5 Eukaryotic Linear Motif (ELM Analysis) for Protein Interaction Sites of
Human p62/SQSTM1 (UniProt q13501). A) Interactive Summary and Graphic
representation shows the canonical T6IM with favorable context toward the
carboxy end of p62 B) Linear Sequence of T6IM within SQSTM1 and its positioning
in at residues 320-328.
This comports with Sanz et al. who demonstrated that p62 interacts specifically with the
ccMATH (TD) of TRAF6 and not TRAF2 (Sanz, Diaz-Meco et al. 2000); although, they
identify the region 228-254 as necessary for p62 binding TRAF6. Additionally, in their
study, TRAF6 and p62 only co-localized upon IL-1 stimulation in HepG2 cells. They
suggested that adding IL-1 was necessary to increase the endogenous concentrations of
TRAF6 and IRAK1, but another possibility could be the need for an “open” TRAF6
structure, where IL-1 recruits IRAK1 to activate TRAF6 and expose its TIM binding
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groove to interact with p62/SQSTM1. To address this, TRAF6-YFP, ccMATH-YFP or
MATH-YFP was ectopically expressed in in 293 cells. As expected, punctae were only
visible with the addition of TRAF6-YFP, while ectopic ccMATH-YFP or MATH-YFP
do not localize to punctae because they presumably inactivate TRAF6 ubiquination
events and block NF-κB activity (Figure 4.6). Co-expression of ectopic RZ or IRAK1
with TRAF6-YFP was found to reduce the number of cells that display large TRAF6
punctae or the number of punctae per cell respectively (Figure 4.6). This modulation of
sequestosome size or number can be correlated with the NF-κB activity, in luciferase
reporter assays where transfecting mTRAF6 + IRAK1 into 293 cells synergize, superactivating NF-κB, while transfecting RZ + mTRAF6 decreased NF-κB, activity by ~10%
as compared to mTRAF6 alone (Figure 4.7). Interestingly, the addition of both RZ and
IRAK1 with TRAF6-YFP completely abolished the formation of sequestosomes (Figure
4.6, left column). On the other hand, neither RZ nor IRAK1 was able to induce TRAF6
punctae when co-expressed with either ccMATH- or MATH-YFP (Figure 4.6). While
deletion of the RZ domain seemed to be sufficient to disrupt punctae formation, in some
cases punctae were still formed when either ccMATH-YFP or MATH-YFP coexpressed
with IRAK1-HcRed (Figure 4.8). Here, coexpression of ectopic IRAK1-HcRed along
with either the ccMATH-YFP or MATH-YFP in 293 cells revealed colocalization of
IRAK1-TRAF6 mutein pairs into cytosolic sequestosomes (Figure 4.8). When IRAK1HcRed was coexpressed with only RZ-YFP, devoid of the MATH domain, there was no
colocalization (Figure 4.8).

75

Figure 4.6 IRAK1 Opens TRAF6, Inducing Localization to Large Sequestosomes.
24 hours prior to transfection, 293 cells were seeded into 24 well tissue culture plates
and then transfected the next day with 40ng of each indicated plasmid with each
condition receiving 120ng of total plasmid DNA. Adding an appropriate amount of
pFLAG-CMV5 empty vector equalized differences in total DNA. Epiflourescent
images demonstrate that ectopic TRAF6 localizes to cytosolic speckles or punctae.
Co-expression of either the RZ domain or IRAK1 with wtTRAF6 reduces the
number of large punctae, but addition of both RZ + IRAK1 completely abrogated
sequestosome formation.
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Since, sequestosomes correlate with excessively ubiquitinated TRAF6 and/or other
interacting proteins which inhibit TRAF6 (Wang, Galson et al. 2010), a decrease in
sequestosomes can be understood to result from co-expression of a TRAF6: RZ or
IRAK1 activation pair. The co-localization of the punctae with the protein p62/SQSTM1
and the finding that IRAK1 plus the RZ domain together disrupt the punctae, suggests
that the punctae are sequestosomes, p62-rich proteasome-like structures, which are
induced by an open-active TRAF6. Overexpression of inactive mutants displayed little
or no sequestosome formation. Collectively, these results demonstrate that IRAK1 colocalization with TRAF6 in the cytoplasm depends on the presence of the TRAF6 MATH
domain and TRAF6 punctae are sequestosomes that can be induced by TRAF6
activation.
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Figure 4.7 IRAK1 Synergizes with TRAF6 Dominant Positive while Coexpression of
a RZ Mutein with TRAF6 inhibits NF-κB Activity. 25ng of each plasmid was
cotransfected with 25ng of NF-κB, Luciferase reporter into 293 cells seeded into 96
well tissue culture plates the previous day. 24 hours after transfection cells were
harvested and assayed for luciferase signal. A representative experiment is shown
for the results of least three biological replicate experiments and quantification as
indicated for three experimental replicates (average±s.d.).
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Figure 4.8 IRAK1 and MATH Domains Colocalize. Expression plasmids (40
ng/each) coding for IRAK1-HcRed and TRAF6-YFP muteins were co-transfected
into 293 cells according to procedures described in Materials and Methods. Left
panels display merged two color confocal mages which are representative subfields
taken from three independent experiments. Correlating highlighted insets are
magnified at right and channels split into green (YFP), red (HcRed), and merged
where yellow represents colocalization.
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4.1.3 TRAF6 RZ and MATH domain interact via the MATH TIM
In order to correlate our microscopic observations with direct evidence for a
physical

interaction

between

IRAK1

and

the

MATH

domain

of

TRAF6,

immununoprecipitation experiments were designed according to the rationale diagramed
in Figure 4.9. Reasoning that TRAF6 may form homotypic interactions between its RZand either the RZ or MATH domain, I anticipated that an untagged-tagged RZ mutein
(RZ) would exhibit increased binding to FLAG-tagged TRAF6-YFP (F-TRAF6-YFP)
with two acceptor sites vs. a FLAG-ΔR-YFP mutein (F-ΔR-YFP) or C70A-YFP mutein
which has been previously demonstrated to exhibit an impaired RZ-RZ interaction
(Wooff, Pastushok et al. 2004).

Figure 4.9 Model of IRAK1 Disruption of TRAF6 RING-MATH Interaction as
Revealed by Immunoprecipitation.
Predictably, ectopic IRAK1 was found to disrupt the wtTRAF6 interaction with a RZ
mutein (Figure 4.10, Table 5). In the left panel, two RZ western signals are detected
following IP with a FLAG antibody and immunoblotting with an antibody (Santa Cruz
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Figure 4.10 IRAK1 Disrupts RZ-MATH interaction (Western blot of IP). A) Left
panel indicates increased RZ western signal with the addition of IRAK B) Right
panel is a separate control IP/IB that confirms identity of TRAF6 species in top
band. HC*: Heavy Chain IgG LC*: Light chain IgG. In both western blots, whole
cell lysates (WCL) extracted from 293 cells transfected with 1μg of each indicated
plasmid were harvested 24h after transfection, incubated with FLAG antibody and
prepared for western blot analysis. PVDF membranes containing 50μg of WCL
protein were then probed with TRAF6 (directed at the RZ) or FLAG antibody. A
representative blot of two independent experiments is shown.
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sc-H274) that recognizes an epitope corresponding to amino acids 1-274 of TRAF6 or the
RZ domain. These two bands represent the RZ mutein (lower) and dual tagged F-ΔR, C70A or -TRAF6-YFP (upper). There is an obvious increase in ectopic RZ mutein signal
between lanes 1&4, which is greater than that seen between lanes 2&5 or 3&6.

In the

right panel (a different membrane in which samples from the same WCL were
immunoprecipitated with FLAG antibody, then immunoblotted with FLAG antibody
before transfer to the PVDF membrane) no RZ western signal e.g. a lower band is
detected and serves as a control. The untagged RZ mutein cannot be precipitated with
FLAG antibody and thus the dual tagged TRAF6 muteins are visualized as higher bands
that correspond to their molecular weights (Table 5). Insomuch, adding IRAK1 increased
the RZ mutein western blot signal, demonstrating that wtTRAF6 but not ΔR
autoinhibition was overcome, increasing mutein RZ binding to both the RZ or MATH
domains of FLAG tagged TRAF6 (Figure 4.10). This result supports the hypothesis that
IRAK1 activates TRAF6 by disrupting the RZ and MATH domain association via the
MATH domain TIM recognition groove. Moreover, there exists a putative T6IM in the
RING domain of TRAF6, as revealed by ELM analysis and scrutiny of the primary
sequence (Figure 4.11). This previously unreported RING domain T6IM is modeled in
Figure 4.12 and could be the basis for a direct TRAF6 RZ-MATH interaction. Such an
interaction would support a structurally “closed” inactive TRAF6 molecule.
Interestingly, this T6IM is adjacent to the cysteine at position 70 (C70) that has been
identified as the critical residue for recruiting the E2 ubiquitin conjugase, Ubc13 (Yin,
Lamothe et al. 2009). The integrity of the Zn2+ finger motif within the RING domain has
been shown as necessary to function and mutation of C70 (TRAF6-C70S) abolishes
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interaction of TRAF6 with Ubc13 (Wooff, Pastushok et al. 2004).

Relatedly, the

TRAF6-C70A mutant inhibited TRAF6 autoubiquitination (Lamothe, Besse et al. 2007).
In our Co-IP experiment, substituting a ΔR (125-522) deletion mutein for wtTRAF6
produced an overall decrease in RZ mutein signal on Western blot (Figure 4.10), both
with and without IRAK1 coexpression. However, adding IRAK1 clearly increased the
free RZ signal in a manner similar to that of wtTRAF6. Using the C70A mutein in place
of wtTRAF6 did not show any differences in IRAK1 modulation of RZ binding to the
MATH domain of TRAF6. Given that addition of a TIM peptide is insufficient to
activate TRAF6 (Poblenz, Jacoby et al. 2007), along with the results in this section, it
seems that IRAK1 activation of TRAF6 depends on factors beyond simple TIM groove
occupation and RZ-MATH dissociation.
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A.

B.

Figure 4.11 ELM Analysis Shows TRAF6 Primary Amino Acid Sequence Contains
a TRAF6 Interaction Motif Sequence in Its RING Domain. A) Analysis for
Q9Y4K3 (human TRAF6) shows global protein domain structure and various
motifs within linear sequence B) sequence for RING domain of human TRAF6
underlined peptide represents internal T6IM peptide.
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Figure 4.12 Molecular Modeling of TRAF6 RING Structure Featuring aa63-69
Putative TIM Sequence. A) Peptide backbone and B) van der Waals space fill
structures indicating the putative TIM amino acids. C) Peptide backbone structure
(Red) with TIM amino acid side chains presented as van der Waals space fill. RING
finger cysteine side chains are presented as yellow tubes with coordinated Zn (Green
spheres). Space fill amino acid side chains are colored according to the Shapely
standard: http://life.nthu.edu.tw/~fmhsu/rasframe/COLORS.HTM.
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4.2 Super-stimulatory effects of ligands demonstrate bimodal inhibition of TRAF6
While some details have emerged, the molecular mechanism by which
endogenous TRAF6 is activated by upstream factors has not yet been fully determined.
In agreement with others, I found that ectopic expression of MyD88, IRAK1 or
wtTRAF6 acts as a dominant positive for Upstream activators potentiate TRAF6
dominant positive when co-expressed. NF-κB activity resulting from co-transfection in
293 cells with indicated expression vectors, and the luciferase reporter previously
described (Wang, Wara-Aswapati et al. 2006). In agreement with others, I found that
ectopic expression of any of these three molecules acts as a dominant positive for NF-κB
activity in 293 cells (Figure 4.13) (Walsh, Kim et al. 2008, Wang, Galson et al. 2010).

Figure 4.13 Ectopic Expression of TRAF6, IRAK1, or MyD88 is capable of
Activating NF-κB. 293 cells were co-transfected with 25ng of indicated expression
vectors and 25ng NF-κB-Luciferase reporter.
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Predictably, titrating increasing amounts of TRAF6 (Figure 4.14A) or RZcc (Figure
(4.14B) acted as a dominant positive with maximal stimulation occurring abruptly in both
cases at high concentration of plasmid, while transfecting a control empty vector had no
affect on NF-κB activity.

Overexpression allows TRAF6 to act as a surrogate for

receptor-dependent upstream stimulation in various NF-κB signaling pathways. To test
the hypothesis that overexpression of TRAF6 was effectually titrating out an inhibitory
molecule(s), I reasoned that NF-κB activity in either RAW264.7 or 293R cells induced
by a minimal amount of ectopic TRAF6, could be increased by addition extracellular
stimulatory ligands IL-1β (Figures 14.15) or LPS (Figure 14.16B) to levels greater than
the saturation point achieved by ectopic TRAF6 alone. Interestingly, “super-stimulation”
by IL-1β in 293R averaged unimpressive 1.5x increases over saturated dominant positive
activity induced by transfecting saturating amounts of TRAF6 (100ng) alone but
costimulation with minimal dose of activating TRAF6 (20ng) or RZcc (10ng) produced a
5-7x “super-stimulation” (Figure 4.15). This supports the model that ectopic TRAF6 or
RZcc acts as a dominant positive by overcoming the stoichiometry of putative inhibitory
proteins interacting that attenuate TRAF6. Unexpectedly, ectopic expression of TRAF6
alone in the pre-osteoclast cell lines, 4B12 (Figure 4.16A) or RAW264.7 (Figure 4.16B)
did not have a dominant effect for NF-κB activity. Despite the unresponsiveness of both
pre-osteoclast lines to ectopic TRAF6, NF-κB activity was still inducible by LPS
stimulation or transfection of the NF-κB-p65 subunit itself (Figure 4.16B). Furthermore,
IL-1β activity in RAW264.7 cells was normal, increasing in response to LPS stimulation
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Figure 4.14 Ectopic expression of either A) TRAF6 or B) RZcc (1-358) acts as a
dominant positive for NF-κB activity in a dose dependent manner in 293T epithelial
cells co-transfected with a NF-κB–Luciferase reporter. A representative experiment
is shown for the results of at least three biological replicate experiments and
quantification as indicated for three experimental replicates (average±s.d.). EV:
Empty expression vector control.
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Figure 4.15 Co-stimulation of 293R cells expressing TRAF6 and RZcc with IL-1β
and “super-stimulates” NF-κB Activity. Stably transfected 293 cells expressing the
IL-1 receptor (293R) were stimulated with IL-1β (10ng/mL) for 6-8 hours 24h after
transfection of A) TRAF6 or B) RZcc as indicated and 25ng NF-κB luciferase
rporter prior to preparation for luciferase assay. A representative experiment is
shown for the results of at least three biological replicate experiments and
quantification as indicated for three experimental replicates (average±s.d.) and fold
increase with co-stimulation. EV: Empty expression vector control.
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Figure 4.16 TRAF6 Does Not Act as a Dominant Positive for NF-κB Activity in Preosteoclast Cells A) 4B12 and B) RAW264.7. 4B12 or RAW264.7 cells were cotransfected with 25ng NF-κB–Luciferase reporter and TRAF6 or p65 (25ng) as
indicated and then in the case of RAW264.7 cells stimulated with LPS (100ng/mL)
for 6-8 hours 24h after transfection prior to harvesting for luciferase analysis. A
representative experiment is shown for the results of at least three biological
replicate experiments and quantification as indicated for three experimental
replicates (average±s.d.). EV: Empty expression vector control.
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as monitored by transfecting either a XN- or XT- IL-1β Luciferase reporters (Figure
4.17). Of these two constructs, the XN IL-1β -Luc, which is driven by an IL-1β promoter
that contains elements that run downstream to the site of the IL-1β promoter, has nearly
three fold greater activity than that of the XT IL-1β promoter when induced by LPS in
RAW264.7 cells (Figure 4.17). Thus, a model emerges where over-expression of TRAF6
has two modalities for increasing NF-κB activity: (1) It can shift the equilibrium of
TRAF6 toward the open active conformation previously reported by our laboratory
(Wang, Galson et al. 2010) and (2) titrate out the inhibitory effects of inhibitory
molecules that depend upon TIM interaction. To address the possibility that murine
RAW264.7 cells were unresponsive to ectopic wtTRAF6 (human) due to species-specific
differences between RAW264.7 and 293 (human) cell lines, both murine (Figure 14.18A)
and human (Figure 14.18B) wtTRAF6 were separately transfected into RAW264.7 cells.
Here, ectopic expression of neither species of TRAF6 sequence activated NF-κB. Any
“super-stimulatory” effect when co-stimulated with LPS was also absent (10ng/mL)
(Figure 4.18A, 4.18B). Additionally, in a manner similar to results when transfecting 293
cells, NF-κB was activated in RAW264.7 cells transfected with IRAK1 (Figure 4.19A).
This suggests a difference in IRAK1 signaling downstream to TRAF6 between the
epithelial/neuronal

(293)

and

macrophage-monocyte/pre-osteoclast

(4B12

and

RAW264.7) cell lines used in this study. Interestingly, while ectopic expression of
wtTRAF6 was not effective at inducing NF-κB in RAW264.7 and 4B12, transient
transfection of RZcc was able to activate NF-κB in both cell lines (Figure 4.19B, 4.19D).
As expected, stimulating RAW264.7 with either IL-1β (Figure 4.19B) or RANKL
(Figure 4.19C) was found to actuate NF-κB.
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Figure 4.17 LPS induces IL-1β activity in pre-osteoclast RAW264.7 cells. RAW
264.7 were transfected with 25 ng/well of either XN- or XT- IL-1β Luciferase
reporters or PGL3 luciferase empty vector (EV) and then stimulated for 6hrs with
LPS (10ng/mL) 24h post transfection before harvested for bulk luciferase assay. A
representative experiment is shown for the results of least three biological replicate
experiments and quantification as indicated for three experimental replicates
(average±s.d.). EV: Empty expression vector control.
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However, co-stimulation with RZcc + IL-1β/RANKL had a greater effect than
costimulation with TRAF6 + IL-1β/RANKL supporting previous reports that the MATH
domain is inhibitory (Figure 14.19B, 14.19C) (Ye, Arron et al. 2002, Poblenz, Jacoby et
al. 2007, Wang, Galson et al. 2010, Trudeau, Nassar et al. 2013). Collectively, these
results suggest that the MATH domain of TRAF6 possesses some inhibitory character,
which may be attributed to either auto-regulation and/or an exogenous inhibitor that
could depend on a T6IM interaction (Table 7). Deleting the MATH domain abrogated
TIM-based inhibitory protein interaction with TRAF6 and increased NF-κB activation
(Figure 4.15, 4.19).

293

RAW264.7

4B12

pre-neuronal

pre-osteoclast

pre-osteoclast

TRAF6

YES

NO

NO

RZcc

YES

YES

YES

Table 7 Summary of TRAF6 dominant positive activity in various cell lines. Full
TRAF6 acts as a dominant positive for NF-κB activity in 293 epithelial but not preosteoclast cell lines 4b12cand Raw264.7.
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Figure 4.18 LPS or ectopic p65 but not ectopic TRAF6 induces NF-κB activity in
murine RAW264.7 cells regardless of any species differences in human and murine
TRAF6 sequences transfected. 25ng of p65 or indicated amounts of TRAF6 were
transfected with 25ng of NF-κB luciferase reporter and appropriate amounts of
pFLAG empty vector so that total DNA transfected totaled 150ng/well. Cells were
stimulated with LPS the next day for 8 hours then assayed for luciferase activity. AB) A representative experiment is shown for the results of least three biological
replicate experiments and quantification as indicated for three experimental
replicates (average±s.d.).
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Figure 4.19 RZcc acts as a dominant poistive in AW264.7 and 4B12 cells. NF-κB is
activated by ectopic IRAK1 or stimulation by IL-1β/RANKL in RAW264.7 cells;
additinally, ectopic RZcc expression can activate NF-κB in 4B12 and RAW264.7
cells. A) RAW264.7 cells were co-transfected with 25ng of each indicated plasmid
and 25ng of NF-κB–Luciferase reporter B) RZcc or wtTRAF6 was transfected as
indicated along with and 25ng of NF-κB–Luciferase reporter and then co-stimulated
with 100ng/mL IL-1β 24 hours post transfection for 8 hours prior to harvesting fro
luciferase assay. C) RAW 264.7 cells were transfected with 25ng of indicated
plasmids and 25ng of NF-κB–Luciferase reporter 24h prior to stimulation with
50ng/mL RANKL the following day for 6 hours before preparation for luciferase
assay. D) 4B12 cells were transfected with indicated amounts of RZcc and 25ng of
NF-κB–Luciferase reporter before harvesting for luciferase assay the following day.
A-D) A representative experiment is shown for the results of least three biological
replicate experiments and quantification as indicated for three experimental
replicates (average±s.d.). EV: Empty expression vector control.
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4.3 Molecular Dynamics of TRAF6-Syntenin Interaction
4.3.1 Syntenin inhibition of NF-κB activators
Seminal work characterizing the ability for a human homologue of
the Drosophila Toll protein to activate NF-κB utilized ectopic expression of a
constitutively active CD4/human Toll receptor construct (Medzhitov, Preston-Hurlburt et
al. 1997, Medzhitov, Preston-Hurlburt et al. 1998). Later, overexpression of CD14,
TLR4, and MD-2 was reported to confer LPS sensitivity to otherwise LPS-unresponsive
293T cells, without disrupting the induction of LPS tolerance (Medvedev and Vogel
2003). In contrast to these studies, I found that ectopic expression of TLR4 alone acts as
a dominant positive for NF-κB activity in 293T cells (Figure 4.20A). As such this system
allowed me to dispense with the need to initially transfect TLR4 into 293 cells so that
LPS could be used to induce NF-κB activity. Instead attenuation of TLR4 signaling by
Syn was assessed by mere coexpression of Syn and TLR4 in 293 cells. Coexpression of
Syn was found to inhibit ectopic TLR4 induced NF-κB activity (Figure 4.20B). Further,
Syn was found to inhibit NF-κB activity in IL-1β stimulated 293R cells (Figure 4.21A) in
a dose dependent manner (Figure 4.21B). As with TLR4, ectopic Syn also inhibited the
NF-κB activity in LPS, IL-1β or RANKL stimulated RAW264.7 cells (Figure 4.22).
Beyond inhibition of NF-κB signaling initiated by the cell surface receptors, NF-κB
activity induced in 293T cells transfected with the intracellular activator MyD88 was also
inhibited by Syn in a dose-dependent manner (Figure 4.23A). Interestingly, although
ectopic TRAF6 fails to act as a dominant positive in RAW264.7 cells, transecting IRAK1
instead was found to induce NF-κB activity. Such NF-κB activity induced by dominant
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positive amounts of IRAK1 In 293T cells was attenuated by coexpression of Syn (Figure
14.23B). Finally, in agreement with Chen et al., ectopic expression of Syn attenuated
dominant positive TRAF6 activation of NF-κB in 293 cells (Figure 4.24A). TRAF6
dominant positive activity in 293T cells was not affected by the addition of EYFP to the
carboxy terminus of the molecule. Moreover, the fluorescent chimera could be inhibited
by ectopic GFP-Syntenin (Figure 4.24B).

Figure 4.20 Syntenin can block NF-κB activity induced by dominant positive ectopic
expression of TLR4 in 293T cells. A) 293T cells were transfected 25ng NF-κB
luciferase reporter and indicated amounts of HA-TLR4 and then prepared for
uciferase assay 24 hours post transfection. B) 293T cells were transfected with
150ng of TLR4 and 50ng of Syn or pHA empty vector (EV) 24 hours prior to
luciferase assay. A representative experiment is shown for the results of least three
biological replicate experiments and quantification as indicated for three
experimental replicates (average±s.d.).
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Figure 4.21 Syntenin inhibits IL-1β activation of NF-κB in 293R cells. A)
Optimization for IL-1β stimulation of 293R cells transfected with 25ng NF-κB
luciferase reporter and stimualtd the next day for 8 hours prior to luciferase assay.
B) 293R cells expressing the IL-1 receptor were co-transfected with indicated
amounts of Syn and 25ng of with 25ng NF-κB luciferase reporter, then simulated
with stimulated with IL-1β (10ng/mL) for 6-8 hours 24 h post-transfection. Bars are
quantification of (average±s.d.) for a representative experiment done in triplicate
and qualitatively similar to at least three independent experimental replicates.
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Figure 4.22 Syn inhibits NF-κB activity induced by LPS, IL-1β or RANKL
stimulated RAW264.7 cells but not NF-κB activity induce by dominant positive
RZcc. RAW264.7 cells were co-transfected with either 100ng pFLAG-RZcc, 25ng of
mSyn or pFLAG empty vector and 25ng of NF-κB–Luciferase reporter and then costimulated with 100ng/mL IL-1β. 50ng/mL RANKL or 100ng/mL LPS 24 hours post
transfection for 8 hours prior to harvesting for luciferase assay. A representative
experiment is shown for the results of at least three qualitatively similar biological
replicate experiments and quantification as indicated for three experimental
replicates (average±s.d.).
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Figure 4.23 Syntenin attenuates NF-κB activity induced by ectopic expression of
MyD88 and IRAK1 wchih signal upstream of TRAF6. A) 293T cells were seeded
into 96 well plates 24 hours prior to transfection with 50ng of expression plasmid of
MyD88 along with 25ng NF-κB Luciferase reporter and indicated amounts of
murine Syntenin expression plasmid. Cells were harvested and processed for
Luciferase Reporter Assay 24 hours following transfection. B) RAW264.7 were
seeded in 96 well plates 24 hours prior to transfection. 50ng of each Indicated
plasmid was transfected along with 25ng of NF-κB Luciferase reporter and
pcDNA3.1 was used to equalize total transfected DNA to 200ng. Bars are
quantification of (average±s.d.) for a representative experiment done in triplicate
and qualitatively similar to at least three independent experimental replicates.
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Figure 4.24 Syntenin attenuates NF-κB activity induced by ectopic expression of
TRAF6. A) 293 cells were seeded into 96 well plates 24 hours prior to transfection
with 50ng of expression plasmid of TRAF6 along with 25ng NF-κB Luciferase
reporter and indicated amounts of murine Syntenin expression plasmid. Cells were
harvested and processed for Luciferase Reporter Assay 24 hours following
transfection. B) 293T cells were seeded into 96 well plates 24 hours prior to
transfection with 50ng of expression plasmid of TRAF6-EYFP along with 25ng NFκB Luciferase reporter and 50ng of GFP-human Syntenin expression plasmid. Cells
were harvested and processed for Luciferase Reporter Assay 24 hours following
transfection. and pEYFP was used to equalize total transfected DNA to 200ng.
Bars are quantification of (average±s.d.) for a representative experiment done in
triplicate and qualitatively similar to at least three independent experimental
replicates.
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4.3.2 Molecular Domains involved Syntenin-TRAF6 interactions
I hypothesized that Syn associated with TRAF6 via a putative T6IM at amino
acids (194-200) in the unstructured linker region between the tandem dual PDZ domains
of Syn to inhibit TIR signaling (Figure 10). The C-terminal TRAF6 MATH domain,
which is often defined as a structure involved in the integration of upstream receptorproximal signals, has also been reported to be involved in downstream signal
transduction.

Examples include RANK ligand signaling through its receptor in

osteoclasts ((Wong, Besser et al. 1999)) and the super-activation of NF-κB p65
homodimers by IL-1 (Yoshida, Kumar et al. 2004). To test this, NF-κB Luciferase
reporter assays were carried out on 293T cells co-expressing ectopic RZcc and Syn.
Surprisingly, ectopic Syn was also able to inhibit NF-κB activity induced by dominant
positive ectopic RZcc (Figure 4.25A), which lacks the MATH domain and does not
possess a T6IM interaction site. This phenomenon was independent of the species
sequence of transfected Syn (Figure 4.25B). Next, TRAF6 was coexpressed with a series
of Syn deletion muteins systematically testing which functional domains of Syn were
necessary for inhibiting TIR signaling.

Deletion of amino acids 194- 298 of Syn

(ΔPDZ2) minimally abrogated Syn inhibition of dominant positive TRAF6-activated NFκB signaling (Figure 4.26).

In contrast, deleting both PDZ domains and the CTD

(ΔPDZ1+2) of Syn did not inhibit the NF-κB signal, but in some cases increased the
signal to suprathreshold levels beyond ectopic TRAF6 alone (Figure 4.26A). Deletion of
1-109 (ΔN) retained WT-like activity, whereas deletion of 1-192 (ΔPDZ1) was super-
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Figure 4.25 Syntenin attenuates NF-κB activity induced by ectopic expression of
RZcc. A) 293T cells were seeded into 96 well plates 24 hours prior to transfection
with 50ng of expression plasmid of RZcc along with 25ng NF-κB Luciferase
reporter and indicated amounts of murine Syntenin expression plasmid. Cells were
harvested and processed for Luciferase Reporter Assay 24 hours following
transfection. B) 293 cells were seeded into 96 well plates 24 hours prior to
transfection with 50ng of expression plasmid of either TRAF6 or RZcc along with
25ng NF-κB Luciferase reporter and 50ng of either murine or human Syntenin
expression plasmids as indicated. Cells were harvested and processed for Luciferase
Reporter Assay 24 hours following transfection. and pEYFP was used to equalize
total transfected DNA to 200ng. Bars are quantification of (average±s.d.) for a
representative experiment done in triplicate and qualitatively similar to at least
three independent experimental replicates.
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Figure 4.26 The CTD Is The Dominant Factor In Syn Attenuation Of TRAF6
Signaling. CTD And NTD Of Syntenin Can Attenuate TRAF6 Induced NF-Κb
Signal. A) 293T cells were transfected with 25ng indicated plasmids and 25ng NFκB reporter 24 before preparation for luciferase assay. Bars are quantification of
(average±s.d.) for a representative experiment done in triplicate and qualitatively
similar to at least three independent experimental replicates. B) schematic of
TRAF6 and Syn plasmids used. Human plasmids were tagged with either a 9aa HA
tag or an 8aa FLAG tag as indicated.
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inhibitory, similar to the mSyn effect. Collectively, these data suggest that the sequence
between 193 and 298 is responsible for TRAF6 inhibition, with 1-192 possibly providing
some intra-molecular regulation of ΔPDZ1. To support the results from the activity
assays for the Syn deletion muteins Co-IP experiments were preformed with HA-tagged
versions of Syn in order to determine whether the putative T6IM of Syn was sufficient
for TRAF6 binding. Strikingly, only full length Syn was found to physically interact
with TRAF6 (Figure 4.27). This could suggest that only full-length Syn binds to TRAF6,
but that the inhibitory activity is associated with some other signaling component.
4.3.3 Syntenin inhibits TRAF6 in an Ubiquitin-dependent manner
The NTD of Syn was recently shown to contain 3 novel Ub binding motifs, which
interact with the carboxy-terminal region of ubiquitin via a non-covalent interaction
(Okumura, Yoshida et al. 2011, Rajesh, Bago et al. 2011). To understand how the
ubiquitination state of TRAF6 might affect interaction with Syn regulation of TRAF6,
ectopic lysine-deficient TRAF6ΔK (Walsh, Kim et al. 2008) was transfected in 293 cells
and NF-κB activity measured by the NF-κB Luciferase reporter assay (Figure 4.28A).
Ectopic Syn was less effective at inhibiting dominant positive NF-κB activity by
TRAF6ΔK, as compared to inhibition of wtTRAF6. Further, over-expression of Syn
deletion muteins with TRAF6ΔK revealed a nearly opposite effect as compared to
wtTRAF6. While, the PDZ2 (+CTD) of Syn seemed to be sufficient for inhibition of
wtTRAF6, the Syn CTD (deletion muteins that lacked the NTD and (ΔN and ΔPDZ1)
were unable to attenuate TRAF6ΔK induced NF-κB activity. Meanwhile, ΔPDZ2 and
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Figure 4.27 Only full length Syn was found to interact with TRAF6. A) 293 cells
were seeded into 6 well plates and transfected with 1μg FLAG-TRAF6 and 1μg
indicated HA-tagged Syntenin construct. Western blots containing 50 μg protein of
whole cell lysates (WCL) of 293 cells harvested 24h after transfection of indicated
plasmids. Lysates supernatants were incubated with anti-FLAG agarose beads for 6
hours at 4°C. Absorbed proteins were eluted and denatured by 1x SDS-PAGE
buffer and β-mercapto ethanol at 95°C and then prepared for western blot.
Proteins were resolved on a 4-12% gradient gel and transferred onto a PVDF
membrane. Membranes were blotted with LEFT) anti-FLAG antibody or RIGHT)
anti-HA antibody. A representative blot of two independent experiments is shown.
Left panel indicates sucessful FLAG-TRAF6 precipitation, right panel indicates that
only full length HA-Syn co-immunoprecipitated with FLAG-tagged TRAF6.
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ΔPDZ1+2 were yet able to inhibit TRAF6ΔK induced NF-κB activity (Figure 4.28B).
This result, taken together with previous reports, supports that the NTD of Syntenin
interacts with ubiquitinated TRAF6 i.e. an active “open” TRAF6 (Wang, Galson et al.
2010) rather than “closed” un-ubiquitinated TRAF6.
4.3.4 Inhibition of Src Family Kinase increases Syn attenuation of TRAF6 induced NF-κB
activity
Syn has been reported to activate NF-κB by binding to c-Src, inducing
downstream target genes leading to cell migration and invasion (Boukerche, Aissaoui et
al. 2010). Classically Src has been found to be neither necessary nor sufficient for NFkB activity, only increasing the activity of NF-B over that derived by IKK-dependent
release of IB by activation of PI-3K and Akt/PKB (Madrid, Mayo et al. 2001, Storz,
Doppler et al. 2004, Wang, Wara-Aswapati et al. 2006). Presumably, TRAF6 can further
activate NF-B via c-Src in this manner.

Additionally, TRAF6 and c-Src induce

synergistic AP-1 activation via a PI3-kinase-AKT-JNK pathway (Funakoshi-Tago, Tago
et al. 2003). However, at least one report implicates c-Src directly activating NF-B
during hypoxic conditions via mROS (Funakoshi-Tago, Tago et al. 2003, Lluis, Buricchi
et al. 2007). In some of our NF-B luciferase assays, Syn appeared to inhibit TRAF6
with a nonlinear dose response (Figure 4.29A). When Syn was overexpressed in 293
cells, it appears to activate NF-κB in an inverted U dose response with a peak centered in
low concentrations (Figure 4.29A). It is possible that ectopic Syn inhibits TRAF6 only
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Figure 4.28 Syntenin inhibits TRAF6 in an Ubiquitin-dependent manner. A) Values
represent NF-κB activity resulting from co-transfection in 293 cells with indicated
amounts of mTRAF6 or mTRAF6ΔK, 50ng mSyn and 25ng NF-κB luciferase
reporter. A) A lysine deficient TRAF6 is inhibited less as compared to wtTRAF6 by
Syntenin. B) Syn ΔN is less effective at inhbiting TRAF6ΔK vs wtTRAF6.
Suggesting that the N terminus may bind to Ubiquinated, activated TRAF6. 293
cells were transfected with 25ng mTRAF6 or mTRAF6ΔK, 50ng of indicated
Syntenin mutein and 25ng NF-κB luciferase reporter. Bars are quantification of
(average±s.d.) for a representative experiment done in triplicate and
qualitatively similar to at least three independent experimental replicates.
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when the amount corresponds to activated “open” TRAF6 with proper stoichiometry, due
to it’s own ability to activate NF-κB. To investigate this further, I sought to remove the
downstream activation of Src. First, I determined the effect of PP2, a selective inhibitor
of Src family kinase (SFK) members (Hanke, Gardner et al. 1996), on activation of the
NF-B pathway (Figure 4.29B-D). Indeed, ectopic Syn was found to activate NF-κB as a
dominant positive in 293T cells and this activity was inhibited by addition of PP2 (Figure
4.29B). Notably, this Src-dependent activity did not have a comparable dose response.
When PP2 was added to 293 cells transfected with a dominant positive amount of
TRAF6, there was an order of magnitude less NF-κB activity, and Syntenin was found to
inhibit TRAF6 induced NF-κB activity, regardless of the presence of the PP2 inhibitor
(Figure 4.29C, 4.29D). Interestingly, inhibition of Src Family Kinases by PP2 was found
to exaggerate the ectopic Syntenin-dependent attenuation of TRAF6-activated NF-κB
activity by six fold in a more linear manner, supporting the hypothesis that Syn inhibition
of TRAF6 has a stoichiometric mechanism, possibly due to the mutual activation of Src
by both TRAF6 and Syn.
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Figure 4.29 Pharmacological inhibition of Src Family Kinases increases the
attenuation of TRAF6 induced NF-κB activity by ectopic Syntenin. A) Ectopic
exprsssion of Syntenin activates NF-κB in a Src dependent but Syn inhibits distinct
dose response. A) 293 cells transfected with indicated amounts of HA-Syntenin and
25ng NF-κB luciferase report activates NF-κB at low dosage B) 293T cells were
plated 24 hours prior to trasnfected with indicated amounts of HA-Syn or EV: pHA
empty vecotor and 25ng NF-κB uciferase reporter, 6 hours after transfection cells
were treated with Src inhibitor PP2 (10μM) and allowed to rest O.N. before
luciferase assay C) PP2 inhibits TRAF6, attenuation of TRAF6 dominant positive is
by Syntenin is not affected by PP2 treatment. 25 ng of Syn and or TRAF6 were
transfected into 293T cells and treated with PP2 to a final concntration of 10μM as
indicated 6 hours after transfection. D) Normalized values indicating effect of PP2
upon Syn attenuation of TRAF6 induced NF-κB acttivty in 293 cells transfetd with
25ng TRAF6 and indicated amounts of mSyn. Cells were treated with PP2 as
indicated to a final concentraion of 10μM. Values are quantified as average±s.d. for
a representative experiment done in triplicate and qualitatively similar to at least
three independent experimental replicates.
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4.3.5 Syntenin can relocalize TRAF6 to the nucleus
Although TRAF6 is typically located in the cytosol in order to act as a signal
transducer in the TIR signaling pathway, there have been reports of intranuclear TRAF6
(Bai, Kitaura et al. 2005, Bai, Zha et al. 2008, Pham, Zhou et al. 2008). Additionally, our
group has reported that truncated inactive TRAF6 muteins (RZ-, ccMATH- and MATH
domains), in contrast to WT, localize to both the nucleus and cytoplasm (Wang, Galson
et al. 2010). To visually contextualize the inhibitory effects of Syntenin upon TRAF6,
the subcellular distribution of both molecules as ectopically expressed fluorescent
chimeras was examined using confocal microscopy (Figure 30). Surprisingly, overexpression of Syn not only attenuates TRAF6 signaling, but also causes nuclear
localization of ectopic WT TRAF6-YFP in 293 cells, as evidenced by colocalization with
the co-expressed HcRed-Nuc nuclear marker.

Similarly, ectopic co-expression of

unlabeled TRAF6 resulted in translocation of GFP-Syn into the nucleus (Figure 4.30).
This nuclear localization correlates with the endogenous subcellular distribution in
RANKL stimulated RAW264.7 cells (Figure 4.31). This result discounts the possibility
that nuclear localization of TRAF6 by Syn is merely an artifact of over-expression.
Immunoflourescent staining of endogenous Syn and TRAF6 reveals both proteins as
largely cytoplasmic, but then simultaneously enter the nucleus (as seen by similar
temporal kinetic) approximately 15min following stimulation of cell surface receptors
that initiate TRAF6 mediated signal cascades.
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Figure 4.30 Expression of ectopic Syntenin translocates TRAF6 into the nucleus.
Expression plasmids (30 ng) coding for TRAF6ccMATH-YFP or YFP control vector
(green) were co-transfected with pHcRed1-Nuc vector (30 ng) into one well of preinoculated 293 cells in a 96-well tissue culture plate. Confocal images were taken
after 24 hours of transfection. The fluorescent signal of HcRed1-nuc, a nuclear
localization marker, is pseudo-colored red. Confocal mages represent a subset of
fields taken from three independent, qualitatively similar experiments.

Traditionally, PDZ domain-bearing proteins are associated with membranes,
suggesting that these domains are involved in either organizing transmembrane protein
complexes at the plasma membranes or recruiting proteins to membranes from the
cytosol. Here, a Syn-TRAF6 complex promotes sequestration of TRAF6 into the nuclear
compartment. Sequestration may promote transcriptional activity or attenuate signaling
to the nucleus by removing TRAF6 from its cytosolic signal transduction location.
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Figure 4.31 Subcellular localization of endogenous Traf6 and Syn in RANKL
simulated RAW264.7 cells. RAW264.7 cells were seeded into 96 well plates, the next
day they were stimulated with RANKL (50ng/mL) for 6-8 hours prior to fixing with
4% PFA and subsequently processed for immunolabelling and confocal imaging.
Syntenin and TRAF6 were immuno-labeled in separate wells and then
counterstained with Alexa488 (green) conjugated antibody. Confocal mages
represent a subset of fields taken from three independent, qualitatively similar
experiments.
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4.3.6 Domains of Syntenin involved in relocalizing TRAF6 to Nucleus
With both the Syn and TRAF6 deletion muteins available, the next set of
experiments aimed to interrogate which domains were either necessary or sufficient for
Syntenin mediated TRAF6 nuclear relocalization. When expressed by itself, GFP-Syn
was found throughout the cell. However, when co-expressed with either RZcc (1-358) or
wtTRAF6, ectopic GFP-Syntenin localizes primarily to the nucleus (visualized by ectopic
expression of HcRED Nuc) and generates filipodia-like structures in 293 cells (Figure
4.32). Expression of inactive vectors coding for either the RZ or MATH domains cotransfected with GFP-Syn did not display differences from control, with Syn expressed
throughout the cell (Figure 4.32).

Figure 4.32 Syntenin is enriched in the nucleus of 293 cells activated by ectopic
TRAF6 or RZcc. 293 cells were seeded into 96 well plates and transfected with 25
ng GFP-Syn, 25 ng of the nuclear marker HcRED Nuc and 25ng of control empty
vector or TRAF6 muteins as indicated.
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These results correlate with NF-κB activity data, demonstrating that the MATH domain
of TRAF6 is not necessary for Syntenin nuclear enrichment or attenuation of TRAF6
signaling.

These findings contradict reports that the nuclear localization of Syn is

inversely correlated with podosome/plasma membrane formation in epithelial cells
(Zimmermann, Tomatis et al. 2001) since an increase in podosome/filipodia is observed
when Syn is enriched in the nucleus. A possible mechanism here could be that activated
TRAF6 must interact with other molecules such as Ubiquitin, before binding and cotranslocating with Syn. Or, perhaps the effects on activity and subcellular localization
have distinct mechanisms. To determine Syn domains critical for TRAF6 nuclear
translocation, Syn deletion mutants were coexpressed with TRAF6-YFP in 293 cells
(Results summarized in Table 8).

Table 8 Summary of Syn Domains Effects upon TRAF6 Activity and Localization.

The addition of wtSyn results in translocation of TRAF6 to the nucleus in nearly all
transfected cells expressing the TRAF6-YFP mutein as demonstrated by colocalization
with ectopically expressed HcRed-Nuc mutein (Figure 4.30, 4.33). Coexpression of
SynΔN with TRAF6-YFP in 293 cells produced a mixed population of TRAF6 in both
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the cytoplasm and nucleus (Figure 4.33). When co-expressed with SynΔPDZ1+2 or
SynΔPDZ2 muteins, TRAF6-YFP remained largely cytoplasmic, which is similar to
normal TRAF6 subcellular expression (Figure 4.33). Collectively these results suggest
that the NTD domain of Syn is necessary but insufficient for TRAF6 re-localization to
the nucleus. Mechanistically this may be due to the ability of the Syn NTD to bind
Ubiquitin ergo “open” TRAF6. On the other hand, coexpression of SynΔPDZ1 (retaining
the PDZ2 and CTD of Syntenin) with TRAF6-YFP was able to relocalize TRAF6-YFP to
the nucleus, suggesting that the dominant factor in Syn mediated relocalization of TRAF6
may be either the CTD or PDZ2 (Figure 4.33).

Figure 4.33 Intranuclear translocation of TRAF6 depends on NTD and PDZ2 and
CTD of Syn. Removal of the C-terminus precludes TRAF6-YFP enter into the
nucleus. Images are merged signals from confocal subfields that represent three
independently conducted experiments the nucleus is visualized by transient
transfection of HcRED-Nuc reporter.
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Unlike wtTRAF6, TRAF6C70A is inactive as an E3 ligase and deficient in polyubiquitination (Walsh, Kim et al. 2008). We confirmed this result and importantly
detected monoubiquitinated. TRAF6c70AYFP and TRAF6ΔRYFP, which in the case of
C70AYFP revealed as a faint but distinct band when FLAG-C70AYFP was transfected
into 293 cells, then immunoprecipitated by FLAG and resolved by SDS page and
revealed by immunoblotted using anti-Ubiquitin antibody (Figure 4.34).

Figure 4.34 TRAF6C70A is deficient in poly-ubiquitination. 293 cells were
transfected with indicated plasmids and then prepared for immunoprecipitation
using FLAG antibody and resolution by SDS page and detection by Immunoblot on
PVDF membrane. At left FLAG-C70AYFP and the ΔR muteins are deficient in
poly ubiquitination while smear above full length TRAF6 represents ply-Ub
modification. At right is control blot confirming FLAG IP occurred and ΔR mutein
is unstable (smear beneath are degradation). *Lowest two bands in each lane
of both micrographs are antibody heavy (HC) and light (LC) chains
respectively (Wang 2010, unpublished).

119

Ectopic expression of TRAF6C70AYFP in 293 cells reveals a subcellular localization,
primarily in the cytoplasm, similar to that of wtTRAF6 (Figure 4.35). When Syn was
co-expressed with TRAF6C70A-YFP, TRAF6C70A-YFP failed to translocate to the
nucleus. Additionally, when TRAF6C70A-YFP was co-expressed with the Syn deletion
muteins, none of them were able to translocate TRAF6C70A-YFP to the nucleus.
Interestingly the large TRAF6C70A-YFP punctae decreased with coexpression of all Syn
muteins except SynΔN and TRAF6C70A-YFP seemed more diffuse or in speckles in the
cytosol (Figure 4.35). This might indicate that Syn may not bind TRAF6 that is not polyUb, but might use it’s others domains to block TRAF6 sequestosome formation, perhaps
by association with another molecule that interacts with the Syn PDZ2 or CTD and in
turn recognizes TRAF6 via a T6IM (i.e. Sox4).

Figure 4.35 Intranuclear translocation of Syntenin and TRAF6 depends on an active
ubiquitylated, TRAF6 and the NTD of Syntenin. Images are merged signals from
confocal subfields that represent three independently conducted experiments the
nucleus is visualized by transient transfection of HcRED-Nuc reporter.
TRAF6C70A displays subcellular localization opposite to that of wtTRAF6. Scale
bar= 20μm.
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Collectively, these results suggest that the PDZ2 and CTD of Syn requires TRAF6 + Ub
to bind TRAF6 and bring it to the nucleus which interferes with TRAF6 signaling in the
cytoplasm. Further, TRAF6 - Ub blocks the Syn NTD from interacting and translocating
TRAF6 to the nucleus. These results are corroborated by reports that Syn binds ubiquitin
directly through a novel Ub binding pocket, using a mechanism where the recognition
involves both N- and C-termini of Syn rather than its PDZ domains, which instead
mediate prerequisite dimerization (Rajesh, Bago et al. 2011). Furthermore, Syntenin
interacts equally well with K48- or K63-linked polyubiquitin chains in a NTD- CTD Syn
homo-dimer dependent manner (Rajesh, Bago et al. 2011). Since the NTD of Syn is
involved in binding to Ub and likely, ubiquitinated TRAF6, the inability of Syn to
interact and relocalize the C70A muteins support this model of interaction. The CTD
(194-298) of Syn, comprised of the linker (T6IM), PDZ2 and CTD, alone are also critical
components of Syn involved in TRAF6 nuclear localization.
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4.4 Characterization of Sox4-TRAF6 Interaction
4.4.1 Sox4 is a novel T6IM bearing protein that inhibits TRAF6
Although TRAF6 and Syntenin co-localize in the nucleus, neither molecule bears
a NLS. Furthermore, Syntenin attenuates RZcc dominant positive signaling to NF-κB.
These two results led to our hypothesis that Syn was acting as an adapter protein for
another T6IM-bearing protein.

Presumably, this novel T6IM-bearing protein would

associate with TRAF6 in a trimeric complex with Syn, mediating the attenuation of NFκB signaling and intranuclear localization of TRAF6.

Sox4 has been reported to

accumulate with Syntenin in the nucleus (Beekman, Vervoort et al. 2012). Sox4 has a
bipartite nuclear localization signal (BP-NLS) at positions 60-77 and 129-136, as
identified by the Nuclear Protein Database(NPD,
http://npd.hgu.mrc.ac.uk/user/index.php).

Furthermore, analysis of the Sox4 primary

amino acid sequence revealed a perfect TRAF6 TIM immediately adjacent to the HMGBox DNA binding domain at AA 147-154 (Figure 4.36).
To investigate the possibility that Sox4 cooperates with Syn to modulate TRAF6
signaling and subcellular localization, a similar strategy to that employed for
interrogating the nature of Syn-TRAF6 interactions was utilized, with Sox4 substituting
for Syntenin in the experiments. Subsequent experiments were designed to assess
changes

in

activity,

subcellular

morphological/developmental effects.

localization,

physical

interactions

and

NF-κB-Luciferase reporter assays from bulk

cellular extracts revealed that ectopic Sox4 attenuates NF-κB activity in a dose dependent
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Figure 4.36 Sox4 and Syntenin share many motifs for binding proteins that have
been either previously implicated with TRAF6 signaling or direct TRAF6 binding.
Putative TIMs were discovered in both Syn-1 & Sox4 primary sequences. The Sox4
TIM is a consensus sequence also predicted by ELM Analysis. A) Schematic of Sox4
domains and important binding motifs. B) ELM Analysis confirms canonical
TRAF6 TIM next to DNA binding domain of Sox4.

GRR: glycine rich region of Sox4 (151-155; 333 - 397)
SRR: serine-rich region
TAD/DD: Transactivation/degradation domain
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manner when either 293R cells were stimulated with IL-1β or 293T cells transiently
transfected with TLR4 (Figure 4.37).
In the case of the ectopic TLR4 dominant positive, Sox4 is more effective than
Syn at attenuating the NF-κB signal when equivalent amounts of plasmid was
transfected. This suggests that Sox4 is the dominant factor in Syn inhibition of TRAF6
dependent receptor
signaling to NF-κB (Figure 41B). Similarly, Sox4 was also able to inhibit the upstream
TIR adapter, MyD88, in a dose dependent manner (Figure 4.38).
The next step was to use TRAF6 as a surrogate for upstream signaling events in
TIR signaling and determine whether Sox4 inhibited the TRAF6 dominant positive in a
manner that depends upon the MATH TIM groove. In accordance with my hypothesis,
ectopic Sox4 was able to attenuate wtTRAF6-induced NF-κB activity in 293R cells, but
was unable to attenuate the RZcc dominant positive (Figure 4.39A). Similar to Syn,
attenuation of TRAF6 signaling by Sox4 was affected by the Ub state of TRAF6. Both
Sx4 and Syn were reduced in their ability to inhibit NF-κB activity induced by
TRAF6ΔK (Figure 4.39B).

This suggests that Syn and Sox4 cooperatively inhibit

TRAF6 possibly through Syn interaction with Ubiquitinated TRAF6 and Sox4.
Encouraged by these results, I sought to correlate the activity assays with information on
the physical interaction of Sox4 with TRAF6. First, confocal microscopy revealed that
endogenous Sox4 and TRAF6 colocalize within cytoplasmic punctae pre-osteoclast 4B12
cells upon RANKL stimulation (Figure 4.40). Co-immunoprecipitation of WCL from 293
cells revealed that Sox4 precipitated with TRAF6-YFP but not RZcc-YFP (Figure 4.41).
Thus, TRAF6- Sox4 interactions depend on the MATH domain.
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Figure 4.37 Sox4 inhibits TIR receptor dependent NF-κB activation. A) 293R cells
were transfected with 25ng NF-κB luciferase reporter and indicated Sox4. 24 hours
later the cells were stimulated with IL-1β (10ng/mL) for 6-8 h and assayed for NFκB activity. B) 293 cells were transfected with 200ng TLR4 or EV and 50ng of LVSyn or LV-Sox4 as indicated along with 25ng NF-κB luciferase reporter to examine
the effect of Sox4 on TLR4 signaling. EV= pcDNA3.1 empty vector. Values are
quantified as average±s.d. for a representative experiment done in triplicate and
qualitatively similar to at least three independent experimental replicates.
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Figure 4.38 Sox4 inhibits NF-κB activation induced by dominant positive ectopic
expression of MyD88. 293T cells were transiently transfected with 50ng MyD88,
indicated amounts of LV-Sox4 expression plasmid or EV (pcDNA 3.1 empty vector),
and 25ng NF-κB luciferase reporter. The next day cells were prepared for
luciferase assay. Values are quantified as average±s.d. for a representative
experiment done in triplicate and qualitatively similar to at least three independent
experimental replicates.
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Figure 4.39 Sox4 inhibition of TRAF6 activated NF-κB depends on the MATH
domain and Ubiquitinated TRAF6. A) 293 cells were transiently transfected with
25ng NF-κB luciferase reporter along with 25ng (EV) pFLAG, TRAF6 or RZcc and
indicated amounts of LV-Sox4 24 hours prior to lysis and harvesting for luciferase
assay. B) Normalized luciferase activity of 293T cells transfected with 25ng of
indicated plasmids and 25ng NF-κB luciferase reporter 24 hours prior to
preparation for luciferase assay. Values are quantified as average±s.d. for a
representative experiment done in triplicate and qualitatively similar to at least
three independent experimental replicates.

127

Figure 4.40 Endogenous Sox4 and TRAF6 co-localize in cytoplasm of stimulated
4B12 cells upon RANKL stimulation. 4B12 cells were fixed and immunostained
following 5min stimulation with 50ng/mL RANKL or a control stimulation
(optimum only). Confocal mages are a subfield of at least three fields taken from
three experimental and two biologically independent experiments that are
qualitatively similar.
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Figure 4.41 Sox4 interaction with TRAF6 depends on the MATH domain. Western
blots containing 50 μg protein of whole cell lysates (WCL) of 293 cells plated into 6
well tissue culture plates and harvested 24h after transfection of 1μg TRAF6-YFP,
RZcc-YFP and LV-Sox4 plasmid as indicated. Lysates were incubated with antiYFP antibody and subsequently blotted with anti-Sox4 (left) or anti-YFP (right)
antibody following SDS-PAGE and transfer to PVDF membrane. A representative
blot of three independent experiments is shown. Left panel indicates interaction
with full length TRAF6-YFP but not RZcc-YFP, Left panel indicates that YFP IP
occurred.
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To expand on this data, the comparative subcellular localization of IRAK1, Sox4,
Syntenin and TRAF6 was visualized by confocal microscopy.

Consistent with our

observations thus far, in 4B12 cells, ectopic Syn disrupts IRAK1 and TRAF6
colocalization and neither Syn nor Sox4 colocalizes with IRAK1 in 4B12 cells (Figure
4.42). To underscore the visual data, Sox4 was knocked-down by co-transfecting siRNA
against Sox4 in 293 cells concurrently with transient transfection of TRAF6
±Syntenin/Sox4 and an NF-κB Luciferase reporter.

Without Sox4, TRAF6 activity

increased, arguing that Syntenin was unable to attenuate TRAF6 dependent NF-κB
activity (Figure 4.43). Taken together, these data suggest that TRAF6 and Sox4 bind in a
MATH domain-dependent manner with Syntenin, serving cooperatively to stabilize the
cargo carrying capacity of Sox4 for TRAF6 nuclear translocation and the attenuation of
NF-κB activity.
4.4.2 Quantification of relative Sox4, TRAF6 and Syn mRNA levels in various cell types
The differential ability of ectopic TRAF6 to act as a dominant positive for NF-κB
activity in cell lines of different lineages is a novel finding that prompted further
examination. One possibility for the observed difference could be that the molecules
regulating TRAF6 (Sox4 and Syn) are differently expressed in the pre-osteoclast
RAW246.7 and 4B12 lines vs. the commonly used 293 epithelial cells. To test this
hypothesis, the appropriate primers were designed to quantify relative amounts of
endogenous mRNA expression of TRAF6, Sox4 and Syn by qPCR was conducted in LPS
stimulated THP-1 and RAW264.7 cells and compared against steady-state mRNA levels
in 293 cells (Figure 4.44). Interestingly, 293 cells were found to have relatively low
amounts TRAF6 and virtually no Syn mRNA expression as compared to Sox4. At
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steady state, THP-1 has equally low amounts of TRAF6, Sox4 and Syn, with Sox4 levels
nearly 30 fold lower than that found in 293 cells. Upon LPS stimulation Syn levels
tripled before falling to tice that of steady state by 5 hours and persisting at two fold
steady state for 24 hours. Sox4 mRNA rose progressively to 20% the steady state levels
found in 293, but 10 fold higher than base line levels in unstimulated THP-1 cells. In
RAW 264.7, TRAF6 mRNA expression was 3 fold higher than that found in 293 cells at
steady state, increasing two fold by 3 hours post LPS stimulation and persisting for 24
hours. This represents a 6-fold increase over 293 steady state levels of TRAF6 mRNA
expression. Syn mRNA expression in RAW264.7 was the highest in RAW264.7 of the
three cell lines compared, at least 5 fold higher than that of THP-1 or 293 expression
levels. Upon LPS stimulation, Syn mRNA expression increased to 10x then 15x at 3h
and 6h respectively over 293 steady state levels, or 2x and 2.5x the baseline Syn levels in
RAW264.7 itself. Elevated Syn mRNA was sustained in response to LPS stimulation in
RAW264.7 for upon to 24 hours, although by 24 hours the levels were reduced to 2x,
similar to levels at 3hours.

Surprisingly, RAW264.7 seemed to be devoid of Sox4

mRNA expression in both steady state and LPS stimulated conditions. In summary, 293
cells have low TRAF6 and Syn mRNA expression but high Sox4 expression that are
consistent with the embryonic origin of the epithelial cell line.

On the other hand,

RAW264,7 cells express higher levels of Syn and TRAF6 but virtually no Sox4. Upon
stimulation, TRAF6 mRNA levels increase in RAW264.7 but, Syn levels elevate
dramatically in response to LPS stimulation. THP-1 cells on the other hand, show similar
starting points for TRAF6, Syn and Sox4 mRNA expression and LPS increases Syn and
Sox4 expression but the increase in Sox4 is later and more robust. Collectively, these
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data suggest that mRNA expression of Syn critically regulates NF-κB activation in TIR
signaling. Further, ectopic TRAF6 may act as a dominant positive in 293 cells and not
RAW264.7 cells because the inhibitory effect of Syn is more readily overcome in 293 vs
RAW264.7.

Figure 4.42 Syntenin disrupts IRAK1 and TRAF6 colocalization. 4B12 cells were
transiently co-transfected with the indicated plasmids 24h prior to fixation with 4%
PFA and DAPI staining to visualize the nuclei. Confocal mages represent a subset
of fields taken from three biological replicates.
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Figure 4.43 Syntenin inhibition of TRAF6 is dependent on Sox4 interaction with
TRAF6. Sox4 was knocked down in 293 cells by transfection of siRNA to Sox4 and
the 25ng indicated plasmids and 25ng NF-κB luciferase reporter. 24h later cell
cultures were lysed and harvested for luciferase assay. Values are quantified as
average±s.d. for a representative experiment done in triplicate and qualitatively
similar to at least two independent experimental replicates.
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Figure 4.44 Kinetic profile of mRNA expression of TRAF6, Syn and Sox4 in 293 vs.
LPS (1μg/mL) stimulated THP-1 or RAW264.7 cells. mRNA was extracted from
cells at indicated timepoints following stimulation by LPS and processed for qPCR.
Values represent relative expression levels were calculated using Ct method and are
average±s.d. for an experiment done in duplicate and qualitatively similar to at least
two independent experimental replicates.
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4.5 Syntenin and TRAF6 involvement in Neurite Formation
Amongst the inputs following injury to the nervous system, TRAF6 can transduce
many of the signals intended for cell survival, death or proliferation. For example,
TRAF6 mediates p75 neurotrophic signaling, which is essential for activating either
apoptosis or survival of the cell dependent cellular context and p75 stimulation
(Khursigara, Orlinick et al. 1999, Wu and Arron 2003). Syntenin has been shown to both
couple transmembrane proteoglycans to cytoskeletal components and play a role in
targeting receptors to the synaptic cleft (Zimmermann, Tomatis et al. 2001, Beekman and
Coffer 2008, Chen, Du et al. 2008). Previously, our group demonstrated that overexpression of c-Src, MyD88 or TRAF6 in 293 cells, or addition of IL-1β to 293R cells,
created long filipodia like cellular structures, reminiscent of axons or neurites (Wang,
Wara-Aswapati et al. 2006). These results, and our examination of TRAF6 and Syntenin
interaction, prompted us to ask whether 293 cells could be differentiated into a neuronallike cell merely by ectopic expression of TRAF6. Consequently, I sought to characterize
the roles of Syntenin and TRAF6 in a neuronal PC12 cells. PC12 cells are an established
neuronal cell line derived from rat pheochromocytoma cells. PC12 are widely used to
study neurobiology and neurotoxicology as a model of neuronal differentiation.
Importantly, PC12 cells respond to NGF with morphological changes phenotypically
resembling sympathetic neurons. In PC12 cells, NGF stimulation causes proliferation,
extension of neurites and membrane excitability (Drubin, Feinstein et al. 1985,
Schimmelpfeng, Weibezahn et al. 2004, Garcia, Castillo et al. 2013). To test this, neurite
growth was compared in PC12 cells either transfected with TRAF6 or stimulated with
NGF (Figure 4.45). Transient transfection of PC12 cells with TRAF6 was found to
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Figure 4.45 Ectopic TRAF6 or NGF-induced neurite extension in PC12 cells. 24
hours prior to transfection with 50ng of pF-TRAF6 or pFLAG empty vector
(control), cells were plated on matrigel at a low density of (2x103 cells/cm2). The
next day, selected cells were treated with 50 ng/mL of human recombinant NGF
(Millipore). Top: Phase contrast images of cells on Day 0 prior to treatment with
NGF. Bottom: Phase contrast image of cells after 96h of NGF treatment.
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induce neurite formation over 96 hours with qualitatively similar lengths. Next, an
expression vector for PKB/Akt Plekstrin-homology domain joined to GFP (PH-Akt-GFP)
was used to detect phosphoinositol 3-kinase produced in response to either transfection of
TRAF6 or NGF stimulation in both PC12 and 293 cells for comparison. Phospho-Akt
(and also its PH domain when expressed ectopically) is localized at the tips of growth
cones, which supports a role for Akt in the regulation of neurite elongation (Higuchi,
Onishi et al. 2003, Read and Gorman 2009).

293 cells have been previously

characterized as pre-neuronal despite the widely held belief that they are kidney cells
(Shaw G 2002). Indeed, microarray data show that 293 are positive for the NGFR
receptor and they might be responsive to NGF stimulation. In both 293 and PC12 cells,
TRAF6 was able to induce neurite/filipodia like structures of qualitatively similar
morphologies (Figure 4.46, Figure 4.47).

This suggests that TRAF6 can drive the

differentiation events by over-expression, expanding on demonstrations that it is critical
by elimination (Geetha, Jiang et al. 2005, Wooten, Geetha et al. 2005).
Having confirmed and clarified the mechanisms by which Syntenin negatively
regulates TRAF6 signaling, I sought to evaluate whether Syntenin can inhibit the ability
of TRAF6 or NGF to differentiate 293 cells. Using ectopically expressed PH-Akt-GFP
reporter to monitor recruitment to growth cones and newly formed neurites, wtTRAF6
and/or mSyn was co-transfected into cells that were either stimulated with 50ng/mL NGF
(+NGF) for 96 hours or a control vehicle (-NGF) 24 hours after transfection. Confocal
images were then taken at 24h, 48h, and 96h post transfection for analysis (Figures 4.484.50). At 24hours, cells that were transfected with either mSyn or wtTRAF6 alone
displayed filipodia/neurites. However, transfection of both mSyn and TRAF6 seemed
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to have a cancelling effect, and neurite outgrowth was not observed. Cells that were
stimulated with NGF all displayed neuronal growth with the exception of the condition
where mSyn and TRAF6 were transfected in addition to NGF stimulation. Furthermore,
stimulation of the cells with NGF produced a more robust overall length in neurite
growth.

In particular, cells stimulated with NGF+mSyn or NGF+TRAF6 had

dramatically longer neurite formation vs. NGF alone (Figure 49). Neurite extension are
marked with blue wedges, but only extensions that were at least 1x the diameter of the
cell. By 48 hours post-transfection, 293 cells co-transfected with wtTRAF6 and mSyn
seemingly overcome the inhibitory effect of ectopic expression of both plasmids.
However, the overall length lagged behind the other conditions where neurites began to
appear at 24hours post transfection. Notably, the PH-Akt-GFP displayed a neuronal
buton like appearance, decorating the lengths of the membrane extensions, suggesting the
development of a neuronal phenotype (Figure 4.49). The phenomena observed at 48hours
post-transfection continued for up to 96 hours post-transfection (Figure 51). By 96 hours,
though the “buton -like” structures seems to have largely disappeared, but the presence of
multipolar-, bipolar-r and unipolar-like “neurons” persisted (Figure 4.50).
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Figure 4.46 Ectopic expression of TRAF6 can act as a surrogate for NGF induced
neurite formation. PC12 cells were seeded onto covered chamber slides (Nunc) pretreated with matrigel. 24 hours later, Cells were then transfected with 25ng of
indicated plasmids or mock transfected with vehicle (optimum). The following day,
select cells were stimulated with 50ng/mL NGF. NGF stimulated cells were
subsequently stimulated at 72hours with 50ng/mL NGF (Millipore).
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Figure 4.47 Ectopic expression of TRAF6 can act as a surrogate for NGF induced
neurite formation. 293cells were seeded onto covered chamber slides pre-treated
with matrigel. 24 hours later, Cells were then transfected with 25ng of indicated
plasmids or mock transfected with vehicle (optimum). The following day, select
cells were stimulated with 50ng/mL NGF. NGF stimulated cells were subsequently
stimulated at 72hours with 50ng/mL NGF (Millipore).
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Figure 4.48 Ectopic expression of TRAF6 is sufficient to induce neurite formation,
but inhibits neurite formation when coexpressed with Syn. 293 cells were seeded
onto chambered cover slides pre treated with matrigel and transfect with 25ng of
indicated plasmids and stimulated with NGF as previously described. Total amount
of DNA transfected was normalized across all conditions with pcDNA3.1.
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Figure 4.49 Ectopic expression of TRAF6 or Syntenin in 293 cells induces a
neuronal differentiation state. Inhibition of neurite extension by co-expression of
ectopic Syntenin and TRAF6 is overcome 48 hours post transfection.
293 cells
were seeded onto chambered cover slides pre treated with matrigel and transfect
with 25ng of indicated plasmids and stimulated with NGF as previously described.
Total amount of DNA transfected was normalized across all conditions with
pcDNA3.1. Wedges indicate extensions that are at least twice the diameter of the
cell.
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Figure 4.50 PH-AKT-GFP localizes to membrane extensions induced by ectopic
expression of TRAF6 or Syntenin or NGF stimulation in 293 cells and persists 96
hours post transfection. Inhibition of neurite extension by co-expression of ectopic
Syntenin and TRAF6 is overcome 48 hours post transfection. 293 cells were seeded
onto chambered cover slides pre treated with matrigel and transfect with 25ng of
indicated plasmids and stimulated with NGF as previously described.
Total
amount of DNA transfected was normalized across all conditions with pcDNA3.1.
Wedges indicate extensions that are at least twice the diameter of the cell.
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4.6 The Osteological Synapse
4.6.1 Rationale
It has been reported that RANK accumulates in membrane rafts, and these
specialized domains may play an important role in the RANK signal transduction (Ha,
Kwak et al. 2003, Ha, Kwak et al. 2003). Further, DAP12, BTK, BLNK, and PLC, as
well as RANK, were recruited to caveolin-rich membrane domains, which are the crucial
signaling domains contained in lipid rafts, after RANKL stimulation (Shinohara, Koga et
al. 2008). Thus, I hypothesized that a synaptic complex between RANK bearing stromal
cells and osteoclast precursors similar to the immunological synapse exists.

This

“osteosynapse” (OS) would contain (on the osteoclast-side) both the RANK and ITAM
signaling pathways is generated by RANKL stimulation and contribute to the facilitation
of the osteoclastogenic signal transduction (Figure 4.5). Synapses are stable adhesive
junctions between two cells across which information is relayed by directed
secretion. The nervous system and immune system utilize these specialized cell surface
contacts to directly convey and transduce highly controlled secretory signals between the
constituent cell populations. The phagocytic synapse has also been described to form
when dectin 1-expressing phagocytes are exposed to particulate β-glucans, initiating
phagocytosis (Goodridge, Reyes et al. 2011).

Such examples suggest a conserved

organizational scheme that might be utilized by other biosystems, such as in the bone.
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Figure 4.51 Extracellular and Intracellular signaling molecules involved in
osteoclastogenesis that might comprise the osteosynapse.
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4.6.2 BTK but not Tec Kinase is recruited to the plasma membrane upon RANKL
stimulation
Based on the general structure of synapses, and the fact that osteoclast already
form an adhesive junctions with bone, I looked at the subcellular localization of the Tec
kinases BTK and Tec in the osteoclast precursor cell line RAW264.7.

Plasmids

containing Tec- or BTK-GFP were transfected into RAW264.7 cells and then stimulated
with RANKL. Confocal microscopy revealed that BTK and Tec are normally expressed
through the cytoplasm. Upon RANKL stimulation, within 5 minutes, BTK was recruited
to the plasma membrane as compared to control (GFP) or Tec Kinase-GFP.

The

relocalization of BTK was sustained for nearly an hour (Figure 4.52).
4.6.3 BTK is a component of Osteoclast Transcytotic Machinery and FSD
Osteoclasts are the primary cells responsible for bone resorption. Waste products
created by this process are transcytosed through the osteoclast and released through
the functional secretory domain (FSD). The mechanisms of this process are not fully
understood. To understand to the temporal stability of the OS, I stimulated RAW264.7
cells transfected with PH-BTK-GFP with RANKL for up to 96 hours. Interestingly, with
extended differentiation by RANKL, visualization of PH-BTK-GFP reveals a structure
that resembels the osteoclast FSD. Further, the appearance of negatively stained tunnels
from apical to basolateral membrane in RANKL differentiated RAW264.7 cells
expressing PH-BTK-GFP, possibly representing a means for resorbed bone to be
transcytosed through the cell and released by exocytosis at the FSD (Figure 4.52-4.54).
Of note, finger like projections did not appear to be localized to a single FSD but rather in
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multiplicity of FSDs. This suggests a scenario where the FSD is built at the sRANKLsignaling site. Such a scenario would help to explain why pre-osteoclasts differentiated
by membrane bound RANKL are more robust, functional osteoclasts (Galson, personal
communication). Here, in a co-culture cell-cell signaling system the RANKL signaling
complex is amplified and focal, producing single FSD structure.

Figure 4.52 Subcellular Distribution of Full length BTK-GFP and Tec-GFP. BTK is
recruited to Plasma Membrane but not Tec or GFP upon RANKL simulation. 50ng
of A) GFP B) BTK-GFP C) Tec-GFP was transfected in RAW 264.7 and seeded
onto a 96 well plate. 24h after transfection, cells were stimulated with RANKL
[50ng/mL] and imaged by confocal microscopy. Images are representative confocal
images extracted from z-stacks. Each pattern was observed consistently over the
course of 1-3 experiments in dozens of cells imaged. D) 3D Perspective view E) Max
projection of the same field of view.
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Figure 4.53 Left: 3D Max projection of PH-BTKGFP localization. Middle: z-stack
demonstrates the localization of BTK to ‘finger like’ villi of FSD in basolateral
membrane Right: 3D reconstruction from stack (Max projection) show FSD is not
only localized to one spot of basolateral membrane. Media was changed and fresh
RANKL was introduced every 48 hours during differentiation. 24h after
transfection, cells were stimulated with RANKL [50ng/mL] and imaged by confocal
microscopy. Images representative confocal images of consistently observed pattern
for 2 experiments in dozens of cells imaged.
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Figure 4.54 Visualizations of BTK-GFP expression and localization in osteoclasts
generated by 44-68h RANKL stimulation of RAW 246.7 cells. Images are
representative 3D Max projection of z stacks. Red arrows point out FSD; Blue
arrows denote transcytotic passageways.
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Chapter 5
DISCUSSION

5.1 Summary
Among the members of the TRAF protein family, TRAF6 has been uniquely
demonstrated to transduce both TNFR family signaling and the unrelated Interleukin-1/18
receptor/Toll-like receptor (IL-1R/TLR). The goal of my research was to elucidate novel
mechanistic details by which TRAF6 is activated under stimulating conditions and
characterize how TIM (TRAF Interaction Motif) bearing molecules regulate TRAF6
signaling across various cell types and receptor systems. Due to the intramolecular
association of its amino-terminus RING and carboxy-terminus MATH domains, TRAF6
exists in either an active-open or inactive-closed (autoinhibited) conformation (Wang,
Galson et al. 2010). Interaction of TIM bearing molecules with the TRAF6 MATH
domain modulates this state and downstream signaling. The experimental data suggests
that an open TRAF6 state facilitates both the activity and subcellular localization of the
molecule.

Furthermore, besides auto-inhibition, the adapter protein Syntenin

coordinately attenuates TRAF6 signaling to NF-κB in cooperation with the transcription
factor Sox4. While the interaction of TRAF6 and Syntenin has been previously reported,
as well as that between Sox4 and Syntenin, there has been no previous report of the
interaction between Sox4 and TRAF6. Interestingly, the TRAF6 interactions with Sox4Syntenin appear to relocalize normally cytoplasmic TRAF6 to the nucleus, providing a
novel mechanism for this largely unexplored, but previously reported, phenomenon
(Nakamura, Kadono et al. 2002). The results obtained by this study support the model of
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TRAF6 activation from a closed autoinhibited state by IRAK1 and attenuation by
association with a Syntenin/Sox4 complex, with possible sequestration of TRAF6 within
the nucleus (Figure 4.57), concomitant with the termination of cytoplasmic signaling.
Furthermore, in the nucleus TRAF6 can regulate transcription in a manner reported by
others (Bai, Zha et al. 2008, Pham, Zhou et al. 2008).

Figure 5.1 Summary of TRAF6-Syntenin-Sox4 interactions. Syntenin stabilizes
Sox4, which binds to TRAF6 after it has been opened and activated. TRAF6 autoubiquitination supports Syntenin binding possibly stabilizing the Sox4 TRAF6
interaction. Attenuation of TRAF6 signaling is either via the relocalization of
TRAF6 to the nucleus, away from cytoplasmic substrates for downstream signaling
or by direct inhibition of the RZcc by interfering with E2 binding or E3 ligase
activity.
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5.2 Activity of keystone molecules like TRAF6 involves multiple regulatory mechanisms
TRAF6 is associated with several distinct receptor signaling pathways, including:
p75 NTR neurotropic receptor, IL1R/TLR (TIR) and nucleotide-binding oligomerization
domain (NOD)-like receptor inflammatory responses, and RANK differentiation of
osteoclasts. Therefore, TRAF6 mediated signals are not only important for normal bone
homeostasis, but also host defense and development. Accordingly, TRAF6 has been
implicated in several disorders and disease (Table 9). Overexpression of immune-related
genes chronically stimulates the immune system and increases the risk for development
of disorders such as myelodysplastic syndrome (MDS) and rheumatoid arthritis. Somatic
mutations and copy number alterations (resulting from deletion or amplification of large
portions of a chromosome) are implicit in human lung cancer development. Detailed
analysis of lung cancer-associated chromosomal amplifications could identify novel
oncogenes. Reportedly, TRAF6 was highly expressed in non-small cell lung cancer
(NSCLC), small-cell lung cancer (SCLC) cell lines and tumors. Inhibiting TRAF6 in
these, two human lung cancer cell lines suppressed NF-κB activation, anchorageindependent growth, and tumor formation and were found to be necessary for
oncogenesis. Furthermore, TRAF6 overexpression in NIH3T3 cells resulted in NF-κB
activation, anchorage-independent growth, and tumor formation. TRAF6 is an oncogene
that is important for constitutive of NF-κB activation in RAS-driven lung cancers
(Starczynowski, Lockwood et al. 2011). Additionally, TRAF6 has been identified as a
target for cancer therapeutics due to its ability to amplify the expression of hypoxiainducible factor-1α (HIF-1α) and tumor angiogenesis (Luong le, Fragiadaki et al. 2013,
Sun, Li et al. 2013, Sun, Li et al. 2014).
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Disease

PubMed IDs
9432981(2)
9625770(2)
9915784(1)
9990007(1)
See all 63 »
9432981(2)
9625770(2)
9915784(1)
9990007(1)
See all 60 »
14579250(1)
16143987(2)
17925880(1)
18093978(1)
16527194(1)
18778854(1)
18759964(1)
19479062(1)
20097753(1)
12716453(1)
15320903(1)
16697380(1)
14579250(1)
12975380(1)
18036806(1)
17270016(1)
19439102(1)

necrosis

tumors

inflammation
ectodermal dysplasia
bone diseases
rheumatoid arthritis
virus infection
bone loss
pathological processes
osteoporosis
osteopenia
lymphoma
cancer

Table 9 Diseases associated with TRAF6 Gene. This table was generated from the
literature and the Gene Cards database.
http://www.genecards.org/cgi-bin/carddisp.pl?gene=TRAF6
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As such, it is necessary for cells to tightly regulate TRAF6 activity to preserve
normal physiological function and prevent pathogenesis. Understanding the mechanisms
of TRAF6 inhibition and activation can assist in rational drug design, targeting either
TRAF6 directly or its immediate interacting partners to avoid poor efficacy and off target
effects of current therapeutics. In particular, there is mounting evidence that warrants a
concerted focus on IRAK1 and its interaction with TRAF6 as a therapeutic target (Jain,
Kaczanowska et al. 2014, Rhyasen and Starczynowski 2015). Clarification of the nature
of these interactions is necessary because the details remain unclear and at times contrary
to expectations. For example, among the intracellular TLR signaling molecules MyD88,
IRAK4, IRAK1 and IKKβ, only IRAK1 expression down-regulates TRAF6 in 293 cells
(Hayden and Ghosh 2004, Muroi and Tanamoto 2008, Muroi and Tanamoto 2012).
5.3 IRAK1 disrupts TRAF6 autoinhibition
Previously our group reported data (Wang, Wara-Aswapati et al. 2006) supporting
a model for TRAF6 activation where, prior to stimulation, an intra-molecular interaction
between the RING-Zinc and MATH domains of TRAF6 generated an inactive “closed”
state reminiscent of protein kinase autoinhibitory mechanisms (Huse and Kuriyan 2002).
Others have reported autoinhibition in E3-ligases; for example, with SCF (Skp1 x CUL1
x F-box protein x ROC1) E3 ubiquitin ligase, where Nedd8 conjugation acts as a
molecular switch to drive the E3 into an active state by diminishing the inhibitory ECTD
x ROC1 interaction (Yamoah, Oashi et al. 2008). This study demonstrates that ectopic
expression of IRAK1 is able to disrupt the intramolecular RZ-MATH interaction, as seen
by an intermolecular interaction between RZ-only mutein with wtTRAF6 when coprecipitated in 293 cells co-expressing IRAK1 (Figure 4.10). Overexpression of IRAK1
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acts as a surrogate for receptor-dependent recruitment of TIM-bearing proteins and the
activation of TRAF6. Interactions with the TIM-recognition groove contained within the
MATH domain (Ye, Arron et al. 2002) disrupts the “closed” autoinhibited TRAF6,
opening the molecule, thereby enabling the RING-Zinc and coiled-coil domains to
interact with E2 conjugating enzyme (Yin, Lin et al. 2009) resulting in transubiquitination events. It is possible that the intramolecular RZ-MATH interaction is
between an internal TIM within the RZ (Figure 4.12) and the MATH TIM groove.
Mutation of the identified residues in a future study would easily resolve this question,
possibly producing a constitutively open TRAF6. Another possibility raised by this study
is that the inhibitory pair: Syn-Sox4 bind to open TRAF6, with Syn associating with
ubiquitinated TRAF6 via its NTD (as a dimer) while associated with the C-Terminus of
Sox4.

In this model, Sox4 associates with TRAF6 in a T6IM dependent manner.

Effectively then Sox4 and Syntenin bridge TRAF6 to associate the RZ and MATH
domains and conferring a “closed” conformation to TRAF6 (Figure 5.2). Importantly,

Figure 5.2 Model of TRAF6 RZ-MATH interacting to form closed TRAF6 via a
Syn-Sox4 bridge.
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this model does not preclude direct RZ-MATH interaction; as with all molecular
associations, there is an on-off rate and when the closed TRAF6 molecule breathes or is
opened by activators such as IRAK1, the opportunity for Syn/Sox4 to associate with
TRAF6 emerges. It would be interesting to see how IRAK1 affects the ubiquitination
state of TRAF6 or whether IRAK1 could rescue NF-κB activity in cells co-expressing
wtTRAF6+RZ dominant negative. One reason why ectopic expression of TRAF6 acts as
a dominant positive in 293 cells is that overexpression increases the concentration of a
low abundance equilibrium open TRAF6 state, permitting intermolecular RZ-RZ or RZMATH interactions (Figure 4.9). However, when poly-ubiquitination of TRAF6 exceeds
the recycling capability of the sequestosome, recycling ceases and activity is lost due to
the sequestration of inactive TRAF6 (Wang, Galson et al. 2010). This can be visualized
by the co-localization of p62 and TRAF6 (Figure 4.4) as well as the large cytoplasmic
TRAF6 punctate aggregates (Figure 4.6). IRAK1 was found colocalizes with the MATH
domain of TRAF6 (Figure 4.8) and that coexpression of IRAK1 with TRAF6-YFP
reduced the number and size of sequestosomes. One explanation might be that bound
IRAK1 prevents excessive ubiquitination by sterically shielding Lysines on the TRAF6
molecule or mono Ub from Ubiquitylating events. Ubiquitination of TRAF6 may also
have steric bulk effects, thus sustaining the active conformation, by preventing
intramolecular re-association.

Another mechanism of TRAF6 dominant positive

induction of NF-κB activity besides driving inter-molecular TRAF6 activation
interactions could be the that an excess of TRAF6 saturates the antagonistic effect of an
inhibitory molecule that associates with TRAF6 either constitutively (like a
safety/modulator), or in response to stimulatory or activating conditions (like a brake).
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5.4 IRAK1 and TRAF6 sequestosomes
From the literature and findings in this study, it seems clear that IRAK1 associates
with TRAF6 in a MATH and thus, T6IM dependent manner, However, the effect and role
that IRAK1 has on TRAF6 subcellular localization is less clear. The only published
mutations done in this area seem to affect SQSTM1 binding to autophagy effector
proteins LC3-A and -B.

Disrupting this event compromises the degradation of

ubiquitinated protein aggregates by autophagy (Pankiv, Clausen et al. 2007). Here,
IRAK1 was found to induce TRAF6 localization from cytoplasmic speckles into to large
sequestosomes (Figure 4.6), and activating TRAF6 by disrupting the RZ-MATH
interaction, possibly by disrupting the Sox4-Syn pair. This model comports with reports
that IRAK disrupts Syn interaction with TRAF6 and increases TRAF6 polyubiquitination (Chen, Du et al. 2008). Further, since the T6DP is insufficient to inhibit
TRAF6 signaling, a new peptide could be synthesized that more closely resembles either
the Syn T6IM or Sox4 T6IM. Such rational drug design of a peptide that resembles
physiological, endogenous inhibitors of TRAF6 might assist in attenuating TRAF6
signaling that is the basis for the various inflammatory and bone related diseases listed in
Table 9.
5.5 TRAF6 MATH domain recruits inhibitory molecules via its TIM groove
The TIM groove of the TRAF6 MATH domain (amino acid residues 346-522) is
involved in receptor binding upon different signaling events. Ectopic expression of the
MATH domain itself acts as a dominant negative for downstream events such as NF-κB
activity. Others have suggested that the MATH domain competes with endogenous
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TRAF in binding with upstream activators (Darnay and Aggarwal 1999, Yoshida, Kumar
et al. 2004).

Our group has suggested that the MATH domain is necessary for

autoinhibition of TRAF6 signaling (Wang, Galson et al. 2010). Here, the results of this
study suggest that the MATH domain is involved in recruiting inhibitory molecules to
regulate TRAF6 conformation and activity. Dominant positive signaling to NF-κB by
ectopic TRAF6 is independent of upstream activators.

I hypothesized that ectopic

expression of TRAF6 was providing a substrate for TRAF6 inhibitory binding.
Therefore, I reasoned that induction of TRAF6 dominant positive activity by a minimal
amount of ectopic TRAF6 should provide a reserve capacity for increased NF-κB activity
by increasing the stimulatory input using either LPS or IL-1β, Surprisingly, the superstimulatory effects of IL-1β were modest in 293R cells transfected with wtTRAF6
(Figure 4.14, 4.15), but much greater when the MATH domain was removed and the
RZcc dominant positive was additionally stimulated by exogenous ligand (Figure 4.15).
Unexpectedly, I was not able to induce a dominant positive effect using wtTRAF6 in
monocytic cell lines RAW264.7 and 4B12, but those same cells could be stimulated by
the RZcc dominant positive (Figure 4.16). These phenomena could be due to the fact that
different cell lines of various lineages express either different proteins or the same protein
in differing amounts to enable differential cellular functions. Indeed, when mRNA levels
were examined in monocytic-macrophage THP-1 or pre-osteoclast RAW264.7 vs preneuronal 293 epithelial kidney cells, the expression profile of our two putative inhibitory
molecules Syn and Sox4 showed marked difference between 293 and RAW264.7 cells
(Figure 4.44). Since TRAF6 acts as a dominant positive in 293 cells, and Sox4 levels are
high, the data suggest that ectopic TRAF6 is overcoming the inhibition of Sox4.
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However, RAW264.7 cells are deficient in Sox4 mRNA expression (Figure 4.4),
suggesting that Sox4 is not the dominant factor in the inability for TRAF6 to act as a
dominant positive for NF-κB activity.

Since the Sox4 protein is unstable without

Syntenin it would make sense to increase Syntenin expression and subsequently Sox4
protein levels in response to stimulatory events (LPS) to attenuate TRAF6 signaling.
This is exactly what the THP-1 data suggest, that Syn mRNA increases first, followed by
a delayed more robust Sox4 mRNA expression. Of course, mRNA expression doesn’t
always correlate to protein expression and so a logical follow up to this study would be to
examine the steady state and stimulated protein levels for TRAF6 Syn and Sox4 in the
various cell lines used in this study. Taken together, the data that describes differential
activation of NF-κB activity by TRAF6 in different cell lines point to the inhibitory
proteins identified in this study, that interact with the MATH domain. Additionally, these
inhibitory proteins are expressed differentially in various cell lines or tissue types s seen
at least at the RNA message level. This expands the capacity of the MATH domain to
inhibit beyond competition for upstream activators in experimental situations or
autoinhibition. It is estimated that 80% of proteins function within protein complexes
(von Mering, Krause et al. 2002), rather than as isolated species. For autoinhibited
proteins, an inhibitory module regulates activity of a functional domain. TRAF6 is
autoinhibited by the association of its MATH and RZ domain (Wang, Galson et al. 2010).
Although previously unreported, the RING domain of TRAF6 possesses a perfect
T6IM (Figure 4.12) that could be the basis for this interaction. Validation of this would
affirm the existence of a structurally “closed” inactive TRAF6 molecule. Generally,
autoinhibition can be either alleviated or reinforced by binding partners and post-
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translational modifications. Since the TRAF6 MATH domain is necessary for both
autoinhibition and extramolecular interactions with potential inhibitory molecules, our
next goal was to identify novel proteins that might compete with upstream effectors
possessing a T6IM peptide. Such inhibitory proteins could explain why either a putative
TRAF6 interaction peptide or a TRAF6 decoy peptide (T6DP) is insufficient for
activation of TRAF6 while functioning as an inhibitor (Ye, Arron et al. 2002, Poblenz,
Jacoby et al. 2007, Trudeau, Nassar et al. 2013). However, an IRAK1 based T6DP can
disrupt recruitment of TRAF6 to the cytoplasmic T6IM of RANK (Poblenz, Jacoby et al.
2007). A T6DP is available commercially for research purposes and inhibits RANKL
mediated osteoclast differentiation.

Small molecule inhibitors targeting the TRAF6

MATH domain have not been discovered and the T6DP is not currently in clinical use
(Morrow, Du-Cuny et al. 2011).
In general, the results of this study and those of others argue that a T6IM can
inhibit TRAF6 recruitment to, and activation by, receptor-activated IRAK1, but requires
full-length IRAK1 for downstream signaling. This suggests that domains of the IRAK1
molecule other than the T6IM are responsible for this activation.

Our group reported

that a majority of the IRAK1 kinase domain could support TRAF6 interaction (Boch,
Yoshida et al. 2003). Similarly, multiple T6IM have been located within the kinase
domains of IRAK-1 and -3 (Ye, Arron et al. 2002). This suggests that the whole IRAK1
molecule, either directly or indirectly, provides an activation function beyond the T6IM.
Although our group has reported that LPS-activated TRAF6 can recruit c-Src kinase that,
in turn, phosphorylates TRAF6 (Liu, Gong et al. 2012)this appears to occur downstream
of IRAK-dependent activation. In addition, the above-described direct interaction of
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TRAF6 with the IRAK kinase catalytic domain may suggest an inhibitory, rather than
activating function. A possible mechanism may simply be steric clashing with the RZMATH domain kinetic interaction that our group previously reported (Wang, Galson et
al. 2010). Since the results obtained in this study describe that full-length IRAK1 can
open/activate TRAF6, activation may simply be the result of the binding of a bulky
molecule to the TRAF6 MATH domain. In particular, the amino terminal Death domain
of IRAK1 that our group reported to not be critical for TRAF6 interaction (Boch,
Yoshida et al. 2003) but is associated with upstream receptor recruitment and may
provide steric bulk for maintaining TRAF6 in an open and active state or disrupt a Sox4Syn bridge between the TRAF6 RZ- and -MATH domains.
5.6 Molecular Dynamics of Syntenin TRAF6 Interaction
De novo identification of protein-protein interactions can be accomplished by in
vitro, in vivo, and in silico techniques. Often, several techniques are concomitantly used
by researches to find novel protein-protein interactions. Initially, an in vitro approach
was considered to identify T6IM bearing proteins that might regulate TRAF6
autoinhibition. In vitro methods for protein-protein interaction detection include tandem
affinity purification, affinity chromatography, co-Immunopreciptation, protein arrays,
protein fragment complementation, phage display, X-ray crystallography, and NMR
spectroscopy (Rao, Srinivas et al. 2014).

However, the discovery that ectopically

expressed Syntenin inhibits TIR signaling to NF-κB, but not TNFα induced NF-κB
activity, spared us this initial effort (Chen, Du et al. 2008). Therefore, I sought increased
understanding of the molecular details of this Syn-TRAF6 interaction. To obtain novel
details of the interaction in other receptor systems that signal to NF-κB required careful
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investigation. Incorporating new findings would facilitate the refining of our model of
TRAF6 inhibition and activation.

Syntenin seemed an attractive candidate for a TIM

inactivation pathway due to its demonstrated ability to negatively regulate the TRAF6
dominant positive effect for NF-κB activity (Chen, Du et al. 2008), in addition to a
putative TIM sequence identified between its two PDZ domains (Figure 1.12). Notably,
the linker region of Syn is unstructured and disordered. Such disordered regions have an
increased ability to conform and bind to other proteins in a specific, yet transient, manner
that enable their central roles in signaling pathways and act as hubs of protein interaction
networks (Meszaros, Dosztanyi et al. 2012). The results herein confirm that Syntenin can
inhibit TIR signaling by ectopically expressing Syn in cells stimulated by TIR receptors
(whose signals are transduced by TRAF6) such IL-1R (Figure 4.21 4.22) and, TLR4
(Figure 4.22) and newly demonstrate inhibition of RANK signaling (4.22). Arguably,
suing of a cell line (RAW264.7) that endogenously expresses these receptors provides
more relevant, physiological evidence of inhibitory effects of Syntenin, especially when
considering that 293 expresses a low level of Syntenin (Figure 4.44). Further, RANK
signaling is unique to osteoclasts and so Syntenin can inhibit some TNFR family
signaling but not other such as TNF-α (Chen, Du et al. 2008). Since ectopic expression
of TLR4 in 293 acts as a dominant positive for NF-κB and Syn can attenuate this activity
(Figure 4.37), it would be interesting to see whether our 293R cells have mRNA
expression of Syn, Sox4 and TRAF6 more similar to RAW 264.7 cells or stimulated
THP-1 cells. Notably, unmodified TLR4 has not previously been shown to act as a
dominant positive for NF-κB activity, and others usually transient transfect 293 to
express TLR4 prior to LPS stimulation. Relatedly, 293R cells used in this study did not
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have a high background level of NF-κB activity when transfected with empty vector
(Figure 4.15). Results from this study newly demonstrate that NF-κB activity, induced
by ectopic IRAK1 and MyD88, is also attenuated by Syn (Figure 4.23). I hypothesized
that this was because Syn interacted with the TRAF6 MATH domain, although
collectively the data seem to suggest that the Syn T6IM might be less important than the
Sox4 T6IM. When the putative TIM (194-198) spanning the PDZ tandem linker region
was removed (ΔPDZ2) Syn was no longer able to attenuate ectopic TRAF6 induced NFκB activity (Figure 4.26, Table 8). While this could be interpreted as the importance of
the T6IM, PDZ2 and/or CTD, it also suggests that the NTD of Syn is insufficient to
attenuate TRAF6 signaling. Furthermore, I expected that Syn would not be able to
inhibit RZcc if Syn associated with the MATH domain, using its putative TIM. Contrary
to my expectation, Syn was equally able to inhibit RZcc induced NF-κB activity (Figure
4.25A). This finding contradicts other reports that that full length Syn is required to both
interact with TRAF6 and inhibit TRAF6 signaling and (Chen, Du et al. 2008). As such, a
more complex mechanism for attenuation of TRAF6 signaling by Syntenin must exist.
Furthermore, although the ΔPDZ1 or ΔN muteins could inhibit TRAF6 signaling the
ΔPDZ1 and ΔN was insufficient for physical interaction with TRAF6 (Figure 4.27).
Here, the underlying mechanism might be that the putative T6IM in Syn is not binding
tightly to the MATH TI6M due to minor degeneracy in the sequence. When the sequence
was initially identified, I reasoned that while the last position, which calls for an (Ar/Ac)
residue, was substituted in Syntenin for other hydrophobic residues, the final two
positions for the T6IM were hydrophobic as seen in (Figure 5.3) and would be adequate
to mitigate TRAF6-Syn interaction, perhaps as a minor TRAF6-binding motif. Such
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minor binding motifs have previously been reported (Schneider, Zimmermann et al.
2012).

These data, coupled with the fact that the putative T6IM resides in an

unstructured region, along with the robust activity data where the CTD was found to be
inhibitory in wt. and RZ conditions (Figure 4.25) may yet allow this sequence to be
confirmed as the binding motif for TRAF6 in Syn. To be sure that the putative T6IM is
dispensable, point mutations of the site or a small deletion of the site should be generated
and used for assays similar to those performed in this study.

Analysis of Syntenin TIM sequence
P X E X X ψ (acidic residue)

Canonical TIM

P X E X Φ

(aromatic residue)

194

P F E R T I

198 T

194

P F E R T V 198 T S M

PDZ2 Human
PDZ2 Mouse

I is very hydrophobic aliphatic
V is very hydrophobic
T is hydrophobic as well

Figure 5.3 Deviations of murine and human Syn T6IM from canonical T6IM.
P-X-E-X-X-aromatic (F/W/Y)-acidic (D/E) is the TRAF6-binding motif (where 'X'
indicates any amino acid and '/' indicates 'or').
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5.7 Syntenin associates with TRAF6 in an Ubiquitin-dependent manner
Ubiquitination has been shown to be an important post-translational modification
for protein function and cellular control. Ubiquitin is covalently bound to proteins via an
isopeptide bond between the carboxy-terminal glycine (G76) of ubiquitin (Ub) and the ε
amino group of a lysine in target proteins. Ubiquitin contains seven lysine residues (K6,
K11, K27, K29, K33, K48, and K63) which can attach to another Ub to form poly-Ub chains
attached to a single lysine (Nath and Shadan 2009). Ubiquitinated TRAF6 recruits
TAB1/2 and TAK1 kinase leading to the activation of TAK1, which phosphorylates both
MAPK and IKK complexes to activate NF-κB (Figure 4.2).

Although auto-

ubiquitination is insufficient for NF-κB activity, our results and the literature suggest that
TRAF6 auto-ubiquitination serves to sustain TRAF6 signaling by keeping it in the
“open” state (Walsh, Kim et al. 2008, Wang, Galson et al. 2010). Deletion of all lysines,
which are potential ubiquitination sites, in TRAF6 reduces, but does not abolish, its
signaling capacity (Walsh, Kim et al. 2008).
Syn was found to inhibit the RZcc mutein in 293 cells (Figure 4.25), implying that
it does not directly bind TRAF6 via a Syn-MATH interaction or that Syn binds to TRAF6
through multiple interactions (Figure 5.1, 5.2).

When a lysine deficient TRAF6

(TRAF6ΔK) was ectopically expressed in 293 cells, Syn inhibition was reduced (Figure
4.28A). Additionally, Syn ΔN was less effective at inhbiting TRAF6ΔK vs wtTRAF6.
This suggests that the Syn NTD which has been shown to bind Ub in a novel manner
(Rajesh, Bago et al. 2011) may bind to Ubiquinated, activated TRAF6 (Figure 4.28B).
This conclusion is corroborated by differential colocalization of Syn and TRAF6 vs a
poly-Ub deficient TRAF6c70A mutein (Figure 4.33, 4.34). While Syn colocalizes with
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TRAF6 in the cytoplasm and translocates TRAF6 into the nucleus under stimulating
conditions (dominant positive or ligand stimulation; Figures 4.30, 4.31) TRAF6C70A
r3mained in the cytoplasm (Figure 4.32), Collectively, these results suggest that the
PDZ2 and CTD of Syn requires TRAF6 + Ub to bind TRAF6 and bring it to the nucleus
which interferes with TRAF6 signaling in the cytoplasm. Further, TRAF6 (-) Ub blocks
the Syn NTD from interacting and translocating TRAF6 to the nucleus. These results are
corroborated by reports that Syn binds ubiquitin directly through a novel Ub binding
pocket, using a mechanism where the recognition involves both N- and C-termini of Syn
rather than its PDZ domains, which instead mediate prerequisite dimerization (Rajesh,
Bago et al. 2011). Furthermore, Syntenin interacts equally well with K48- or K63-linked
polyubiquitin chains in a NTD- CTD Syn homo-dimer dependent manner (Rajesh, Bago
et al. 2011). Since the NTD of Syn is involved in binding to Ub and likely, ubiquitinated
TRAF6, the inability of Syn to interact and relocalize the C70A muteins supports this
model of interaction. The CTD (194-298) of Syn, comprised of the linker (T6IM), PDZ2
and CTD, alone are also critical components of Syn involved in TRAF6 nuclear
localization.
A future study should include a co-IP of C70Aand Syn, which should not bind if
Ub-TRAF6 is critical for Syn interaction. Additionally, the study should test whether
Syn can inhibit RZcc dominant positive in RAW264.7 and 4B12 cells. The mechanism
by which Syn binds to TRAF6 might be that ubiquitinated TRAF6 is necessary, but
insufficient, for the Syn-TRAF6 interaction. Taken together, the results that both the
CTD and NTD of Syntenin are required for interaction with TRAF6, along with the
demonstration that IRAK1 binds to the MATH domain of TRAF6 and disrupts RZ-
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MATH interaction, lead to consider the temporal dynamics of a Syn-TRAF6 association
and regulation. Specifically, IRAK1 opens the TRAF6 conformation allowing TRAF6 to
be auto-ubiquitinated, optimizing the Syn interaction and attenuation of TRAF6
signaling. This model conflicts with reports that Syn and TRAF6 are pre-associated and
that IRAK1 disrupts this interaction in concert with an increase in TRAF6
polyubiquitination (Chen, Du et al. 2008). Since Syn dimerization is required for Ub
binding (Rajesh, Bago et al. 2011), this may reconcile the fact that TRAF6 was not
crystallized as a trimer (McWhirter, Pullen et al. 1999, Park, Burkitt et al. 1999, Ely,
Kodandapani et al. 2007) like other TRAFs, but rather as a MATH domain monomer
devoid of a coiled-coil (cc) multimerization domain (Ye, Arron et al. 2002, Ye, Cirilli et
al. 2002).
5.8 Syntenin and Sox4 interact with TRAF6 cooperatively Protein interactions with
TRAF6
Examination of Syn and Sox4’s primary amino acid sequences yielded two novel
TIM-bearing TRAF6regulatory proteins: the adapter protein Syntenin-1 and the
transcription factor Sox4 (Figures 9, 10, 21, 40). Syn is a dual PDZ domain-containing
adaptor protein consisting of asymmetric N- and C-terminal domains joined by a linker
peptide (Beekman and Coffer 2008, Pham, Zhou et al. 2008). Often PDZ containing
proteins bind to the carboxy-terminal residues of other proteins, which is in keeping with
the C terminus position of The MATH domain or the reported stabilization of Sox4’s last
33 C-terminus residues by Syntenin (Beekman, Vervoort et al. 2012). PDZ proteins can
act as multi-functional adaptor proteins, playing a role in assembling multi-protein
complexes in appropriate regions of the cell (Harris and Lim 2001). Proteins of the PSD167

95/Discs large/ZO-1 (PDZ) class can interact with Sox factors. All Sox-family proteins
share a conserved High Mobility Group (HMG)-like DNA binding domain.

Sox

transcription factors can activate or repress many target genes associated with
development using the conserved HMG domain. However, it is the non-HMG domains
that have been proposed to influence partner protein selection and binding stability
(Wilson and Koopman 2002). There are three different classes of Sox protein–protein
interaction: 1) DNA-binding proteins that partner with Sox proteins to regulate
transcription 2) adaptor-proteins, that link Sox factors to other proteins; and 3) Importins,
required for the nuclear import of all Sox proteins, all of which have relevance to this
study. Poulat et al. demonstrated that the PDZ protein, SIP-1 interacts with the carboxyterminal seven amino acids of SRY and proposed SIP1 connected SRY to other,
unidentified proteins (Poulat, de Santa Barbara et al. 1997). By interacting with both
Sox4 and the interleukin 5-receptor α subunit (IL-5α), Syntenin acts adapter facilitating
IL-5R stimulated Sox4-dependent transcriptional activity. The results of my research
support a new model where Syn works as an adapter protein possibly by both protecting
Sox4 from proteosomal degradation and TRAF6-Sox4 interaction to attenuate TRAF6
signaling and TRAF6 nuclear import. Ectopic Sox4 was found to inhibit TIR signaling
at multiple levels in the TIR signaling pathway to NF-κB (Figure 4.37, 4.38) but perhaps
most telling of its specificity for TRAF6 was the ability to inhibit the TRAF6 dominant
positive for NF-κB, which is independent of upstream events (Figure 4.39).

Sox4

associated with TRAF6 in a MATH dependent manner (Figure 4.39-4.41) since the RZcc
was not able to co-precipitate with Sox4 and ectopic Sox4 was unable to attenuate the
RZcc dominant positive for NF-κB activity.
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Tellingly, Syntenin was unable to inhibit

TRAF6 when Sox4 was knocked down in cells treated with si-RNA directed against
Sox4 expression. One possible experiment for a future study would be to see if si-Sox4
could induce dominant positive NF-κB activity in RAW264.7 or $b12 cells, either alone
or in conjunction with ectopic wtTRAF6. These results found in this study suggest that
the inhibition of TRAF6 by Syntenin is dependent on Sox4 and that Syn acts as an
adapter to facilitate Sox4 binding to TRAF6, possibly stabilizing the Sox4-TRAF6
interaction by associating with open Ubiquitinated TRAF6 or a transient association of its
degenerate TRAF6 interaction motif. Sox4 was initially identified as a transcription
factor required for B- and T-lymphocyte differentiation (Beekman, Vervoort et al. 2012,
Vervoort, van Boxtel et al. 2013). Among the genes targeted by Sox4, are the cmyb and
FHL2, which have been previously implicated as regulated by nuclear TRAF6 (Bai,
Kitaura et al. 2005, Bai, Zha et al. 2008).

These studies do not provide a clear

mechanism for the nuclear import of TRAF6 from the cytoplasm.

I found that over-

expression of Syn translocates TRAF6 to the nucleus. Importantly, neither TRAF6 nor
Syn possess a nuclear import signal (NLS). Therefore, my results provide the first
description of a mechanism by which TRAF6 enters the nucleus using Synteninstabilized Sox4 as the cargo carrying protein for nuclear import and attenuation of
TRAF6 signaling.
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5.9 TRAF6 Interaction Motif Directs Subcellular Localization
Many TRAF family members translocate from their normal cytoplasmic residence
to various subcellular compartments including: the plasma membrane, sequestosome, and
nucleus upon stimulating conditions in various receptor systems. TRAF2 and TRAF3
move from the cytoplasm to plasma membrane raft microdomains of anti-CD40 antibody
treated B cells upon CD40 engagement (Hostager, Catlett et al. 2000). Moreover, CD40
engagement initiates formation of the immunological synapse has which contain TRAF2
and TRAF3 (Dustin, Chakraborty et al. 2010). RANKL induced recruitment of TRAF6
to detergent resistant lipid microdomains was demonstrated biochemically in RANKL
stimulated RAW264.7 cells and osteoclasts (Ha, Kwak et al. 2003, Ha, Kwak et al.
2003). In cells that were pre-treated with a lipid raft disruption reagent, methyl-βcyclodextrin (MBCD), there was a decrease in the presence of TRAF6 in the detergent
insoluble fraction. Coupling the results with the observation that TRAF2/3 are recruited
to the IS, points to the possibility that lipid rafts were as an osteoclastogenic signaling
platform to support a RANK/TRAF6 complex resembling the immunological synapse.
While TRAF6 is normally associated with signal transduction in the cytoplasm, others
have noted that TRAF6 is dual target to both the nucleus on the cytoplasm. This study
demonstrates that ectopic TRAF6 resides in punctae (Figure 4.3) whose size has been
shown to correlate with TRAF6 activity as measured by a NF-κB Luciferase reporter
(Wang, Galson et al. 2010).

Cytoplasmic granules enriched in Sequestosome-1

(p62/SQSTM1), an ubiquitin-binding scaffold protein (Geetha and Wooten 2002,
Donaldson, Li et al. 2003) that activates p38 MAPK (Diradourian, Le May et al. 2008)
and IKK (Sanz, Diaz-Meco et al. 2000). SQSTM/p62 is dual targeted to proteasomes
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and autophagosomes (Wojcik 2013) and inhibition of the TRAF6-p62 interaction has
been shown to blocks TRAF6 activity, reducing K63 linked ubiquitination of its target
substrate, the tyrosine receptor kinase A (TrkA) (Geetha, Jiang et al. 2005) and
neurotrophin receptor interacting factor (NRIF). Intranuclear TRAF6 has been reported
in lymphoma B cells where it interacts with c-Myb and represses c-Myb-mediated
transactivation (Pham, Zhou et al. 2008).
This study demonstrates that ectopic Syn can translocate normally cytosolic
TRAF6 to the nucleus (Figure 4.32, 4.33). Similarly, ectopic co-expression of unlabeled
TRAF6 resulted in translocation of GFP-Syn into the nucleus (Figure 38). To determine
the important domains of Syn for TRAF6 translocation to the nucleus, deletion mutants
of Syn were coexpressed with TRAF6-YFP in 293 cells. The results suggests that the Cterminus (194-298) of Syn comprised of the linker (TIM) PDZ2 & C-terminal Domain,
along with the unstructured N-Terminus, are the critical components of Syn involved in
TRAF6 nuclear localization (Figure 4.33). TRAF6C70A is inactive and deficient in
poly-ubiquitination (Figure 4.34) (Walsh, Kim et al. 2008).

Ectopic expression of

TRAF6C70AYFP in 293 cells reveals a subcellular localization, primarily in the
cytoplasm, similar to that of wtTRAF6 (Fig 17 Bottom). When Syn was co-expressed
with TRAF6C70A-YFP, TRAF6C70A-YFP failed to translocate to the nucleus.
Additionally, when TRAF6C70A-YFP was co-expressed with the Syn deletion muteins,
the opposite effect to that of co-expression with wtTRAF6-YFP was seen. SynΔPDZ2
was unable to translocate wtTRAF6 to the nucleus, but was able to support translocation
when co-expressed with TRAF6C70A-YFP.
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I have already determined that the N-

terminus of Syn are involved in binding to Ubiquitinated TRAF6; thus, the effects
observed here support this interaction.

Traditionally,

PDZ

domain-bearing

proteins

are

associated

with

membranes, suggesting that these domains are involved in either organizing
transmembrane protein complexes at plasma membranes or recruiting proteins to
membranes from the cytosol.

However, Syn was observed to have nuclear

enrichment in an inverse correlation with plasma membrane localization. The
authors imagine that syndecans sequester Syntenin to the plasma membrane and
depleting it from a nuclear pool. This suggests that when syndecans are down
regulated, Syn moves to the nucleus, where it could have transcriptional activities
(Zimmermann, Tomatis et al. 2001). By extension, I proposed a model where Syntenin
interacts with activated TRAF6 at the membrane, and that this association then sequesters
TRAF6 into the nucleus in order to attenuate receptor signaling and propagate TRAF6
transcriptional activity, such as that reported by others (Bai, Kitaura et al. 2005, Bai, Zha
et al. 2008, Pham, Zhou et al. 2008). In these reports, TRAF6 was previously found in
the nuclei of both normal and malignant CD40 stimulated B-lymphocytes. TRAF6 does
not possess a nuclear localization signal but enters the nucleus through the nuclear pore
complex containing RanGap1 a Ran GTPase-activating enzyme. Nuclear TRAF6 is
modified by SUMO-1 at lysines 124, 142 and 453, interacts with HDAC-1, repressing cMyb-mediated transactivation. Of the SUMO proteins, only SUMO-1 contains a nuclear
localization signal that functions by transporting the cargo protein into the nucleus.
Interestingly, Syn also contains two Small Ubiquitin-related Modifier-1 (SUMO1) binding motifs (Vijayakumaran, Wong et al. 2015). Nuclear TRAF6 is reportedly
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modified by (SUMO-1), interacts with histone deacetylase 1, and represses c-Mybmediated transactivation (Pham, Zhou et al. 2008). This could indicate the potential for
Syn to recruit SUMO-1 for targeting TRAF6 within the nucleus.
To ensure that nuclear localization of TRAF6 by Syn was not an artifact of overexpression, I confirmed that endogenous Syn and TRAF6 enter the nucleus with similar
kinetics upon RANKL stimulation of RAW246.7 cells (Figure 39). Immunoflourescent
staining of endogenous Syn and TRAF6 revealed both proteins as largely cytoplasmic,
but then simultaneously enter the nucleus upon stimulation of cell surface receptors that
initiate TRAF6 mediated signaling cascades. This was also observed for LPS stimulation
(data not shown), which comports with data presented by others, although misrepresented
or incorrectly interpreted as cell surface membrane aggregations (see Fig 6b of Yin et al.
(Yin, Lamothe et al. 2009)). Altogether, it can be concluded that attenuation of TRAF6
signaling may also result from sequestration of cytoplasmic TRAF6, providing a
mechanism for previous reports of nuclear translocation of cytoplasmic TRAF6.
While ectopic Syn can translocate normally cytosolicTRAF6 to the nucleus,
neither Syn nor TRAF6 has a Nuclear Localization Signal (NLS).

Sox4 has been

reported to accumulate with Syntenin in the nucleus (Beekman, Vervoort et al. 2012).
Sox4 has a bipartite nuclear localization signal (BP-NLS) at positions 60 -77 and 129136, as identified by the Nuclear Protein Database (NPD,
http://npd.hgu.mrc.ac.uk/user/index.php) (Figure 1.11). Endogenous TRAF6 and Sox4
were found to colocalize in 4B12 cells (Figure 4.40) and that LPS stimulation resulted in
intranuclear TRAF6 accumulation in a manner similar to that of Syntenin.

Ectopic

IRAK1 and TRAF6 colocalize in cytoplasmic punctae but ectopic Syntenin disrupted this
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and neither Sox4 nor Syn seemed to affect IRAK1 localization. These results underscore
a model where the T6IM bearing molecules IRAK1, Sox4 or Syn can either activate or
attenuate TRAF6 by affecting its subcellular distribution or conformation and presumably
Ubiquitination state.

We have recently undertaken some pilot studies where, it seems

that there may be a constitutively high amount of Syn mRNA that is followed by an
increase in Sox4 mRNA in response to LPS stimulation in THP-1 and 293 cells. We are
further examining whether there is any message difference in the monocytic cell line
RAW264.7 that would account for the inability for wt. TRAF6 to act as a dominant
positive in those cells.

Upon first examination, the data supports model where Syn is

available to interact with activated TRAF6, perhaps stabilizes Sox4 and then the two
cooperatively translocate TRAF6 into to the nucleus to attenuate signaling to NF-κB by
sequestration and possibly allowing for TRAF6-Sox4 transcriptional events, including the
repression of FHL2 and cMyb expression.
5.10 Syntenin and TRAF6 involvement in Neurite Formation
Nervous system disruption often results in irreversible loss of sensation and
paralysis. This is in part because neurons in the central nervous system (CNS) are unable
to overcome an unfavorable extracellular environment to regrow long cellular processes
(axons) after they have been damaged. Neurotrophic factors, proinflammatory cytokines,
and transcription factors are often reported to have conflicting trophic and inhibitory roles
in neurite extension. As such, the success of regeneration depends largely on the severity
of the initial injury and resultant degenerative changes (Harrington, Kim et al. 2002).
The processes of injury-induced neuronal cell death and subsequent regeneration remain
poorly understood. However, conditions within the local microenvironment of the injury
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site, and the intercellular signaling cascades they trigger, are undoubtedly important. The
regenerative capacity of the peripheral nerve microenvironment has been studied since
the early 1900s when Cajal proposed that it was the peripheral nerve milieu, rather than
intrinsic neuronal differences between peripheral and central nervous system neurons,
that explained the failure of regeneration in the latter (Yiu and He 2006, Lobato 2008).
Since then, it has been demonstrated that CNS neurons can regenerate in a peripheral
nervous system (PNS) environment and that peripheral neurons lose this ability when
placed in a central environment (Harrington, Kim et al. 2002). The presence of growthsupportive Schwann cells in the PNS, and inhibition by oligodendrocytes and glial scar in
the CNS, contribute to this difference in regenerative capability. Upon injury, CNS
axonal growth cones undergo Wallerian degeneration, while the PNS axons assemble
new actin-rich growth cones after injury (Knoll and Nordheim 2009). Clearly, the PNS
environment facilitates a program of cytoskeletal rearrangement in response to neuronal
injury in order to initiate the actin polymerization necessary for axonal growth and
synapse formation (Revenu, Athman et al. 2004, Chia, Patel et al. 2012, Montani and
Petrinovic 2014). Yang et al reported that TRAF6 is a direct E3 ubiquitin ligase for Akt
kinase K63 linked poly-ubiquitination. Such modification is critical for Akt recruitment to
the plasma membrane and activation (Yang, Zhang et al. 2009). In this study, they found
that two lysine residues (K8 and K14) located inside the PH (Plekstrin Homology) domain
of Akt were targeted for: TRAF6 directed ubiquitination; ubiquitination of Akt, required
for its phosphorylation and membrane recruitment; and contribution to both survival and
oncogenic signaling pathways (Restuccia and Hemmings 2009). A construct containing
the PH-domain of AKT fused to GFP was used P to see whether TRAF6 could induce
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neurite extensions or neuronal like filipodia in either PC12 cells or 293 cells.
Interestingly, 293 cells were found to be responsive to NGF (Nerve Growth Factor) and
produced extensions in response to the NGF stimulation (Figure 4.47), in a manner
similar to a previous study published by our group where 293 cells produced extensions
in response to either TRAF6 overexpression or IL-1β stimulation (Wang, Wara-Aswapati
et al. 2006).

Interestingly, when Syntenin was co-expressed with TRAF6, the two

ectopic molecules seemed to have antagonistic morphological effects (Figure 4.48-4.50),
analogous to Syn attenuation of TRAF6 signaling to NF-κB). Of note, either TRAF6 or
Syn alone seemed to induce either neurite formation or enhance neurite formation in cells
additionally stimulated with NGF (Figures 4.48-4.50). It was not unexpected that Syn
would generate extensions, since the overexpression of wild-type MDA-9/Syn has been
shown to increase migration in non-metastatic cancer cells, and correlates with a more
polarized distribution of F-actin and increased pseudopodia formation (Grootjans,
Zimmermann et al. 1997). Further, deleting the PDZ tandem inhibits the formation of
filipodia, suggesting that Syn plays an important role via interaction with ubiquitin in the
regulation of cancer metastasis and invasion (Okumura, Yoshida et al. 2011). These
results underscore that different tissues may utilize the same adapter protein to
accomplish different cellular outputs, dependent on the biophysiological system.
However, some of the molecular componentry and mechanisms remain constant across
these systems.
5.11 Tec Kinases Osteosynapse and Transcytotic Machinery
Osteoclasts are multinucleated giant cells (MNC) responsible for bone resorption.
These syncytial cells are differentiated from hematopoietic myeloid precursors of the
176

monocyte/macrophage lineage.

Mature osteoclasts are polarized cells with a ruffled

border and a sealing zone at the apical membrane towards bone surface. To differentiate
osteoclast precursors into mature osteoclasts, a cell-cell interaction between osteoclast
precursors and osteoblasts/stromal cells is required (Udagawa, Takahashi et al. 1990). In
the late 1980’s an in vitro culture system for osteoclast formation was established. This
system revealed the importance of the cell-to-cell contact of osteoblast/stromal cells and
hematopoietic cells for osteoclast differentiation (Takahashi, Yamana et al. 1988).
Specifically, the system enabled production of the TNF-related cytokine RANKL and the
polypeptide growth factor colony-stimulating factor-1 (CSF-1) that were subsequently
shown to induce, together, the expression of genes necessary for osteoclastogenesis
(Nakagawa, Kinosaki et al. 1998, Boyle, Simonet et al. 2003). The sealing zone between
an osteoclast and the resorbed bone is a large F-actin rich structure that is important for
the bone-resorbing activity of osteoclasts, anchoring it to the mineralized extracellular
matrix. Additionally, in order to generate a bone resorption pit, osteoclasts may form
other F-actin rich structures known as podosomes, which are used for migration in a
manner similar to focal adhesions plaques, but independent of actin stress fibers (Jurdic,
Saltel et al. 2006). These two structures share molecular components and architecture
with other integrin-mediated adhesive structures, and parallels exist between the
regulatory mechanisms that contribute to the formation of these adhesive structures
(Wernimont, Cortesio et al. 2008).

An osteopetrotic phenotype in Tec-/- BTK-/- mice

revealed these two kinases to play a crucial role in the regulation of osteoclast
differentiation. This study establishes their crucial role in the integration of the two
essential osteoclastogenic signals, RANK and ITAM (Figure 4.51).
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Thus, although

immune and bone cells share components of signaling cascades, they play distinct roles
in each cell type. Furthermore, our studies identified an osteoclastogenic signaling
complex composed of Tec kinases and adaptor proteins that may provide a new paradigm
for

the

signal

transduction

mechanism

of

osteoclast

differentiation:

ITAM

phosphorylation results in the recruitment of Syk, which phosphorylates adaptor proteins
such as BLNK and SLP-76, which in turn function as scaffolds to recruit the Tec kinases
activated by RANK and PLCγ to the osteoclast signaling complex so as to induce
maximal calcium influx. Such complexes are similar to those formed in the
immunological synapse in T cells, which are associated with membrane rafts (Cherukuri,
Dykstra et al. 2001). Each of these synaptic types is built around a microdomains
structure comprised of central active zones of exocytosis and endocytosis encircled by
adhesion domain surface molecules that may be incorporated into and around the active
zones, contributing to modulation of the function state of the synapse. Similarly, T cell
activation and function requires a structured engagement of antigen-presenting cells. The
cell contacts are characterized by two distinct dynamics in vivo: transient contacts
resulting for promigratory junctions called immunological kinipsases or prolonged
contacts from stable junctions called immunological synapses. Synapses are induced by T
cell receptor

(TCR) interactions with agonist self-peptides (MHC) under specific

conditions and correlate with robust immune response that generate effector and memory
T-cells. Additionally, parallels exist between the regulatory mechanisms that contribute
to the formation of these adhesive structures (Wernimont, Cortesio et al. 2008). This
study demonstrated the rapid recruitment of BTK and Tec kinases to the plasma
membrane of RAW264.7 cells stimulated with RANKL (Figure 4.52). This patterning
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could indicate that the signaling complex activated by RANK includes these two bridge
molecules (Figure 4.51). Attempts to visualize TRAF6 as part of this complex were
unsuccessful and TRAF6 was not observed to be recruited to the membrane (data not
shown). Instead, TRAF6 was observed to relocalize to the nucleus in a concomitant
manner with Syntenin in stimulating conditions (Figure 4.31).

However, when

RAW264.7 were stimulated with RANKL rapid recruitment of fluorescently labeled PH
domains or full-length Tec kinases BTK and Tec kinases to the membrane was seen, in a
manner similar to reports of CD40 induced recruitment of TRAF2/3 to the plasma
membrane (Hostager, Catlett et al. 2000). Confocal microscopy revealed that BTK and
Tec are normally expressed through the cytoplasm. Upon RANKL stimulation, within 5
minutes, BTK was recruited to the plasma membrane as compared to control (GFP) or
Tec Kinase-GFP. The relocalization of BTK was sustained for nearly an hour (Figure
4.52).
Another important question is how the dissolved mineral within the sealed
resorption pit is transported away from the bone surface. It has long been suggested that
a transcytotic process accomplishes this. Using transfected fluorescent BTK, I observed a
continuous collection of vesicles suggestive of the proposed transcytotic mechanism.
Osteoclasts are the primary cells responsible for bone resorption. Waste products created
by this process are transcytosed through the osteoclast and released through
the functional secretory domain (FSD). The mechanisms of this process are not fully
understood. Serendipitously, in an effort to understand to the temporal stability of the
OS, I stimulated RAW264.7 cells transfected with PH-BTK-GFP with RANKL for up to
90 hours. Interestingly, what appeared to be a structure resembling the osteoclast FSD
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was formed and the appearance of negatively stained tunnels from apical to basolateral
membrane, possibly representing a means for resorbed bone to be transcytosed through
the cell and released by exocytosis at the FSD (Figure 4.53, 4.54). Of note, finger like
projections did not appear to be localized to a single FSD but rather in multiples, perhaps
suggesting that the FSD is built at the sRANKL signaling site, whereas in a co-culture
cell-cell signaling system the RANKL signaling complex might be concentrated into a
single structure analogous to the Immunological Synapse.
5.12 Conclusions
TRAF6 is an E3 ubiquitin ligase that is unique among TRAF family proteins in
both its structure and protein-protein interaction specificity. It is further distinguished by
its ability to transduce a multiplicity of receptors in varied biological systems. Although
TRAF6 is recruited by these receptors, the mechanisms by which TRAF6 is activated
under these stimulating conditions remain largely unclear.

To address this, I used

standard molecular biological techniques to gain insight into the interplay of three
proteins with TRAF6: 1) Syntenin-1 (Syn); 2) SRY (sex determining region Y)-box 4
(Sox4); and 3) IL-1 receptor associated kinase 1 (IRAK1). These three proteins
physically interact with TRAF6 and affect its signaling activity by modulating subcellular
localization and activation of the NF-κB/Rel family of transcription factors under
stimulating conditions in cell lines of various tissue types. While many studies have
focused on cytoplasmic TRAF6 and its activation, there are a several reports on the
localization of TRAF6 (Geetha and Wooten 2002, Nakamura, Kadono et al. 2002, Bai,
Zha et al. 2008, Pham, Zhou et al. 2008) as well as TRAF3 (Gamper, van Eyndhoven et
al. 2000) and TRAF4 (Regnier, Tomasetto et al. 1995) to the nucleus in response to either
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extracellular stimulation or disease. Overexpression of either Syn or Sox4 was found to
not only attenuates TRAF6 signaling, but results in its nuclear localization in
hematopoietic and monocytic cells. This study demonstrates that IRAK1 can activate
TRAF6 by disrupting a constitutively closed, autoinhibited conformation. Syn attenuates
TRAF6 activity in an ubiquitin and Sox4 dependent manner. This study demonstrates
that either mutagenesis or deletion of a newly identified TRAF Interaction motif (TIM) in
Syn and conjunction with the PDZ2 and CTD can affect TRAF6 signaling and
localization. Moreover, in agreement with previous reports, Syn appears to interact with
TRAF6 directly when TRAF6 is in an ubiquitinated, open-active state. This, and our
observation that Syn is impaired in its ability to attenuate a non-ubiquitinated TRAF6
mutein (TRAF6ΔK), led to a hypothesis that Syn associates with TRAF6 in the
cytoplasm following activation by IRAK1. Furthermore, knockdown of Sox4 potentiates
TRAF6 activation and abrogates Syn inhibition of TRAF6. Contrary to prior reports,
protein domain deletions in both TRAF6 and Syn show that the full-length molecules are
not necessary for their interaction. Interestingly, Syn also localizes to the nucleus when
overexpressed with either wild type (WT) or a constitutively active TRAF6 (RZcc).
Lastly, Syn binds to the transcription factor Sox4, resulting in Sox4-Syn relocalization to
the nucleus.

This study demonstrates that Sox4 also induces TRAF6 nuclear

translocation that depends on a unique Sox4 TIM, providing a novel mechanism for
TRAF6 entry into the nucleus.

Thus, intranuclear TRAF6 suppresses either

morphogenesis or differentiation and that inactivation of TRAF6 dependent NF-κB
activity involves a novel interaction with the Sox4 transcription factor that controls
TRAF6 nucleocytoplasmic partitioning, conformation and modification state.
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